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BLOCK COPOLYMER BASED MAGNETIC NANOCLUSTERS FOR
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“There is plenty of room at the bottom”. In this visionary lecture in 1959 Prof. Richard
Feynman spoke of the interesting ramifications of working with matter at the atomic scale.
Since then, scientists have worked relentlessly towards realizing his vision. The influence
of nanobiotechnology on material science and polymer chemistry has given rise to a new
field called ‘theranostics’, combining drug delivery and diagnostics within the same
nanostructures, thereby enabling simultaneous diagnosis, targeted drug delivery and
continued therapy monitoring. Iron oxide nanoparticles (MNPs) are one such class of MRI
contrast agents that can be converted into theranostic nanomedicines for cancer therapy.
However, development of a stable theranostic contrast system comprising of MNPs is
complex and requires a careful balance between the therapeutic diagnostic components.
We explored the potential of biodegradable hydrophilic block ionomers such as anionic
poly (glutamic acid-b-ethylene glycol) and cationic poly (l-lysine-b-ethylene glycol) in
formulating stable magnetic nanoclusters (MNCs). These MNCs were extensively
characterized for their composition, colloidal stability and factors influencing their MRI
capability. Extensive in vitro studies revealed that the anionic cisplatin-loaded MNCs
showed minimal non-specific uptake, a highly preferred feature for targeted cancer
therapy. Luteinizing hormone releasing hormone receptor (LHRHr) targeting significantly
enhanced the uptake of these formulations in LHRHr-positive ovarian cancer cells. LHRHr
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targeting also helped improve the theranostic efficacy in cisplatin resistant ovarian cancer
cells. One the other hand, cationic MNCs were used to demonstrate the potential of MNCs
to function as stimuli-responsive theranostic systems capable of releasing the payload in
the acidic milieu breast and ovarian cancer cells. These cationic MNCs also exhibited
significantly enhanced T2-weighted MRI contrasts at much lower concentrations than the
anionic counterparts.
Finally, we successfully evaluated the feasibility of kinetically controlled flash
nanoprecipitation technique using multi-inlet vortex mixer (MIVM) to formulate welldefined MNCs from non-ionic amphiphilic Pluronic tri-block copolymers. In comparison to
self-assembly techniques, flash nanoprecipitation resulted in significant reduction in
polydispersity. It was observed that the hydrophobic block-length of the copolymer dictates
the extent of encapsulation hydrophobic therapeutic agents along with the MNPs.
exhibited the potential to function as both T1 and T2 contrast agents.
In summary, looking at the bigger picture, the work presented here emphasizes on the
importance of product development in establishing a critical balance between the
therapeutic and imaging functionalities when designing an efficient targeted theranostic
nanosystems.
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CHAPTER ONE
INTRODUCTION
1.1.

THERANOSTIC SYSTEMS FOR SIMULTANEOUS DETECTION AND
DRUG DELIVERY: AN OVERVIEW

For many decades’ clinicians and researchers have desired to develop non-invasive
strategies for diagnosis, therapy and monitoring of numerous pathological conditions in
humans. The advent of nanotechnology and the extensive research into its medical
applications has spawned a new era in the field of pharmaceutics and drug delivery. The
development of novel nano-vehicles such as liposomes, nanogels, micelles etc. for
delivery of therapeutic payloads to specific target organs has significantly improved the
treatment of diseases such as cancer. Their successes in significantly reducing undesired
side effects in healthy tissues has directed the research towards developing systems
capable of concomitant detection and localized treatment while allowing for therapy
monitoring

1-3

. Such single-entity nano-platforms capable of simultaneously targeting,

detecting and treating diseased tissue for a prolonged period of time are much desired in
clinical settings and thus, the field of ‘theranostics’ has emerged. The term “theranostics”
has been coined by the combination of the terms ‘therapy’ and ‘diagnostics’ to describe
this promising new field of research that focuses on the creation of a single therapeutic
carrier system with integrated diagnostic agents for combined capabilities 4, 5.
The theranostic approach promises therapeutic specificity due to the molecular
characters of the disease and also promises a broader choice of contrast agents to
objectively monitor therapeutic response. The current focus of theranostic formulations is
development of systems with stealth properties that enable prolonged circulation times
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and sustained release of the drug while simultaneously providing noninvasive in vivo
imaging capability 6, 7. It would be highly beneficial from the pharmacokinetic standpoint if
the circulation time and organ accumulation of the various nanomedicines could be
studied in real time. Such systems can also help in formulation characterization by
studying the in vivo drug release patterns. Targeted theranostic nano-systems go a step
further in terms of tissue-specificity due to their ability to accumulate preferentially at the
desired site of action. As exciting as the potential applications of theranostic nanosystems
are, the formulation process of such multi-component systems is complex and requires
meticulous control. The following section briefly describes the different fabrication
approaches used for different theranostic systems.
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1.2.

DESIGN COMPONENTS OF A THERANOSTIC NANO-FORMULATION

Figure 1.1. Components of a theranostic nanosystem

4
A typical targeted theranostic nano-particulate system is composed of the following
components (Figure 1): a) Therapeutic agent, which can include small molecules, protein and peptide
therapeutics or nucleic acids
b) Diagnostic/contrast or some other type of imaging agent
c) Nano-vehicle
d) Targeting moiety
1.2.1. DESIGN CRITERIA AFFECTING THE CHOICE OF THE THERANOSTIC
COMPONENTS
Several factors have to be considered in the design of a theranostic nanosystem.
These include: 1. Physico-chemical properties of the therapeutic and contrast agents: Physicochemical properties such as the solubilities of the drug and contrast agents affect the
choice of nano-vehicle, which can carry both the components simultaneously. For
example, the combination of a water-soluble therapeutic agent such as gemcitabine and
a hydrophobic contrast agent such as magnetic nanoparticles demands a multicomponent nano-vehicle comprising of both hydrophilic and hydrophobic compartments.
Multilamellar vesicles such as liposomes and polymersomes serve as superior delivery
vehicles in such cases.
2. Pathological condition and target tissue: The disease and physiology of the target
tissue dictate the choice of contrast agent in terms of circulation time and tissue perfusion.
For example, positive contrast gadolinium-based imaging compounds are the agents of
choice for magnetic resonance imaging (MRI) which is known to provide superior contrast
in soft tissues and is generally preferred in nasopharyngeal and other soft-tissue
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carcinomas including brain tumors

8, 9

. In comparison, blood pool agents, which are a

special class of MR angiography contrast agents, require significantly longer vascular
circulation times which is achieved through the use of higher molecular weight compounds
10, 11

. The high molecular weight prevents leakage into interstitial spaces and diffusion in

the vascular epithelium. This also enables higher relaxivities and a better signal-to-noise
ratio (SNR) leading to superior images

12

. Thus, blood pool agents are usually larger

molecules such as albumin13 or high molecular weight polymers conjugated to the MR
contrast agents 14,15.
3.

Biocompatibility

and

biodegradability:

Biocompatibility

and

preferably

biodegradability are an absolute requirement when designing theranostic nanosystems16.
These factors have proven to be substantial roadblocks in regulatory approval and
commercial acceptance of nanoformulations. Numerous contrast agents such as Gd suffer
from low circulation half-lives (t1/2) which then necessitates higher doses of this
nephrotoxic compound17-20. Hence, several successful attempts were made to enhance
the t1/2 and simultaneously increase the biocompatibility of such contrast agents by
conjugating them to materials capable of masking the toxicity21-23. Liposomes have been
studied extensively and rendered safe as nanovehicles for delivery of various payloads
including various contrast agents24, 25. Other biodegradable materials such as poly(amino
acids) serve well as biodegradable building blocks for various nanovehicles such as
polymeric micelles26-28 and nanogels29,

30

. Pluronic®, also generically known as

poloxamers, are another class of biocompatible tri-block copolymers which are used
extensively in the design of nanoparticulate drug delivery vehicles31-33. Pluronic® have
been used to formulate magnetic nanoparticle-based theranostic systems for sustained
delivery of anti-cancer agents such as doxorubicin34-36. These examples show the variety
and importance of nanomaterial choice in the design of theranostic nano-systems.
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1.3

CLASSIFICATION OF THERANOSTIC NANOSYSTEMS
The different theranostic systems are classified below based upon the imaging

modality for which they were designed.
1.3.1 OPTICAL THERANOSTIC SYSTEMS
These nanoformulations constitute the simplest of all the classes of theranostic
systems that can be developed for simultaneous drug delivery and imaging. The relative
small molecular size of the various flurophores opens numerous avenues for
encapsulation.
1.3.1.1. Organic fluorescent dyes
The use of fluorescent probes as ligands on several nanosystems is probably the
simplest and earliest class of theranostic nanosystems developed by researchers. Even
today, fluorophore-based formulations are predominantly used in research for in vivo
animal studies and histological analysis of excised tissue. Fluorescent dyes are used
extensively in understanding the trafficking of nanoformulations and subsequent
endocytotic paths followed by the nanoparticles into the cells and various cellular
organelles. For this purpose, several nanovehicles such as micelles, liposomes,
dendrimers or simple ionic polyplexes have be developed and studied in great detail for
their theranostic capabilities. For instance, Kleemann et al. investigated the intracellular
trafficking of polyplexes comprised of poly(ethyleneimine) (PEI)-plasmid peGFP-N1
targeted to the lungs by the TAT peptide domain of HIV-1 37. The targeting and transfection
efficiency of the targeted polyplexes was determined by measuring the fluorescence of
the green fluorescence protein (GFP) in the plasmid. In a similar study, the intracellular
trafficking of PEI-DNA polyplexes was studied by confocal laser scanning microscopy. PEI
and DNA were labeled with Oregon Green 488 and rhodamine respectively and the co-
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localized yellow signal was monitored to determine intracellular fate of the polyplexes. This
method was used to observe that the polyplexes were intact when entering the nucleus.
Recently, more sophisticated imaging techniques such as fluorescence resonance energy
transfer (FRET)38 and fluorescence correlation spectroscopy (FCS)39 have been employed
to overcome the drawbacks of traditional confocal microscopy such as inherently low
spatial resolution. These advances have enabled more precise information regarding the
dissociation of DNA complexes within the cells thereby improving the theranostic efficacy
of the formulations. For instance, Lucas et al. utilized fluorescence fluctuation
spectroscopy (FFS) to study the trafficking and intracellular fate of DNA polyplexes labeled
with Cy5 and rhodamine. FFS enabled the researchers to distinguish between the intact
and dissociated complexes. It was also observed that the fate of the polyplex was
dependent on the molecular weight of the cationic polymer. The poly(L-lysine)oligonucleotide complexes made from 30 KDa poly(L-lysine) dissociated upon entry into
the nucleus while the polyplexes comprised of poly (2-dimethylaminoethyl methacrylate)
(pDMAEMA), a 1700 KDa polymer, dissociated in the cytoplasm itself40. Self-fluorescing
small molecule therapeutics such as doxorubicin provide a dual functionality and added
advantage in enabling extensive characterization of the encapsulating nanosystems in
that the in vivo accumulation and release of the formulation can be monitored continuously
while also providing therapeutic effect25.
However, theranostic nanosystems based on fluorescent dyes, show numerous
limitations such as photo-bleaching, self-quenching, rapid decay of signal and non-uniform
labeling of the nanoformulations. Furthermore, certain fluorophores such as Cy5 have also
been shown to inhibit the ability of the backbone polymer to bind to the nucleic acids41.
These limitations have been addressed by other imaging agents called quantum dots
(QDs), which will be discussed next.
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1.3.1.2. Quantum Dots
Quantum dots (QDs) are a novel class of inorganic fluorophores, which are gaining
widespread recognition as a result of their exceptional photophysical properties. They are
defined as particles with a crystal size on the order of the size of the exciton Bohr radius42.
QDs are typically 2-7nm in size and made from semiconductor materials such as
Cadmium-Selenium composites (CdSe). After excitation by visible light, energy is emitted
in the form of a photon with a characteristic frequency and wavelength, which is dependent
upon the QD material and structure. QDs have unique advantages over current
fluorophores including having broad absorption spectra and narrow emission spectra with
wavelengths ranging from ultraviolet (UV) to infrared (IR). This enables excitation of
multiple different colored QDs using a single wavelength. QDs are also easily tunable in
that altering the particle size, composition and surface stabilizing coatings can easily
control the emission spectra of QDs. Another highly desirable feature of QDs is their photo
stability. While conventional organic fluorophores are prone to photo-bleaching after only
a few minutes, QDs are extremely stable and can undergo many recurring
excitation/emission cycles while retaining high brightness 43, 44. Comparative studies have
shown QDs to be significantly more photostable than Alexa-Fluor dyes,45 which are
regarded as some of the most stable organic dyes available 46.
Bare QD nanocrystals are prone to emission irregularities such as fluorescence
blinking and photochemical degradation which leads to the need for surface stabilization.
Zinc sulfide (ZnS) capping of the QDs is a widely used process and has been found to
improve stability and fluorescence. However, for biomedical applications, QDs require
coating which can render them soluble in physiological fluids, impart stealth properties,
biocompatibility and enhance in vivo stability and circulation times. These surface
modifications influence the physico-chemical properties and the toxicity of QDs

47

. These
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stabilizing moieties allow for further functionalization of QDs with targeting ligands. To this
end, Wu et al.45 used two different QDs conjugated with immunoglobulin G (IgG) and
streptavidin to label the breast cancer marker human epidermal growth factor receptor 2
(HER2). QDs have also been successfully co-delivered with therapeutic molecules leading
to the development of QD-based theranostic systems. One such example involves
development of D-alpha-tocopheryl polyethylene glycol 1000 succinate mono-ester
(TPGS) coated multi-functional (theranostic) liposomes, which contained both docetaxel
and quantum dots (QDs) for cancer imaging and therapy 6. These liposomes were further
conjugated with folic acid to target the folate receptor overexpressed in a large percentage
of breast cancers. The inclusion of QDs enabled the researchers to qualitatively track the
internalization of the liposomes at the target site and also monitor the therapy for an
extended period of time. Functionalized QDs have also been employed as intracellular
tracers to monitor plasmid DNA (pDNA) delivery 48.
Multimodal contrast agents based on the combination of QDs and MNPs are an
exciting class of bioimaging nanosystems. With two functionalities integrated in a single
nanoparticle, a sensitive contrast agent for two very powerful and highly complementary
imaging techniques (fluorescence imaging and MRI) is obtained. Such magnetic QDs can
be obtained by four different approaches. In the first, QDs are overgrown as a uniform
layer on the MNP surface followed by stabilization of the entire particle. Gao et al. reported
the synthesis of FePt cores with a diameter of 3 nm, surrounded by a 3–5 nm CdSe (QD)
shell through this method 48. The second approach involves doping of ions of the magnetic
material into the QDs to impart magnetic properties to them. Paramagnetic ions that have
energy states within the QD bandgap introduce ‘trap’ states that determine the wavelength
and lifetime of the doped QD luminescence. In a study by Santra et al.,49 the use of
CdS:Mn/ZnS QDs for bimodal imaging was demonstrated prominently for the first time.
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The third method simply involves co-encapsulation of QDs and MNPs in single
nanoparticulate structures such as PLGA matrix nanoparticles or mesoporous silica. This
method was used by Kim et al. to obtain uniform mesoporous silica spheres embedded
with monodisperse magnetic and semiconductor nanocrystals50. Finally, paramagnetic
substances such as gadolinium can be chelated into the coordination shells of the QDs.
Mulder et al.,51 used a lipidic micelle surrounding a QD to incorporate Gd-DTPA
complexes. Surface coating of this type of multi-modal imaging agents is critical from the
point of increasing colloidal stability and enhancing solubility as well as reducing
degradation of the QDs and increasing the biological half-life of the MRI contrast agent.
Thus, QDs have significantly superior optical properties than organic fluorophores,
which makes them a better alternative to the organic fluorescent dyes. However, the
toxicity of QDs is still a concern and most of the research currently is directed towards
reducing the toxicity through the use of different coating techniques that will have minimal
impact on the optical properties.
1.3.2

RADIO-THERANOSTIC SYSTEMS

Radiopharmaceuticals are an important class of therapeutic compounds, which have
been in clinical use for more than 20 years. Also known as radiotracers, these molecules
are routinely used in clinical practice either as diagnostics or for treatment of certain
pathological conditions such as cancer, myocardial infarction and several inflammatory
conditions

52, 53

. Current diagnostic techniques in nuclear medicine include non-invasive

Positron Emission Tomography (PET) and Single Photon Emission Computed
Tomography (SPECT).

These techniques utilize positron and gamma ray emitting

radionuclides respectively for generation of a signal. There is great utility of these
radionuclides in early detection strategies, first-line therapy and then also prognostic
follow-up. The ability of a single system to perform all these functions simultaneously is a
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very desirable feature and constitutes the main rationale behind development of
theranostic radiopharmaceuticals. To this end, significant amount of data is available on
the efficacy of theranostic radionuclides in targeting various molecular targets expressed
in different types of cancers.
Numerous physico-chemical factors are considered when formulating such radiotheranostic agents comprising of separate imaging and therapeutic modalities. First and
foremost, it is very essential to compare and match the pharmacokinetic properties of the
compounds. Maximum tolerated doses for critical normal tissues are necessary to know
so that the maximal possible dose can be given to the tumor cells. One of the critical
parameters to be considered in designing radio-theranostics is the residence time of the
molecules. Given the rapid radioactive decay that these radionuclides undergo, it is of
paramount importance to ensure the time accumulation of formulations in sufficient
concentrations in the target tissue. Radiopharmaceuticals with short radioactive t1/2
ranging from as low as several minutes to about two months have been approved for
radiotherapy in several conditions such as cancer. These include β-particle emitting
radionuclide molecules such as Iodine-131 (131I; t1/2 193 h), Strontium-89 chloride (89Sr; t1/2
50 days), Yttrium-90 (90Y; t1/2 64 h) and Lutetium-177 (177Lu; t1/2 161 h) and α-emitters such
as Astatine-221 (211At; t1/2 7.2h), Bismuth-212 (212Bi; t1/2 1h), Bismuth-212 (213Bi, t1/2 45min),
Actinium-225 (225Ac; t1/2 10 days), and Thorium-227 (227Th; t1/2 19 days) to name a few
On the other hand, radionuclides for imaging purposes include
SPECT or
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F,

64

Cu,

68

Ga, 76Br,

86

Y,

89

Zr,

110

In, and

124

99m

Tc,

111

In, and

123

54

.

I for

I for PET. Several of these

radionuclides have been formulated into peptide or monoclonal antibody (mAb) targeted
cancer therapeutics.

For instance, targeted radionuclide therapy using radiolabeled

somatostatin analog peptides (177Lu-Octreotate) for treatment of neuroendocrine tumors
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and radiolabeled anti-CD20 antibodies (90Y-Zevalin) for treatment of chemotherapyresistant lymphomas have been used clinically for a long time 55.
While research on targeted radionuclides conjugated with synthetic peptides and
mAbs has been at the forefront of product development efforts in cancer radiotheranostics, significant amount of work is currently underway towards development of
radio-theranostic nano-vehicles loaded with or conjugated with different radionuclides. Li
et al.56 designed and constructed a multifunctional theranostic liposomal drug delivery
system, which integrated multimodality magnetic resonance (MR), near infrared (NIR)
fluorescent and nuclear imaging of liposomal drug delivery. The payloads comprised of a
lipidized NIR fluorescent tracer, IRDye-DSPE and Doxorubicin post-loaded into the
multifunctional liposomes. The multifunctional doxorubicin-liposomes were further stably
radiolabeled with

99m

Tc or

64

Cu for SPECT or PET respectively. This multifunctional drug

carrying liposome system exhibited superior imaging capability in squamous cell
carcinoma of head and neck (SCCHN) tumor xenografts in nude rats following intratumoral
injection. NIR fluorescent, SPECT and PET images clearly showed either the high
intratumoral retention or distribution of the multifunctional liposomes.

Similarly,

unimolecular micelles were formed by dendritic amphiphilic block copolymers poly
(amidoamine)–poly (l-lactide)-b-poly (ethylene glycol) (PAMAM–PLA-b-PEG–TRC105)
and

conjugated

with

anti-CD105

monoclonal

antibody

(TRC105).57

1,4,7-

64

Cu) was

triazacyclononane-N, N’, N-triacetic acid (NOTA, a macrocyclic chelator for

conjugated as the radiotracer while Doxorubicin was loaded into the hydrophobic PAMAMPLA core. The 64Cu-label enabled continuous monitoring of the biodistribution as well the
therapeutic efficacy of the chemotherapeutic agent. Simultaneous radiotherapy and
photodynamic therapy (PDT) has also attempted by Sugiyama et al.58 The tumor response
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to this combination therapy was continuously monitored by use of 3′-Deoxy-3′-18FFluorothymidine radionuclide.
Despite the plethora of research efforts, radio-theranostics are still in a nascent stage
of development due to numerous shortcomings that need to be addressed. Most important
is the rapid decay of the radionuclides in vivo, which requires rapid uptake of the
formulations in the target tissue. This necessitates very careful product development
strategies and choice of radioisotopes, which can compliment each other in terms of their
biological t1/2. The physical stability, leakage of the payloads and stray exposure of the
healthy tissue are issues that plague the development of these theranostic agents even
today, although encapsulation within vesicular nanosystems such as liposomes shows a
potential solution to this problem. In all, radio-theranostic nano-systems have a
considerable distance to cover before they find clinical acceptance though current
research shows promise for the future of this class of theranostic agents.
1.3.3 PHOTO-ACOUSTIC AND PLASMONIC RESONANCE THERANOSTIC AGENTS
1.3.3.1. Porphyrins
Porphyrins exist abundantly in nature. In humans, the porphyrins in blood (i.e.
hemoglobin and myoglobin) serve not only as carriers of oxygen, but also as the bright
red contrast agent that clearly demarcates injury sites. They have proven valuable as
whole body imaging modalities have emerged, with endogenous hemoglobin porphyrins
being used for new approaches such as functional magnetic resonance imaging (fMRI)
and photo acoustic tomography (PAT). Functional MRI has been used effectively in
detailed three-dimensional volumetric mapping of brain activity. The presence of the
hemoglobin in abundance enables indirect measurement of intracranial metabolic activity
and blood changes caused by neural activity

59, 60

. Hemoglobin, in the form of oxy-
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hemoglobin, shuttles molecular oxygen to and from the cells for cellular respiration. The
iron chelated in the center of this hemoglobin can change its valency between Fe2+ and
Fe3+ to help enable precise oxygen delivery. The differences between oxy and
deoxyhemoglobin can be detected by fMRI because it has been shown that when
diamagnetic oxyhemoglobin releases its oxygen, the de-oxyhemoglobin becomes
paramagnetic, which influences the transverse relaxation rates of water proton spins in
the immediate vicinity of vessels, resulting in the blood oxygenation level dependent
contrast 61-63.
With the capability for both NIR fluorescence imaging and phototherapy, porphyrins
were the first exogenous molecules that were used with inherent multimodal theranostic
properties64. Porphyrins have been used as tumor-specific diagnostic fluorescence
imaging agents since the early 1920’s,65, 66 as positron emission agents since 1951,67 and
as magnetic resonance (MR) contrast agents since 1987. In addition, exogenous
porphyrins such as Photofrin® remain in clinical use for photodynamic therapy
applications. However, these exogenous porphyrins suffer from the drug delivery issues
seen with other hydrophobic pharmaceuticals. Researchers have attempted to address
these issues using polymeric nano-vehicles, which serve well for stabilization and stability
enhancement of porphyrins. For example, Hsu et al.68 fabricated a robust polymersome
nano-vesicle comprising of a 4-armed porphyrin conjugated to poly lactic acid (PLA). The
so-called ‘porphysomes’ combined the cytotoxicity of PDT with ultra-sound based imaging
capability thereby serving as an ideal theranostic system for cancer therapy. In another
study, a porphyrin−phospholipid conjugate with quenched fluorescence was developed to
serve as both the Raman dye and a stabilizing, biocompatible surface coating agent on
gold nanoparticles

69

. Here the porphyrin molecule was chelated with a central Mn2+ to

quench the fluorescent properties of the porphyrin while enhanced MR capability. This
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AuNP-porphyrin conjugate served as a novel surface enhanced Raman scattering (SERS)
probe capable of being used for cellular imaging. Porphyrins have also been encapsulated
into stable polymeric micelles systems. For example, micelles made of poly- (ethylene
glycol)-co-poly (D, L-lactic acid) (PEG-PLA) yielded 85% loading of tetrakis (mesohydroxyphenyl) porphyrin (mTHPP) while micelles made from poly(ethylene glycol)-copoly(caprolactone) (PEG-PCL) yielded approximately 70% encapsulation efficiency of
silicon pthalocyanine 4 (Pc 4), a porphyrin derivative 70, 71.
Thus to summarize, endogenous porphyrins enable optical and magnetic detection
serving as an effective natural theranostic agent. Exogenous porphyrins have also been
developed successfully into stable theranostic nanosystems, with new agents facilitating
multimodal imaging and therapy for numerous pathological conditions.
1.3.3.2. Micro/ nanobubbles
Microbubbles and nanobubbles are spherical cavities less than 10μm in size that are
filled with different perfluorocarbon (PFC) gases such as octofluoropropane (C3F8),
decafluorobutane (C4F10) or sulfur hexafluoride (SF6). Microbubbles are formed by ultrasonication resulting in the encapsulation of the sterile PF gases into amphiphilic polymeric
micelle solutions to form nanoemulsion foams at low temperatures. Advanced techniques
such as microfluidics have also been employed to produce these microbubbles.72, 73 The
encapsulated microbubbles undergo oscillations in an acoustic field depending upon the
field strength. These oscillations result in the generation of strong acoustic signals that
produce a contrast in comparison to the surrounding medium. The microbubble signal and
the resulting contrast are dependent on a number of factors such as the bubble size, the
density and viscosity of the entrapped gas, the density of the surrounding medium, and
the applied field power and frequency

74

. These unique contrast agents have

revolutionized the field of ultrasound imaging. Microbubbles have been used extensively
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in imaging blood-flow related conditions such as arterial inflammation, angiogenesis,
restenosis and even cerebrovascular conditions such as stroke

75, 76

. Recently,

researchers have attempted to go a step further and add a co-therapeutic dimension to
these imaging systems, resulting in the development of theranostic micro/nanobubbles
systems. Gao et al.77 successfully incorporated doxorubicin into the polymeric shell of
perfluoropentane microbubbles prepared from PLA-PEG and poly(ε-caprolactone)-PEG
(PCL-PEG). The non-targeted microbubbles were shown to accumulate passively in tumor
tissues and coalesce at physiological temperature to form microbubbles. Under an
ultrasound field these microbubbles oscillate and collapse to release the encapsulate drug
while simultaneously enabling visualization of the tumor tissue.
Microbubbles have also been studied as potential carriers of oxygen to the hypoxic
area of tumors.78 This strategy is seen as a means to reduce the hypoxia-induced
resistance to radiotherapy and photodynamic therapy. Another unique approach, as
demonstrated by Lukianova-Hleb et al.79 involved the formation of transient plasmonic
photothermal vapor nanobubbles from gold nanoparticles. When activated by a laser
pulse, an intracellular AuNP acted as a heat source and generated a transient plasmonic
nanobubbles (PNBs) in the surrounding medium. PNBs of nanometer-scale size and
nanosecond-scale duration act as diagnostic probes by scattering light from the probe
laser. Larger micron-scale PNBs provide a localized therapeutic action through a
mechanical, non-thermal impact due to their rapid expansion and collapse, thus disrupting
the cell membrane. Ultrasound imaging of the disruptive PNBs can guide their therapeutic
action. Thus, the PNBs may combine diagnostics, therapy, and therapy guidance. This
group of researchers went a step further and demonstrated the theranostic ability of these
PNBs generated by AuNPs within the liposomes to disrupt liposomal membranes thereby
enabling optically guided delivery and release of the therapeutic payloads

80

. Another
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potential application is to use microbubble disruption to accelerate thrombolysis.81 The
same mechanism that promoted clot lysis in the former case has been applied to
permeabilize and disrupt the blood–brain barrier, which could be useful for enhancing
delivery of therapeutic agents to brain tissue while continuously monitoring the therapy by
ultrasound.82
Although a relatively new field in ultrasound imaging itself, micro and nanobubble
research has rapidly expanded beyond mere ultrasound imaging. The astounding success
of the initial attempts at developing theranostic micro/nanobubbles are very successful
and have paved way for the next step in development of targeted theranostic microbubble
systems. The ability to generate plasmonic nanobubbles within nanovehicles is the first
step towards directing the bubbles in the desired tissue site. The main limitation of the
PNB technology is that it shows less potential in deeper tissues where laser penetration
is difficult and hence generation of transient PNBs is a perceived challenge. Nonetheless,
this technology shows tremendous promise as a potential theranostic nano-system.
1.3.3.3. Carbon nanotubes (CNTs)
Over the last decade, carbon nanotubes (CNTs) have attracted the attention of many
scientists across the globe. These hollow cylindrical nanosized tubes are composed
entirely of carbon and can be either single walled (SWCNTs) or multi-walled (MWCNTs).
The uniqueness of the nanotube arises from its structure and the inherent subtleness in
the structure, which is the helical arrangement of the carbon atoms in hexagonal arrays
on their surface honeycomb lattices. The helicity (local symmetry), along with the diameter
introduces significant changes in the electronic density of states, and hence provides a
unique electronic character for the nanotubes. These novel tunable electronic properties
create a range of fascinating applications, including those in the biomedical field.
Numerous studies have shown their ability to carry large payloads, either therapeutic83-86
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or contrast agents87 alone or a combination of both agents88, 89. There are a few studies
that have attempted to ‘think outside the box’ and exploit the optical properties of CNTs.
For example, Zarda et al.90 explored the optical imaging capabilities of SWCNTs in tumors
planted in murine models. The successfully showed that intravenously administered
SWCNTs conjugated with cyclic Arg-Gly-Asp (RGD) peptides showed eight times greater
photoacoustic signal in the tumor than mice injected with non-targeted nanotubes. While
a very enticing proposition, it remains to be explored whether drug loading can affect these
photoacoustic properties.
What is even more fascinating about the use of CNTs is that surface modification does
not affect their photoacoustic ability while still rendering them non-toxic and biocompatible;
a drawback that significantly retarded the pace of research into the biomedical applications
of CNTs in the initial years of this century. But the current efforts in the direction of
exploring the diagnostic capabilities of CNTs will definitely usher in a new era in CNT
biomedical research.
1.3.3.4. Gold nanoparticles
In the last decade, gold nanoparticles (AuNPs) have risen as one of the most
extensively utilized nanosystems for the imaging, diagnosis, monitoring and treatment of
various diseases, predominantly cancer. AuNPs have been successfully applied in a
broad range of biomedical fields such as analytical chemistry, biological sensing and
immunoassays, optical bioimaging, photothermolysis of cancer cells and targeted delivery
of drugs, peptides, DNA, and antigens.91 The unique optical properties of AuNPs are
related to localized plasmonic excitations in metal nanostructures interacting with light
which cause enhanced optical phenomena such as absorption, Mie scattering, Raman
scattering, and various nonlinear effects.92 AuNPs have been used as non-fluorescent
probes owing to their photostability, small toxicity, high light scattering efficiency, and
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ability to serve as carriers for different molecular cargos.93 AuNPs have also been used in
designing theranostic nanosystems capable of simultaneous imaging and therapy either
in the form of photothermal therapy or by co-encapsulating with several conventional
therapeutic agents. Photothermal therapy involves the use of light and a photosensitizer
to generate heat for therapeutic purposes. In contrast to conventional photodynamic
therapy, PTT does not require the presence of oxygen, which may be of importance when
a tumor is large enough to have a hypoxic center. Moon et al.94 reported development of
a new theranostic system comprising of hollow AuNPs filled with a low melting point (3640°C) phase-changing material (PCM) carrying the therapeutic agent. This system had
capabilities to both enhance the contrast of photoacoustic (PA) imaging and control the
release of a chemical or biological effectors by high-intensity focused ultrasound.
Exposure to the ultrasound caused heating of the AuNPs, which melted the PCM. So long
as the light was incident on the AuNPs, the molten PCM leached out of the hollow vehicles
thereby allowing for controlled release of the payload. In another study Heo et al.95
developed targeted AuNPs conjugated with anti-cancer agent paclitaxel. The biotinconjugated formulations were rapidly internalized preferentially in the cancer cells and
were easily detected as bright areas when observed in dark field microscopy. Similar study
performed by El Sayed et al.96 reported the diagnostic efficacy of EGFR-targeted AuNPs
in oral cancer cells. In addition to their photoacoustic properties, AuNPs have also been
reported to be useful in computed tomography aided imaging studies.97
Thus, numerous nanoparticulate systems have been studied for potential theranostic
applications combining photo acoustic imaging with various forms of therapeutic
approaches for the diagnosis and treatment of several condition, the primary focus being
cancer.
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1.3.4. MRI CONTRAST AGENTS
Magnetic resonance imaging (MRI) has become an essential tool for diagnosis and
evaluation of a broad variety of diseases. This technique was first developed in early 1973,
thanks to the pioneering work of Paul Lauterbur.98 Briefly, MRI relies on the imaging of
water molecule protons found in abundance in the tissues in the body. Due to its spin and
charge, protons have a minute magnetic field and hence, when placed in a magnetic field,
the protons align themselves either parallel or anti-parallel to the field. Upon application of
radiofrequency energy of a specific strength (Larmor frequency) the protons originally
aligned with the field absorb the energy and reverse their direction. Upon removal of the
field they eventually release this energy and relax back into their original alignment. The
rates at which this relaxation occurs are known as T1 and T2 relaxation times. These times
vary with the tissue properties. The relaxation produces a magnetic resonance signal.
Depending on the imaging technique, magnetic pulse sequence, intensity of the signal
and the type of relaxation, a specific region of interest (ROI) in the final image is
represented as a bright or dark spot.99
It is particularly helpful in diagnosis of intracranial anomalies.100-102 One important way
to improve the contrast in MRI is to introduce contrast agents, which are a unique class of
pharmaceuticals that augment the image contrast between normal and diseased tissue.
They can indicate the status of organ function or blood flow by increasing the relaxation
rates of water protons in the tissue in which the agent accumulates.
1.3.4.1. Basic Principals of MRI
Magnetic resonance imaging (MRI) is an imaging technique based on the nuclear
magnetic resonance phenomenon. Due to its ability to provide images of various soft
tissues in the body non-invasively, it has continued to be one of the widely used diagnostic
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techniques for imaging of various organs for nearly last 25 years. In contrast to other
techniques such as computed tomography (CT) and x-rays MRI provides a stronger tissue
contrast and minimum energy deposition in the tissues. The development of various
contrast agents for MRI has further added to the benefits of this technique. Before delving
the field of biomedical applications of MRI contrast agents, this section will provide the
necessary background for understanding the fundamentals of MRI.
In conventional MR imaging, the main source of signal that generates an image is the
nucleus of the hydrogen atom (1H) consisting of a single proton and half-integral value of
this integral spin angular momentum (I = ½), which is abundant in the living tissue in the
form of water and fat.103, 104 The 1H nucleus has one of the largest magnetic moments of
all nuclei, resulting in a significant MR signal. The quantum mechanical properties of the
1

H nucleus impart a high magnetic moment to it.105 Such nuclei with net magnetic dipole

moments have odd number of protons and neutrons.106 When exposed to an external
magnetic field (B), these protons are aligned parallel and antiparallel to magnetic field.
This is essentially a quantized system comprising of two energy levels wherein the protons
with antiparallel spins are at the higher energy level than those with parallel spins. These
protons constantly move or ‘precess’ around the external magnetic field. The speed at
which they precess is known as precession frequency. Precession frequency is governed
by the external magnetic field strength (B).107 The stronger the B value, the higher is the
precession rate and frequency of the protons. The precession frequency is calculated by
the ‘Larmor equation’108
ω 0 = γ. B 0

…Eqn. 1.1

where:ω0 is the precession frequency, γ is the gyromagnetic ratio and B0 is the magnetic field
strength in Tesla (T).
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The ω0 value for 1H protons is approximately 42MHz at B of 1T.104, 105 The opposing
magnetic forces arising from the protons precessing in the opposing directions cancel
each other. Only the magnetizations along the direction of the magnetic field do not cancel.
All magnetic moment vectors add up resulting in net magnetization along the direction of,
or longitudinal to, the applied external magnetic field. This is known as longitudinal
magnetization (M0).109, 110 Thus, if a patient is placed in an external magnetic field of a
MRI scanner, (s)he has a net M0 which cannot be measured. The inability to measure the
static magnetic moment is due to it being in the same direction as that of the external
magnetic field (B) and very small in comparison. However, it is possible to ‘flip’ the net
longitudinal magnetization at a right angle to the direction of the external field by using a
radiofrequency 111 pulse at the ‘Larmor’ frequency. This external pulse provides the energy
necessary to disturb the equilibrium arrangement of the spins parallel and antiparallel to
B and transiently point the net magnetization towards a plane transverse to the external
magnetic field thereby producing a signal, which is recorded by a receiver coil The instant
this 90° RF pulse is turned off, the newly established transverse magnetization gradually
decays by dissipating the stored energy to the surrounding (lattice). This dissipation of
energy results in re-alignment of the magnetization in the longitudinal direction to reestablish the original equilibrium. This process is known as T1 relaxation.104, 112 Once back
to the equilibrium state the protons are ready again for a new RF pulse. However, if the
TR is less (TR < 5.T1), the previous relaxation is not complete and hence the subsequent
RF pulse generates lower signal. This is the source of T1-based contrast since the tissue
with a shorter T1 will undergo a more complete recovery, thereby producing a brighter
signal.
Relaxation is a time-dependent process characterized by relaxation time, which is a
rate constant for this phenomenon. There are two distinct relaxation processes occurring
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simultaneously namely longitudinal relaxation, also known as spin-lattice relaxation,
denoted as T1 and transverse relaxation or spin-spin relaxation, denoted as T2. T2
relaxation occurs due to a complete loss of signal following the RF pulse. It is a
phenomenon dominated by entropy rather than energy transfer. While both T1 and T2
measure the natural energy transfer by an excited proton, they differ in the final disposition
of the energy.
a. Relaxation
Measurement of magnetic resonance (MR) can be analyzed in terms of energy
transfer. The process by which the protons release energy absorbed from the applied RF
pulse is known as relaxation.104 Relaxation is the fundamental property of MR and affords
the principal mechanism for image contrast or MRI.
i. Longitudinal (T1) relaxation
T1 relaxation time is the time required for the disturbed M0 (M) to return to 63% of its
original M0. T1 relaxation provides the mechanism by which the protons give up their
gained energy to return to their original orientation and magnetization (M0). This return of
magnetization typically follows an exponential growth process. T1 relaxation times in the
tissues are relatively slow with the values ranging from few milliseconds to several
seconds.113, 114 In practice pulsed RF energy is applied to the protons repeatedly with a
delay time (TR) between the pulses, which allows for T1 relaxation to occur. As the protons
return to their original orientations, a difference is established between protons in the
parallel and anti-parallel spins. This allows for the energy absorption to recur after the next
RF pulse. These repetitions cause more dissipation of energy and hence generation of a
larger signal following repeated pulses. TR is generally insufficient for complete T1
relaxation to occur. Application of a second RF pulse before complete relaxation causes
M to flip again in the transverse plane, albeit with a smaller magnitude than the previous.
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After a few repetitions M returns to its original magnitude prior to the RF pulse, thus
achieving a steady state value, which depends five parameters namely106, 110, 113
1. The external magnetic field B. The larger the field, larger is M
2. Proton density per unit volume of the tissue
3. The amount of energy absorbed by the protons (flip angle)
4. The repetition time or rate of RF pulse application
5. T1 relaxation time
The repetition time (TR) is a critical parameter since it controls the efficiency of energy
transfer. If TR is significantly smaller than T1 relaxation time, the spin will not relax
completely and hence the next pulse will produce a proportionately smaller magnetization
signal which will undergo relaxation at a faster rate, thereby producing a brighter signal.
In practice, each tissue saturates differently due to different T1 relaxation times, which
affects its maximum potential signal.
As discussed previously, spin-lattice relaxation measures the rate of energy transfer
from an excited proton to the surroundings. Such a transfer also relies on the presence of
either a vibrational or rotational molecular motion of the lattice in the vicinity of the excited
protons. The intrinsic frequency of such a motion (ωL) matches ω0. The closer these two
frequencies are, the sooner do the protons return to their equilibration state.105 Thus the
presence of several protein structures and metal ions in the tissue greatly influences the

ωL. Iron (Fe) and Manganese (Mn) have significant magnetic moments that can potentially
affect the local environment. T1 decreases with decreasing B. However, a larger B does
not necessarily mean a greater signal since longer T1 times are prone to saturation.113
ii. Transverse (T2) relaxation
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T2 relaxation or spin-spin relaxation time is the time required for the transverse
component of M to decay to 37% of its initial value, the loss of signal occurring due to
irreversible processes. As described previously, when a RF pulse is applied, the
precessing protons absorb this energy and hence the longitudinal magnetization (M0) is
disturbed and rotates in the transverse plae.103, 105, 106, 113
When in the transverse plane, all protons precess with the same Larmor frequency ωO.
Thus a proton having a similar molecular milieu and precessing with the same frequency
can absorb the energy being dissipated by its neighboring proton. This transfer of energy
from between two excited protons of the same kind in a similar environment is called spinspin relaxation. The absorbed energy is retained as spin relaxation without being
transferred to the surroundings as in T1 relaxation. Several inter and intra-molecular
interactions such a vibrations and rotations cause transient fluctuations, which lead to
gradual loss of the transverse magnetization. T2 is the time when this transverse
magnetization is at 37% of this original value immediately after the RF pulse. If the TR is
faster than the relaxation time, the corresponding M will rotate continuously and while
doing so gradually decrease in magnitude until it disappears as the proton populations at
the higher and lower energy levels will equalize leading to zero net magnetization. As a
result, no signal is produced; a condition known as saturation or magnetization saturation
(Ms).115, 116 There is a limited amount of energy that the protons can absorb before reaching
saturation. If more time relapses, this transverse coherence completely disappears and
T1 relaxation occurs. One important difference between T1 and T2 relaxation is the
influence of B. T1 is sensitive to B while T2 is relatively insensitive to B.
1.3.4.2. Contrast agents
MRI revolutionized the field of medical diagnostics. It has perhaps been the most
powerful method for the non-invasive investigation of human anatomy, physiology and
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pathophysiology. Compared to other imaging techniques, such as computed tomography
(CT), MRI does not involve radiation or radionuclides and provides significant amount of
intrinsic contrast between different tissues, making it widely used in neurological,
musculoskeletal, cardiovascular, and oncological imaging. This contrast is based upon
different signal intensities between the adjacent tissues. This contrast is obtained primarily
due to the differences in the T1/ T2 relaxation times of the different tissues accentuated by
the chosen parameters such as TR and TE.
In spite of this intrinsic contrast between the tissues, distinction between diseased and
normal tissue can still be challenging as the pathological organ may have similar T1/ T2
times as that of the adjacent normal tissue. In other situations, the region of interest may
contain significant amounts of normal tissue, making the contrast low. In either case, a
promising approach is to increase the signal difference between normal and pathologic
tissue, which can be achieved successfully by administering a suitable contrast agent.
Contrast agents for MRI are indirect contrast agents. Unlike those used in CT (direct
agents), most MRI contrast agents are indirect agents and not visualized directly in the
image. Instead, they affect the relaxation times of the numerous water protons in the
nearby tissue. The concentrations at which these agents are used are also very low,
thereby explaining the low occurrence of side effects to MRI agents. MRI contrast agents
can be categorized into three groups with most of them falling into one of two categories:
T1-agents and T2-agents. T1-agents generally increase the longitudinal (spin-lattice)
relaxation rates (1/T1) of water protons in tissue more than the transverse (spin-spin)
relaxation rates (1/T2). With most conventional pulse sequences, this dominant T1lowering effect gives rise to increases in signal intensity predominant on T1 weighted
images; thus, these are positive contrast agents that produce a brighter contrast. On the
other hand, T2-agents largely increase the 1/T2 of tissue rather selectively, leading to
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decreases in signal intensity; predominant on T2 weighted images, and thus these
represent negative contrast agents, which produce a dark contrast. However, non-proton
agents, such as certain perfluorocarbons, by virtue of the absence of hydrogen, do not
affect relaxation rates (or the signal) in MRI but produce low signal intensity at completely
different resonance frequencies (19F) than those of the conventional Gd or iron oxidebased contrast agents. These represent a third class of MRI contrast agents. Whether the
contrast agent functions as a T1-agent or T2-agent depends on a function of the imaging
sequence used, the field strength, the correlation time and how the contrast agent is
compartmentalized in the tissue. The ability of the agent to reduce the T1- and T2relaxation times are respectively described by the r1 and r2 relaxivity values of the agent.
The following section describes in brief, the mechanisms of contrast enhancement in the
presence of T1 or T2 relaxation agents.
a. T1 contrast agents
Almost all T1 relaxation agents currently in clinical use are gadolinium-based
intravenous agents. Gadolinium (Gd) in a rare earth metal with a large magnetic
moment.117, 118 The primary mechanism of contrast generation for T1 contrast agents is by
functioning as a relaxation sink for water protons.119 As described previous in this section,
following a RF excitation pulse, T1 relaxation depends upon the decay of the absorbed
energy from the proton to the ‘lattice’. For the energy transfer to occur efficiently, these
protons should be in the coordination sphere, i.e. in the innermost layer of atoms
surrounding the metal ion.110, 120 Gd-based contrast agents are formulated as Gd chelates
to reduce the toxicity of Gd as a free metal ion.121,

122

These chelate molecules are

relatively larger with multiple bonds to the central Gd metal ion,123 which limits free space
in the inner coordination sphere.110, 113 This limits the fats and other large molecules from
gaining sufficient proximity to central metal ion for efficient energy transfer. However, the
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water present in these tissues can penetrate into the coordination space, dissipate its
energy and subsequently exchange with the bulk tissue water, thus allowing for additional
water molecules to enter the coordination sphere.110 This process occurs very rapidly and
hence the water in the bulk tissue is relaxed and available for the subsequent pulse. As a
result, the tissue water near the contrast agent has a larger net value of M than water in
the neighboring tissue, thus contributing to a greater and brighter signal in a T1-weighted
image. The rapid exchange process ensures that a single Gd-complex can affect
numerous water molecules. This reduces the dose of Gd-based T1 contrast agents.
In addition to gadolinium (Gd3+), the other most common paramagnetic species in
nature are metal ions with unpaired electrons, such as manganese (Mn2+, Mn3+), iron
(Fe2+, Fe3+), lanthanide (La3+) and dysprosium (Dy3+) which have been used in MRI
contrast agents.124-126 The gadolinium ion Gd3+ is the most widely used paramagnetic ion
for MRI contrast agents because it has a high magnetic moment and a symmetric
electronic ground state. However, paramagnetic metals cannot be used as contrast
agents in the ionic form due to their undesirable bio-distribution, very short biological halflives and relatively high toxicities. To address this issue of short circulation times and
severe systemic toxicities, Gd chelates with various stabilizing ligands have been
designed.

Acyclic

and

macrocyclic

polyaminocarboxylates,

such

as

diethylenetriaminepentaacetic acid (DTPA), 1,4,7,10-tetraazacyclododecane-N,Nl,Nll,Nllltetraacetic acids (DOTA), and their derivatives, have been the main ligand used to
stabilize Gd. The Gd (III) chelates such as Gd-DTPA (Magnevist, Schering AG, Germany),
Gd-DTPA-BMA

(diethylenetriaminepentaacetic

acid-(bismethylamide);

Omniscan_,

Amersham-Nycomed, Norway), Gd-DO3A-HP (1,4,7,10- tetraazacyclododecane-1-(2hydroxypropyl)-4,7,10-triacetic acid; ProHance_, Bracco Imaging, Italy), and Gd-DTOA
(Dotarem_, Guerbet SA, France) are currently in clinical use. Gd-chelates have been

29
further modified to target specific tissues in the body. For instance, the first generation
MRI contrast agents, such as Gd-DTPA were modified to form neutral molecules, which
thus exhibit much lower osmolality, longer circulation times and higher safety.127, 128 Some
suitable residues have been incorporated into either the acetic side arms or the
diethylenetriamine backbone of Gd-DTPA and Gd-DOTA to obtain tissue or organ-specific
contrast agents. Thus, Gd-based contrast agents specifically targeted to the liver, tumor
and blood pool have been developed, which can localize in these target sites thereby
producing greater signal in the MR images.129 Gd-based positive contrast agents are in
greater demand and are preferred contrast agents in clinics due to their bright contrast
that enabled clear demarcation and non-invasive visualization of the disease tissue.
Apart from Gd-chelates, Mn-based compounds and ultra-small superparamagnetic
iron oxide nanoparticles (USPIOs; 3-5nm) have also been used to generate positive
contrast. Manganese dipyridoxyl-diphosphate (mangafodipir, Mn-DPDP, Teslascan_,
Nycomed Amersham Imaging, Princeton, NJ) is a contrast agent developed for imaging
of the hepatobiliary system.130 USPIOs, on the other hand, have been incorporated into
numerous nanoformulations such as liposomes,131, 132 micelles,133, 134 polymersomes,135
dendrimers136 to name a few, in order to impart hydrophilicity, enhance stability and most
importantly increase circulation times. Long circulation times are specifically required
since these contrast agents are extensively used blood pool agents.15, 129
b. T2 contrast agents
T2 or negative contrast agents mainly include superparamagnetic magnetite (Fe3O4),
maghemite (ϒ-Fe2O3) (collectively referred to as MNPs hereafter) or their composites with
other ferromagnetic metals such as cobalt (Co), nickel (Ni) and manganese (Mn).137, 138
Paramagnetic substances such as Gd-based complexes have no net magnetization in
absence of a magnetic field.110 However, ferromagnetic macromolecular structures such
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as iron oxide have very high magnetic susceptibility, which can persist even on removal
of the external magnetic field.139 Magnetic susceptibility is the degree of magnetization of
a metal in response to an external magnetic field. This persistence of magnetization
(remnant magnetization) is dependent on the physical properties of the iron oxide such as
particle size.140 These MNPs lose their magnetization upon removal of magnetic field and
hence are known as superparamagnetic nanoparticles.141 Likewise, when an external
magnetic field is applied, due to their high magnetic susceptibility, these nanoparticles
exhibit a very strong net magnetization resulting in distortion of the local magnetic field in
their vicinity.142 The microscopic field inhomogeneity causes the nearby water protons to
dephase more rapidly than the surrounding tissue, thereby leading to significant decrease
in signal intensity as a result of the shortening of the T2 and T2* relaxation times.
Biocompatible MNPs such as magnetite have been widely used for in vivo biomedical
applications including MRI contrast enhancement, tissue specific release of therapeutic
agents, hyperthermia, and magnetic field-assisted radionuclide therapy. Their slower renal
clearance and higher transverse (T2) relaxation values compared to the Gd-based contrast
agents make them more attractive for imaging purposes.143 Biomedical applications
require that the SPIONs be stable in water, in physiological conditions and not be
recognized by the body’s phagocytic mechanisms. Various factors such as core size,
surface charge, surface ligands and chemistry, affect the colloidal stability of the MNPs.
To control the surface properties, MNPs are commonly coated with a biocompatible
polymer, a step that significantly controls the size of the resulting MNP clusters while
preventing formation of large aggregates. In addition, polymer coating can also allow
binding of drugs and targeting ligands onto the MNP surface. Some MNPs with core sizes
of 3–6 nm and dextran coating (with 20–150 nm hydrodynamic sizes) such as Feridex
(discontinued in USA), Endorem, Combidex and Sinerem are approved for MRI in
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patients.144 Recently, Zhao et al.
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synthesized octopod-shaped MNPs with extremely

high T2 relaxivity (six-fold higher) values compared to the spherical counterparts of similar
chemical composition. These MNPs have significantly higher values than all the
commercial MNPs currently available. In addition, drug loaded MNPs have also been
surface-modified with various targeting ligands and can be guided to the desired target
area using an external magnetic field while simultaneously tracking the biodistribution of
the particles.146
Composites of iron oxide nanoparticles are obtaining by replacing a mole fraction of
the Fe moiety by other metals, which exhibit significantly higher (T2) relaxation values.
Magnetite composites with Co having T2 relaxivity values almost 4-fold higher than pure
MNPs have been reported.147 Similar observations have been made with Ni-based MNP
composites.148 However these composites have, so far, suffered from significant toxicity
and biocompatibility issues. Although surface-modification has helped reduce the toxicity
considerably, when compared with pristine MNP formulations these composite cores are
inherently toxic and degradation of the cores has been shown to contribute significantly to
formulation toxicity. Thus, given the extensive research in the field of magnetic
nanoparticles, iron oxide based MNP formulations continue to show tremendous promise
in development as theranostic nanosystems. The fact that these MNPs are already
available for clinical use in European nations and still continues to be used on a proprietary
basis in US further adds to the optimism.

32

1.4.

THERAPEUTIC AREAS WITH POTENTIAL BENEFITS FROM ‘NANO-

THERANOSTICS’
Therapeutic and technological advances in medicine have enabled prompt diagnosis
and improved precision in therapy for many pathological conditions. However, there is a
tremendous scope and an increasing need for improvement in management of certain
diseases.
1.4.1. NON-MALIGNANT NEUROLOGICAL DISORDERS
Nanovehicles capable of carrying multiple payloads present distinct advantages in
targeting the hard-to-reach areas of the brain. Nanoparticles can be surface-functionalized
to readily transmigrate across the blood-brain barrier (BBB), which otherwise posed a
near-impermeable barrier to the delivery of therapeutics to the brain.149 The ability to tailor
nano-formulations as per the requirements of specific pathological conditions is a highly
desired feature. To this end, liposomes serve as the ideal nano-delivery vehicles capable
of carry multiple payloads simultaneously for brain targeting and bioimaging with imaging
agents such as Gd/ MNP-based MRI agents or quantum dots.150, 151 One such example of
brain disorders where nanomedicine and theranostics show tremendous promise is
traumatic brain injury (TBI). Affecting almost 2 million patients annually in the US alone,
there are no FDA approved treatments for TBI. Numerous clinical trials focusing on
conventional single drug therapy have failed.152 Technological advances in proteomics
have enabled the identification of therapeutic pathway-specific biomarkers of TBI.
Although indirect and involving multiple steps, biomarker driven methods of detection and
diagnosis have paved the way for timely and personalized treatment of such patients.
Stroke or cerebral ischemia is another dreaded cerebrovascular condition with very limited
treatment alternatives. The use of theranostics capable of timely treatment and
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subsequent maintenance therapy along with continuous therapy monitoring is considered
to be a very valuable approach to stroke management. To this end, Agulla et al. have
designed stealth immunoliposomes targeted towards HSP72 protein in the peri-infarct
region with dual imaging capabilities (fluorescence and MRI). Loaded with citicoline, these
dual modal theranostic immunoliposomes showed a 30% decrease in lesion volume when
compared to non-encapsulated drugs. Encapsulation of Gd-DTPA-BSA enabled a
continuous monitoring of the targeting efficiency of the formulation, tissue accumulation
and progression of therapy over a period of 7 days.153
During the last decade, there has been an unprecedented increase in the number of
cases of neurodegenerative conditions such as Alzheimer’s disease (AD) and Parkinson’s
disease. The primary hurdle in the management of these conditions is early diagnosis.
CdSe-ZnS quantum dots (QD) conjugated to dihydrolipoic acid have be demonstrated to
successfully detect the amyloid plaques, block their growth and thus reduce the fibrillation
process along with detection.154 Skaat et al.155 used fluorescent maghemite nanoparticles
coated with LPFFD peptide for simultaneous detection, treatment and therapy monitoring.
These theranostic MNPs inhibited the associated fibrillation, which could be monitored by
MRI. In addition, numerous biomarkers such as the new 79-amino acid Alzheimer’s
associated protein ALZAS67 have been identified156, which can aid in early detection of
amyloid plaques, thereby enabling preventive measures against further development of
the condition.
Commercial blood pool agent Endorem® has been used as a marker for long-term
noninvasive MR tracking of transplanted bone marrow and embryonic stem cells in rat
brain and spinal cord.157 In this study, the migration of mesenchymal stem cells labeled
with Endorem could be tracked successfully to the injured site for a prolonged period of
time. While these are only a few representative examples of the relentless efforts currently
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being made towards the development of theranostic systems for brain, they do highlight
the advantages of theranostic nanosystems in several pathological conditions of the brain.
1.4.2. CARDIOVASCULAR DISEASE
Cardiovascular disease is the leading cause of morbidity and mortality all over the
world. Several theranostic nanosystems have been studied for several cardiovascular
conditions with interesting and encouraging findings. Numerous studies have successfully
demonstrated the potential of several theranostic nanosystems in detection and treatment
of atherosclerosis. Certain molecules such as αvβ3-integrin are overexpressed on the
endothelial cells in the atherosclerotic plaques. These molecules serve as direct targets
for long-circulating targeted nanoparticles. Functionalization of nanoparticles to target
macrophages or oxidized low-density lipoproteins (LDL) within the plaques. The ability to
target these processes allows for simultaneous targeting of therapeutic agents as well as
contrast agents. The applicability of theranostic nanosystems was evaluated as follows:
a. Nanoparticulate contrast agents co-delivered with conventional therapeutics to
evaluate the efficacy of the therapy: USPIO’s, popularly used as blood pool agents,
have been shown to have significantly high uptake in macrophages in atherosclerotic
plaques both pre-clinically

158, 159

and clinically160. Morris et al. exploited this finding to

demonstrate the potential of USPIO-enhanced MRI in monitoring the therapeutic efficacy
of p38 kinase inhibitor in mouse model of atherosclerosis. MR images showed reduction
in contrast in the aortic area of animals treated with p38 indicating reduced accumulation
of macrophages in the atherosclerotic plaques in the treatment group.161 This approach
was used successfully for the first time in humans to non-invasively evaluate the efficacy
of treatment of atorvastatin in carotid plaques.

162, 163

Theranostic nanosystems can also

be used in monitoring the treatment of peripheral artery disease. ανβ3-integrin-targeted
perfluorocarbon nanoparticles were used to monitor the effect of dietary L-arginine in
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decreasing the symptoms of peripheral artery disease by increasing arteriogenesis. 164 19F
MRI using perfluorocarbons has been used effectively for the detection of inflammation
due the efficient uptake of these emulsified contrast agents into monocytes and
macrophages, which in turn infiltrate the affected tissue. 165 Targeting of the nanoparticles
to the ischemic tissue enhanced the signal and contrast two-folds in comparison to the
nontargeted nanoparticles thereby significantly improving the ability for non-invasive
monitoring of therapy progression and success wherein oral dietary L-arginine resulted in
significant development of collateral blood vessels in the affect tissue.
b. Nanoparticulate therapeutics co-delivered with free contrast agents to evaluate
efficacy of nanotherapy: Stenotic arteries formed due to progression of atherosclerosis
are often dilated by balloon dilation followed by placement of a metallic stent. However,
restenosis in such arteries often leads to other complications such as myocardial damage
and impeded peripheral circulation. Drug eluting stents, which are often used for such
conditions, can add to the complications by interfering with the healing of the endothelial
membrane. 166-168 αvβ3-targeted rapamycin loaded169 nanoparticles co-encapsulating 20%
(v/v) perfluorooctylbromide and 30 mol% Gadolinium diethylene-triamine-pentaacetic
acid-bisoleate as the paramagnetic components successfully reduced the extent of
stenosis in the related arteries. This improvement was tracked by MR angiograms over a
period of two weeks. Perfluorocarbon-containing nanoparticles conjugated with Phe [D]Pro-Arg-chloromethylketone (PPACK), a molecule with high affinity for thrombin, were
studied in the treatment of thrombosis in a mouse model of thrombosis. The site-specific
accumulation of the 160nm nanoparticles was observed by 19F MRI imaging.170 In another
approach, paclitaxel (PTX)-loaded MNPs were employed to replenish the drug-depleted
stents. While MNPs were used exclusively to aid in targeting and accumulation in the
desired region, fluorescent probes were conjugated on the nanosystems to evaluate the
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therapeutics efficacy as observed by delayed cell proliferation.171 This approach has also
been used to demonstrate improved perfusion of the affected tissue in peripheral artery
disease. Gold nanoparticles carrying vascular endothelial growth factor (VEGF) were
targeted to the ischemic tissue in order to promote angiogenesis and increase perfusion
in a murine hind limb ischemia model. The therapeutic effects of the targeted gold
nanoparticles were visualized by laser Doppler perfusion imaging. The targeted
nanoparticles helped increase the circulation half-life of VEGF while reducing the
undesired side effects. Similarly, adenosine-loaded liposomes administered intravenously
significantly reduced myocardial infarction in murine model.172 Fluorescent ligands
decorated on the liposome surface were used to track the accumulation of the
nanoformulations at the affected site. This formulation was specifically beneficial from the
point of significant reduction in the unwanted side effects of free adenosine when
administered intravenously.
c. Co-encapsulated therapeutic and contrast agents for simultaneous diagnosis
and treatment and subsequent monitoring of therapy: Co-encapsulated theranostic
nano-systems provide significant advantages in terms of spatio-temporal delivery of both
the essential components without measurable loss. This approach helps improve the
treatment and overall management of previously mentioned conditions such as restenosis.
Successful attempts have been made to inhibit the smooth muscle proliferation in the
stented blood vessels. Perfluorocarbon nanoemulsions loaded with anti-proliferation
drugs doxorubicin (DOX) as well as PTX were targeted to tissue factor on the smooth
muscle cells in the restenotic artery walls. In this in vitro study, the uptake of the particles
was detected by T1-weighted MRI imaging while
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F MRI helped further enhance the

contrast and distinguish the tissue from the nanoparticles. The pattern of DOX
fluorescence was monitored to observe and study the pattern of drug release over time.173
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PFCs encapsulated within nanoformulations have shown significant improvement in sitespecific signal enhancement in all cardiovascular conditions associated with inflammation.
The very first study to demonstrate the advantages of co-encapsulation in treatment of
atherosclerosis used perfluorocarbons along with anti-angiogenic drug fumagillin.174 PFCs
were encapsulated in nano-emulsions stabilized by a surfactant co-mixture of lecithin,
polyethylene glycol (PEG)2000- phosphatidylethanolamine, phosphatidylethanolamine and
gadolinium diethylene-triamine-pentaacetic acid-bis-oleate. Fumagillin partitioned into the
surfactant layer surrounding the paramagnetic perfluorocarbon molecule. The therapeutic
response of the drug could be monitored over an extended period of time. Theranostic
nanosystems have also been studied using multiple modes of visualization of a single
contrast agent. Such an approach helps to separate the tracking of the nanosystems from
evaluating the therapeutic efficacy. Labotto et al.175 developed Gd-containing liposomes
co-loaded with anti-inflammatory glycoprotein PLP. The liposomes produced significant
T1-weighted contrast by dynamic contrast enhanced MRI (DCE-MRI), which was used to
monitor the delivery and accumulation of the formulations in the atherosclerotic plaques
while 18F-fluoro-deoxy-glucose (18F-FDG) was injected separately to study the therapeutic
efficacy of the liposomal formulation by PET/CT. In another study, a multi-modal nanotheranostic agent comprising of dextran-coated MNPs and near-infrared fluorophore
AF750 with phototoxic capacity was prepared. These nanoparticles were readily
internalized by murine macrophages as observed in the in vitro experiments. The in vivo
studies revealed preferential accumulation of the nanoparticles in macrophage-rich
inflamed atherosclerotic lesions as visualized by intravital fluorescence microscopy. When
irradiated by 650nm light, AF750 was activated resulting in phototoxicity in the
atherosclerotic area, causing significant reduction in inflammation and lesion stabilization.
Such a theranostic system provided for simultaneous imaging and therapeutic response
by a single multi-purpose NIR fluorophore.176
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While many of the above-mentioned theranostic nanosystems are still in the
experimental stages and thus need further characterization, quality control and
toxicological evaluation, there is no doubt that compared to conventional formulations and
contrast techniques, such theranostic nanosystems have proven to be superior in terms
of therapeutic efficacy as well as continuous monitoring of therapy in several
cardiovascular conditions, predominantly atherosclerosis and stroke.
1.4.3. CANCER
Cancer is steadily growing into a global public health problem and is feared to take
over cardiovascular diseases and obesity as the disease with the highest mortality and
morbidity rates. Cancer statistics of 2014 estimated over 1.6 million new cases and over
500 thousand deaths in the United States itself.177 These numbers justify the federal
emphasis on research aimed at prevention, early diagnosis and therapy of cancer. Given
the diverse nature of the disease, every new case is unique in terms of the diagnosis, the
molecular markers expressed and the response to therapy. These complexities have
spurred concerted efforts in the direction of personalized therapy wherein each patient’s
biomarker profiling is recommended to design and optimize the therapeutic strategy.
Nanomedicine, via its extensively target-centric approach, has opened new avenues,
which can enable early diagnosis and highly personalized anti-cancer therapy. The ability
to functionalize nanoparticles to target different types of diagnostic and therapeutic
payloads exclusively to the malignancy helps reduce the dose, enhance accumulation of
the therapeutic and also significantly reduce the incidence of unwanted side effects that
plague conventional cancer treatments. The need to detect the malignancy in early
stages, treat it and simultaneously monitor the progression of therapy noninvasively is a
highly desired feature in cancer chemotherapy. This has given rise to what is termed as
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‘cancer theranostics’, i.e. simultaneous therapy and non-invasive diagnostic monitoring of
the disease.
The development of a theranostic nanosystem for cancer is guided by numerous
factors. The location and stage of the disease is a primary factor which dictates the type
of contrast agent to be selected. With that in mind, several potential theranostic anticancer nanoformulations have been reported so far. Radio-theranostic nanosystems
(discussed in section 1.3.2.) are the most versatile since the diagnostic component is not
quenched in deeper tissues and can be consistently monitored. Radiopharmaceuticals
can be used for the treatment of the deepest tissues in the human body such as for
treatment and imaging of bone metastasis.178 Recently, nanobodies radiolabeled with
99

mTc were generated against the paratope of M-protein expressed in multiple myeloma

cells as a tool to image multiple myeloma progression using SPECT/microCT. Targeted
radionuclide therapy using a

177

Lu-labeled anti-5T2 MM nanobody led to an inhibition of

disease progression.54 Optical theranostic nanosystems have also been shown to be
successful. Zhang et al.179developed a multifunctional nanocomposite by loading copper
sulfide (CuS) into Cy5.5-conjugated hyaluronic acid nanoparticles (HANP), obtaining an
activatable Cy5.5_HANP/CuS (HANPC) nanocomposite. Cus quenched the Cy5.5
fluorescent signal inside the intact particles. Upon complete degradation by hyaluronidase
present in the tumor stroma, strong fluorescence signals delineated the tumor. Thus, CuS
with strong NIR absorbance appears to be an excellent contrast agent for photoacoustic
(PA) imaging and an effective PTT agent.
Ultrasound mediated imaging is another technique with potential for applications in
different types of cancer, given the ability of ultrasound to penetrate deep in the body
tissues.180 Carson et al. demonstrated the use of targeted ultrasound microbubbles in
squamous cell carcinoma for detection and burst-initiated siRNA release and therapy.181
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Liposomes have been used extensively in ultrasound-assisted anti-cancer therapy.
Microbubbles conjugated with paclitaxel (PTX)-loaded liposomes were targeted towards
breast cancer.182 Other optical theranostic nanosystems such as porphyrins have also
been successfully shown to inhibit tumors. Shi et al.183 successfully investigated the
potential of a 64Cu-containing nanosystem comprising of porphyrin-peptide-folate
nanoprobe for simultaneous PDT and PET imaging. However, it must be noted here that
PDT application are limited to superficial cancers such as those of the head and neck
since activation of the porphyrin in deeper tissues is difficult. Similar argument can be
made for theranostics with AuNPs for photothermal therapy combined with photoacoustic
imaging. Lastly, MRI contrast agents are another extremely versatile choice across all
types of cancers. The advances in MRI technology enable whole body scans with
excellent contrast between malignant and healthy tissues, including those in the brain. In
the next section we exclusively discuss these applications of magnetic (iron oxide)
nanoformulations.
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1.5. APPLICATIONS OF MAGNETIC NANOPARTICLES (MNPS) IN CANCER
THERANOSTICS
The biocompatibility and biodegradability of magnetic nanoparticles, particularly of
those made from magnetite, coupled with its MRI capability makes them ideal candidates
for numerous biomedical applications. The ease of stabilization and case-specific
functionalization (personalization) of these MNPs finds use in cancer diagnosis,
therapeutics and therapy monitoring. Here we review the different applications of MNPs
and their nanoformulations in overall management of cancer.
1.5.1. MAGNETIC FLUID HYPERTHERMIA (MFH) AND IMAGING
When MNPs are exposed to an alternating current (AC) magnetic field, the resulting
eddy current, hysteresis, and energy losses due to Neél and Brownian relaxation
mechanism experienced by the MNPs result in localized heating in the associated tissue
around the nanoscale source.184 It is known that cells, when exposed to elevated
temperature of about 42-45 °C for sufficient time period initiate apoptotic processes
leading to cell death.185 The capacity to combine MRI capability and therapy in the form of
hyperthermia as well as the possibility of functionalizing particles specific to a patient’s
biomarkers has directed research in this direction to further advance the use of magnetic
nanoparticles in cancer treatment. Classical hyperthermia is known to induce a reversible
damage to cells and tissues and has been known to work very effectively as an adjunct
treatment to conventional radiotherapy or chemotherapy. Maier Hauff et al. studied the
efficacy of intratumorally administered MNPs and radiotherapy on patients with recurrent
gliobloastoma multiforme.186 It was observed that pre-treatment with field –induced
hyperthermia followed by radiotherapy led to longer overall survival following diagnosis of
the first tumor recurrence. The efficacy of the treatment regimen was monitored by regular
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MRI and CT scans. Another study conducted in prostate cancer patients evaluated the
ability of transperinially administered MNPs in monitoring the therapeutic responses of
repeated magnetic fluid hyperthermia (MFH) by CT.187 Simultaneous MFH and MRI
imaging faces challenges related to the properties of MNPs.188 For successful MFH is it
essential that MNPs be localized in the target tissue in high enough concentration.
However, this interferes with ability of MR scanners to produce clear images. At high
enough concentration MRI images are not without any artifacts and hence CT is the
preferred technique in such cases. This has prompted the development of composite
MNPs wherein Fe is doped with high metals such as Co, Mn or Ni in order to increase the
specific absorption rate (SAR) of the resulting MNPs. Such an approach is driven on the
hypothesis that composite MNPs, due to their high SAR will be able to generate sufficient
localized heating at significantly lower concentrations, which can aid in obtaining better
images by MRI itself. Nonetheless,

the

application

of

MNPs

in

simultaneous

hyperthermia and targeted chemotherapy has been successfully tested in human trials as
well189-191 which has renewed the interest in applying MNPs for dual therapy in cancer.
1.5.2. SIMULTANEOUS CHEMOTHERAPY AND MRI
Over the last decade, the availability of a broad range of polymeric and other
biodegradable and biocompatible has led to an explosion in the research in the direction
of development of magnetic nanoparticle-based theranostic systems capable of carrying
a therapeutic payload and simultaneously enabling MR imaging. The ease of
functionalization of these nano-systems has made it possible to target them to patientspecific biomarkers. Extensive research in cancer genetics has shown that cancers show
significant heterogeneity and hence the concept of ‘one size fits all’ cannot work at least
here.192, 193 This has brought about a paradigm shift in the process of oncological drug
development. The focus is now on designing targeted or personalized therapies as per
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the genetic constitution of the disease in every patient. A classic example is breast cancer
wherein different cases present with different biomarkers or, still worst, none at all.194 The
human epidermal growth factor receptor overexpressed in several cases of cancers has
many subtypes namely HER1/EGFR, HER2, HER3 and HER4.195 Accordingly, the
therapeutic strategies differ. For instance, Tarceva® (erlotinib) is the preferred line of
therapy to target HER1 in patients with non-small cell lung cancer (NSCLC). HER2,
overexpressed in breast and ovarian cancer is targeted using mAb Herceptin®
(trastazumab).
Theranostic nanomedicine shows tremendous potential in not only targeting, but also
controlling the release of the payload and monitoring the therapeutic response. Schleich
et al.196 compared the different in vivo targeting strategies of PLGA nanoparticles coloaded with PTX and MNPs. They concluded that dual targeting (i.e. active targeting of
αvβ3 integrin via RGD grafting along with magnetic targeting) resulted in maximum
accumulation of nanoparticles which in turn enhanced therapeutic and MRI contrast
efficacy. Thermoresponsive anti-cancer nanosystems have also been developed to
control the release of the therapeutic payload via the hyperthermic potential of MNPs.
Purushotham et al.197 developed core-shell magnetite (Fe3O4)–poly-n-(isopropyl
acrylamide (pNIPAM) composite MNPs loaded with DOX. In an alternating magnetic field,
the MNPs generated heat leading to localized temperature rise. Above the lower critical
solution temperature of PNIPAM, the nanostructure released DOX thus acting as an on/off
switch to control drug release. Clares et al.198 reported the development of
magnetoliposomes loaded with 5-fluorouracil (5-FU) for the colon cancer. These nontargeted formulations showed thermo-responsive release of 5-FU in response to local
hyperthermia in AC field.
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Physiological stimuli-responsive MNP-based theranostic systems have also been
designed to control the drug release form the nanocarriers. Luo et al.199 exploited the
presence of intra-cellular redox conditions to trigger drug release from MNP-cyclodextrin
nanoformulations loaded with camptothecin. Li et al.200 went a step further by developing
folate-targeted magnetic bovine serum albumin microcapsules loaded with coumarin-6.
The microcapsules exhibited redox-responsive enhancement in drug release. The pH
difference between healthy tissues and tumor microenvironment has also been utilize pH
responsive theranostic nanosystems. Sahoo et al.201 designed DOX-loaded theranostic
MNPs comprising of pNIPAM. These systems showed preferentially release of DOX
conjugated via a pH labile linker only under physiological temperature. Another interesting
attempt was made by Gan et al., who developed ‘MNP-gated’ mesophorous silica
nanoparticles. In this system, MNPs capped the pores on the drug loaded silica
nanoparticles via pH labile linkers. At acidic pH the MNPs opened the pores thereby
causing controlled release of the payload.
Several successful attempts have been made to employ low frequency non-heating
AC magnetic field to release the drug from the theranostic MNPs. In one such example,
polymersomes were loaded with USPIOs and DOX were tested for field-responsive in vitro
drug release and cytotoxicity in HeLa cells.135 They observed that when exposed to 15mT
fields at 750 KHz, the formulation exhibited 18% increase in cytotoxicity. It was postulated
that in response to Neel relaxation mechanisms, the MNPs dissipated heat, which was
sufficient enough to cause poration in the polymersomal membrane and thus release the
therapeutic agents. In the last of their series of four publications demonstrating the
application of various stimuli for drug release from ‘gated mesoporous silica
nanoparticles’, Thomas et al.202 demonstrated that in presence of external AC magnetic
field having a frequency of 500kHz and 37.4 KA/m field strength, Zn-doped MNPs
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generated local heat, which caused the cucurbit(6)uril nanovalves on the pores to open
and release DOX. Controlling the duration of the applied AC field pulse could control the
drug release. These gated systems could also serve as theranostic systems for MRI
imaging.
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1.6. CONCLUSION
Theranostics is emerging as a new field that combines the modalities of therapy and
diagnostic imaging. Nanotechnology holds the key to the fructification of this vision. The
ability to ‘pack’ therapeutic and diagnostic modalities in a single carrier helps overcome
unwanted differences in biodistribution, selectivity thereby ensuring the simultaneous
presence of both the components in the desired site. The eventual aim of the field of
theranostics is to gain the ability to image and monitor the diseased organ, drug delivery
kinetics, and therapeutic efficacy, eventually being able to tune the therapy and dosing as
per the needs of the patient. Clinicians are increasingly advocating such personalization
of therapy. In fact, numerous cancer treatment centers across the US, have started
studying the genetic make-up of the patients in order to design a treatment strategy on a
case-by-case basis. However, given the short response time available once diagnosed
with fatal diseases such as cancer, it is an uphill task to formulate a personalized
formulation with required precision. Hence the onus is now on researchers in the field of
Pharmaceutics and drug delivery to device techniques for addressing this need. As
exemplified in this overview, tremendous efforts are underway in the direction of
development of theranostic nanoformulations for numerous pathological conditions. In
terms of imaging modalities, there are various options available, from simple fluorescence
based systems to complex ultra-sound based photoacoustic agents, each with its
advantages and disadvantages. However, in case of MNP-based theranostic
nanosystems, thanks to the relentless efforts for the last two-three decades, the
advantages outweigh the limitations. The ability to tune almost every character of MNPs,
from their magnetic properties to addition of various targeting moieties makes them a
favorable choice, especially for cancer management. One factor that still plagues this
class of theranostic systems is their systemic stability and associated toxicity.
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We aim to design highly stable and completely biodegradable MNP-based theranostic
nanoclusters capable of targeted drug delivery and MR imaging. Given that the primary
requirement in a theranostic system is to strike a right balance between the amounts of
therapeutic and contrast agents carried by the nanocarrier, development of such a
nanosystems is a very complicated process. Through the next chapters we demonstrate
the challenges faced and the strategies employed to meet these challenges in
development of theranostic magnetic nanoclusters for cancer theranostics.
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CHAPTER 2
LHRHR-TARGETED MAGNETIC NANOCLUSTERS STABILIZED
BY BIS-PHOSPHONATE-MODIFIED POLY (GLUTAMIC ACID)-BPOLY (ETHYLENE GLYCOL) FOR OVARIAN CANCER
THERANOSTICS
2.1. INTRODUCTION
Recent advances in nanomedicine have shown the capability to realize the
long-desired spatio-temporal delivery of drugs, genes and imaging agents. Enhancement
in material sciences has enabled the design of nano-carriers capable of releasing their
payload in response to specific biological stimuli such as pH1-3, temperature4-6, redox
potential7-9 etc. Over the last two decades, superparamagnetic iron oxide nanoparticles
(MNPs) have been studied comprehensively and used in a wide variety of fields ranging
from high capacity data storage and water purification10 to numerous biomedical
applications such as protein and antibody detection11-13, protein14 bacteria15 and toxin16
separation and most importantly as magnetic resonance imaging (MRI) contrast agents15.
The ability of MNPs to interact with protons of water molecule and shorten their transverse
(T2) relaxation times produces dark T2-weighted negative contrasts in the accumulating
tissues. The MRI capacity of MNPs had been applied clinically for diagnosis of several
diseases. MNP formulations have been designed and used clinically as blood pool agents
in magnetic resonance angiography (MRA)17, 18 for imaging of the aortoiliac region and
coronary arteries.19

This Chapter is reprinted with permission from ‘Vishwasrao, H. M.; Master, A. M.; Seo, Y. G.; Liu, X. M.;
Pothayee, N.; Zhou, Z.; Yuan, D.; Boska, M. D.; Bronich, T. K.; Davis, R. M.; Riffle, J. S.; Sokolsky-Papkov,
M.; Kabanov, A. V., LHRH-Targeted Cisplatin-Loaded Magnetite Nanoclusters for Simultaneous MR Imaging
and Chemotherapy of Ovarian Cancer. Chemistry of Materials 2016.’ Copyright 2016. American Chemical
Society (Just Accepted Manuscript Apr 11, 2016)
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The first-generation commercial MNP-based MRI contrast agents such as Feridex®
showed a higher propensity for aggregation in vivo and rapid systemic clearance.20,
21

.Rapid clearance necessitates an increased dose to achieve the desired contrast, which

in turn induces toxicity. All these factors seem to have led to the withdrawal of Feridex®22
in the United States. To be clinically relevant, negative contrast agents depend on higher
transverse (T2) relaxivity. Transverse relaxivity is governed by several factors such as
MNP core size, chemical nature, oxidation state, applied magnetic field, site-specific
uptake and proximity of the metal ions to the water. A formulation that enables deeper
penetration of the water molecules towards the magnetic core allows for faster relaxation
of the protons and a higher T2-relaxivity. Clusters of magnetic nanoparticles experience a
greater force than single, well separated MNPs in a magnetic field gradient.23 Several
successful attempts have been made to functionalize MNPs with therapeutic agents for
specific disease. Such ‘theranostic’ systems, as they are termed, present a desirable
improvement in cancer chemotherapy due to their ability to target the tumor and
simultaneously allow noninvasive visualization and treatment24 25. Development of a MNPbased theranostic nanosystem is an intricate task as it requires correct balance of the
diagnostic and therapeutic components. For example, biodegradable polymersomes
loaded with MNPs and doxorubicin exhibited magnetic field-responsive drug release along
with excellent MRI contrast.26.Similarly MNP clusters stabilized by Pluronic® F127 and
loaded with doxorubicin have been shown to exhibit a sustained drug release in vivo while
simultaneously enabling MR imaging of the target tumor tissue.27 However, formulationrelated issues such as colloidal stability and toxicity still hinder the clinical development of
such MNP-based ‘theranostic’ systems.
Selection of an appropriate polymer for coating is critical to ensure colloidal stability,
long circulation times of the MNCs and to allow effective drug loading. The need for
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biocompatibility and biodegradability of the polymer further limits the choices. Block
ionomers comprising of biodegradable charged poly (amino acid) chains can serve as
ideal stabilizing agents for formation of MNCs. Each year there are about 22,000 new
cases and over 14,000 deaths annually due to ovarian cancer in the US.28 In spite of the
dose limiting nephrotoxicity and other severe side effects,29 cisplatin still remains the first
line of treatment for ovarian cancer. To address the severe toxicity, several successful
attempts have been made at loading cisplatin into nanoparticles and targeting it
exclusively to the malignancy via several targeting ligands. For instance, previously,
cisplatin was incorporated within folate-receptor targeted nanogels to successfully treat
folate-receptor-positive ovarian cancer xenografts in mice.30 The membrane receptor for
Luteinizing hormone releasing hormone (LHRHr) is overexpressed in more than 70%
human ovarian cancers31-33. Luteinizing hormone releasing hormone peptide (LHRH), a
synthetic analogue of the nautral hormone has been used to successfully target
chemotherapeutic agents to LHRHr overexpressed on the tumor tissue.34,

35

LHRH-

targeted nanogels conjugated with cisplatin were used to enhance the in vivo cytotoxic
efficacy in treatment of LHRHr-positive ovarian cancer xenografts in mice.36 In a separate
study MNPs were conjugated directly with LHRH-peptide in order to improve the uptake
in LHRH overexpressing breast cancer cells.37
Herein we report a simple process for formulation of theranostic MNCs for anti-cancer
therapy and simultaneous MR imaging. The MNCs were prepared by stabilization with
anionic bisphosphonate-modified poly (glutamic acid)-b-(ethylene glycol) (PLE-b-PEG) by
an entirely hydrophilic route. The MNCs were loaded with cisplatin though electrostatic
interactions and LHRH was conjugated to the MNCs surface as targeting moiety. Stable
cisplatin-MNC conjugates (PtMNCs) exhibited selective uptake, cytotoxic efficacy
comparable to free cisplatin and significantly higher T2 relaxivity than Feridex® in LHRHr
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overexpressing A2780-wild type (A2780-WT) and cisplatin-resistant (A2780-CisR) ovarian
cancer cells. The LHRHr targeted MNCs is an effective T2 contrast agent for simultaneous
chemotherapeutic efficacy in LHRHr-positive tumors.

2.2. EXPERIMENTAL SECTION
2.2.1. MATERIALS
Chemicals: Poly (glutamic acid)-b-poly (ethylene glycol) block copolymers with different
poly (glutamic acid)

38

block lengths namely PLE10-b-PEG113, PLE50-b-PEG113, PLE100-b-

PEG113 and poly (aspartic acid)100-b-PEG113 (PLD100-b-PEG113) and the respective
homopolymers were purchased from Alamanda Polymers (Huntsville, AL). Here and
below the numbers in subscripts after the copolymer blocks define the number of the
repeating units (r.u.) in the respective block. The free end of PEG contained methoxy
groups. Alendronate sodium trihydrate was purchased from Ultratech (Navi Mumbai,
India). 1-Ethyl-3-(3-dimethylaminopropyl)-carbodiimide (EDC), N-hydroxysuccinimide
(NHS), iron (III) acetylacetonate (Fe(acac)3), benzyl alcohol (anhydrous), nitric acid
(TraceSELECT), hydrochloric acid (TraceSELECT), ICP grade standards for Fe, Pt and P
(Fluka) and 3-(4,5-dimethylthiazol -2-yl)-2,5-diphenyl tetrazolium bromide (MTT) were
purchased from Sigma-Aldrich (St. Louis, MO). Acetone (histology grade), n,ndimethylformamide (DMF), cisplatin, Pyridine, DMSO and all other anhydrous HPLC grade
organic solvents were purchased from Thermo Fisher Scientific (Waltham, MA). Nhydroxysulfosuccinimide (S-NHS) was purchased from Covachem (Loves Park, IL). DLys-6-LHRH (Glp−His−Trp−Ser−Tyr−DLys−Leu−Arg−Pro−Gly) peptide was purchased
from American Peptide Company (Sunnyvale, CA). Alexa Fluor®-647, Lysotracker Green
and Hoechst 33342 were purchased from Life Technologies (Carlsbad, CA).
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Cell lines: A2780 wild-type human ovarian cancer cells were purchased from American
Type culture collection (ATCC, Manassas, VA). Cisplatin-resistant A2780 human ovarian
cancer cells were derived from the wild-type cells by repeated exposure to sub therapeutic
concentrations of cisplatin over a prolonged period.
2.2.2. METHODS
2.2.2.1. One-pot Synthesis of Magnetite Nanoparticles
Magnetite nanoparticles (MNPs) were synthesized by thermal decomposition of iron
(III) acetylacetonate (Fe (acac)3) in benzyl alcohol with minor modifications to the method
developed by Pinna et.al.39 Briefly, 6.2 μmoles of Fe (acac)3 was charged to a threenecked flask containing 45mL anhydrous benzyl alcohol. The reaction mixture was heated
at 110°C for 1h to ensure complete evaporation of water. The size of the MNPs was tuned
by subsequently varying the heating rates of the reaction. Four different heating profiles
were employed as described below and depicted in Figure 1.
Profile A: The reaction mixture was heated gradually at 0.4°C/min to 205°C. Once at
reflux the temperature was kept constant for 40h.
Profile B: The mixture was heated to 150°C at 4°C/min and kept isothermal at 150°C for
2h following which the temperature was raised to reflux at 4°C/min and heated for 40h at
reflux.
Profile C: The reaction mixture was heated to 180°C at 4°C/min and kept isothermal at
180°C for 2h after which the temperature was raised to reflux at 4°C/min and heated for
40h at reflux.
Profile D: The reaction mixture was heated quickly at 5°C/min to reflux and heated at
reflux for 40h.
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All the reactions were conducted under inert atmosphere. After cooling, the
nanoparticles were precipitated and washed in acetone. The final product was collected
by magnetic separation, dried under vacuum and stored for further use under vacuum in
a sealed vial filled with argon. The benzyl alcohol content in the final product was
estimated by thermogravimetry (TGA; TGA Q50, TA Instruments, DE). Briefly, 20 mg
sample was heated at 5°C/min to 1000°C. Benzyl alcohol content was obtained by
subtracting the weight of the residue from the initial weight of the sample. The saturation
magnetization (M; emu/g) of the smallest and the largest particles obtained was
determined by SQUID-VSM (Quantum Design Co.) at 300 K.
2.2.2.2. Alendronate Conjugation to PLE50-b-PEG113
Prior to ALN conjugation, PLE50-b-PEG113 sodium salt was de-protected by dissolving
in de-ionized water and acidified by slow addition of 0.1N HCl to restore the carboxylic
acid functionality. The precipitate was dialyzed overnight against de-ionized water and
lyophilized to obtain the de-protected polymer. For the conjugation reaction, 5μmoles of
the de-protected polymer was dissolved in 3mL DMSO. In a separate vial, 0.16 mmoles
EDC and 0.8 mmoles NHS were dissolved in 0.5mL DMSO and added to the polymer
solution. The reaction mixture was stirred for 4h at RT. 0.44 mmoles ALN.Na was
dissolved in 4mL de-ionized water followed by adjustment of the pH to 9.5 by addition of
NaOH. The EDC-NHS-activated PLE50-b-PEG113 in DMSO was added dropwise to the
aqueous solution of ALN and the reaction was stirred for 48h. The unconjugated ALN as
well as the reaction by-products were removed by centrifugal filtration through 3000
MWCO PES centrifugal membrane filters (Sartorius, NY) and the resultant ALNconjugated PLE50-b-PEG113 was lyophilized. The ALN conjugation was confirmed
qualitatively by

31

P-NMR. The degree of conjugation (Dconj) was quantified from 1H-NMR

of the final ALN-conjugated polymer by comparing the integrals of the multiplet of the
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conjugated ALN at 3.0 – 3.22 ppm with the broad singlet of the H-atom on the chiral carbon
of PLE block at 4.0 – 4.34 ppm (Figure 2.5) and by inductively coupled plasma mass
spectrometry (ICP-MS).40 Briefly, a standard curve was prepared from commercial
standard solution of phosphorus (Fluka) in the 50 – 500 ppb concentration range. The
lyophilized polymer was dispersed in 1 ml of DI water at a concentration of 1mg/mL. 50
μL concentrated HCl (TraceSELECT) was added to it and the mixture was incubated at
70°C for 12h. The sample was allowed to cool to room temperature (RT) after which the
volume was adjusted to 2mL with DI water. The final solution was filtered through 0.2μm
nylon syringe filter and analyzed by ICP-MS to quantify the bisphosphonate end groups in
the polymer using argon and oxygen carrier gases.
2.2.2.3. Preparation of Polymer-Stabilized MNCs
a. 30-40nm MNCs: Briefly, the polymer was dissolved in 10 mL alkaline water (pH 9-9.5)
and added to a 10 mL MNP dispersion in alkaline water (pH 12) in a 2:1 (w/w) ratio.
b. 65-85nm MNCs: Larger sized MNCs were obtained by dissolving the polymer and
MNCs in 5mL of respective solvents.
The mixture was then stirred for 12-15h followed by extensive dialysis for 72h, with six
water changes. To obtain the final product, the dialyzed mixture was further purified by
filtration through 0.45 and 0.22 μm Whatman Anotop syringe filters, lyophilized to dryness
and stored under vacuum in a sealed vial filled with argon for further studies.
2.2.2.4. Preparation of Cisplatin-Loaded MNCs
Cisplatin was loaded by electrostatic interactions onto the free carboxyl groups of the
PLE block of the MNCs. Briefly, prior to loading the number of moles of carboxyl groups
available were quantified by potentiometric titration. The MNCs were dispersed in
deionized water at 5-10mg/mL. The pH of the colloidal dispersion was adjusted to 9.5 with
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NaOH. Cisplatin (equivalent to 50 or 75 mol% of the available carboxyl groups in the
formulation) was dissolved in n,n-dimethylformamide (DMF) and added under stirring to
the colloidal MNCs. The solution was stirred for 48h in the dark. The unconjugated cisplatin
was separated by centrifugal filtration (2000-MWCO, Sartorius, location USA) and the final
product was lyophilized and stored in vacuum at -20°C for further use.
2.2.2.5 Preparation of LHRH-conjugated MNCs
DLys6-LHRH was conjugated to the free carboxylic groups on MNCs by EDC/sulfoNHS coupling reaction via the D-lysine group on the peptide. Briefly, 10mg lyophilized
MNC or PtMNC formulations were dispersed in MES buffer (pH 6; 0.05M) at a
concentration of 20 μg/mL. EDC/sulfo NHS (3 equiv/6 equiv) at RT was used to activate
5 mol% of the total available carboxylic groups (concentration of carboxylic groups was
calculated by potentiometric titrations) for 2h. The excess of the unreacted chemicals was
neutralized by 2-mercaptoethanol (20mM). (D-Lys6)-LHRH was dissolved in PBS (20mM,
pH 7.4) at a concentration of 10mg/mL. 0.4mL of this solution was mixed with the activated
MNC and PtMNC formulations. pH of the mixture was adjusted to 7.4 and the solutions
were stirred for 7h at RT. The dispersions were purified by centrifugal filtration (3000
MWCO; 3 washes) to remove the unreacted peptide and other reactants. The final
formulations were lyophilized and stored under vacuum at -20°C for further use.
2.2.2.6. Physiochemical Characterization of MNCS
a. Dynamic light scattering (DLS). The z-average hydrodynamic diameter (Deff),
polydispersity index (PDI) and ζ-potential was determined by DLS using a Malvern
Zetasizer (Malvern Instruments, MA, and USA). The concentration of the dispersed phase
was 1 mg/mL
b. MNC composition. The composition of the unloaded MNCs was determined by
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thermogravimetric analysis (TGA). Briefly, 5-10mg of the lyophilized unloaded-formulation
was placed on the tared TGA pan. The formulation was dried in the furnace at 110°C in
order to remove the moisture followed by steady heating at 5°C/min to 1000°C. The
obtained thermogram was analyzed using the Universal Analysis software (TA
Instruments, DE) to deduce the total loss of the organic components

41

and amount of

MNPs per mg of MNCs. The content of benzyl alcohol coating was determined by loss of
organic components upon thermal decomposition of MNPs by TGA. The LOI of MNCs
was corrected by subtracting the content of benzyl alcohol in the MNPs to obtain the
content of polymer in the MNCs.
c. Relaxation measurements: A Bruker Biospec MRI and spectroscopy (MS) system
(7T/21 cm, Bruker, Karlshure, Germany) was used to determine the longitudinal (r1) and
transverse (r2) relaxivities of the different MNC formulations. The sequence used for T2
mapping was a CPMG phase cycled single slice multiecho sequence. One 1 mm thick
coronal image was acquired with an acquisition matrix of 256 x 128, 40 mm field of view,
32 echoes at 10 ms first echo time and 10 ms echo spacing, repetition time of 3000 ms,
one average, for a total acquisition time of 6.4 min. The stabilized colloidal particle
dispersions were diluted to 0, 0.018, 0.045, 0.09, 0.18, 0.27 and 0.36 mM Fe with distilled
water and 20mM PBS. T1 and T2 relaxation times were measured and converted to their
corresponding relaxation rates (R1 and R2; 1/T; s-1). The r1 (longitudinal relaxivity) and r2
(transverse relaxivity) values (s-1.mM-1) were obtained as the slope of the plots of R1 or R2
versus the corresponding Fe concentrations.
2.2.2.7. Determination of Drug Release from Cisplatin-Loaded MNCS
The drug release of the anionic formulations was studied in pH 7.4 phosphate buffered
saline (PBS; 20mM) and pH 5.5 sodium acetate buffered saline (50mM). Briefly,
formulation equivalent to 25μg of cisplatin was placed in Float-a-lyzer© dialysis membrane
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tubes (3.5 – 5KDa MWCO; 1ml capacity; Spectrum Labs, USA). The volume in the tube
membrane was adjusted to 1mL and the assembly was placed in a 24ml dissolution
medium and stirred at approximately 125 rpm for five days. At specific time points during
the study, 0.5ml aliquots were removed from the dissolution medium outside the dialysis
membrane and replaced with same volume of fresh buffer. The cumulative release of
cisplatin was quantified by ICP-MS and plotted against time.
2.2.2.8. Cellular Uptake of MNCS
a. Quantitative determination by ICPMS: A2780-WT and A2780-CisR cells (106 cells/
well) were treated with a 2ml colloidal dispersion of the different formulations (equivalent
to Fe concentration of 5μg/ml) and incubated for 24h. At various time points during the
incubation period the medium was removed from the wells and the cells were washed
three times with ice-cold PBS and acid saline (pH 3). The cells were harvested and the
viability was determined by trypan blue assay and centrifuged to form a pellet. The
supernatant was removed completely and 0.5ml of a100ppb solution of Iridium in 2%
HNO3 was added to the pellets. The cells were then lysed mechanically by probesonication. 50μl concentrated nitric acid (TraCERT; Fluka) was added to the lysate, which
was then digested overnight at 70°C. The digested samples were then appropriately
diluted to 5ml with 2% HNO3. The cell debris was separated by ultra-centrifugation at
10000rpm for 30 mins. The supernatant was further filtered through 0.2um syringe filters
and analyzed by Nexion 300-D ICP-MS equipped with collision cell and auto sampler
(Perkin Elmer, USA). The intensities of the
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Fe and

195

Pt isotopes were considered for

quantification of the uptake. The final Fe or Pt content was normalized to the total protein
content of the cells (as determined by standard BCA assay) and uptake was expressed
as μg per mg of total cellular protein.
b. Confocal microscopy: Simultaneously, live-cell confocal microscopy was performed
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to study the cellular localization pattern of the different fluorescent-labeled MNCs. A2780WT and A2780-CisR cells were incubated with Alexa Fluor®-647 labeled MNCs for 1, 3
and 24h followed by visualization under a LSM 710 (Zeiss, CA) confocal microscope
equipped with a live-cell imaging stage.
2.2.2.9. In Vitro Cytotoxicity of PtMNCs
The cytotoxic potential of the cisplatin-conjugated PtMNCs was estimated in vitro in
A2780-WT and A2780-CisR human ovarian carcinoma cell lines. Briefly, the cells were
cultured in complete RPMI 1640 medium in conditions mentioned previously. Twenty four
hours after seeding about 3000 cells per well in 96-well plates, the cells were treated with
either free drug cisplatin, blank MNCs or PtMNCs (+/- LHRH) at different concentrations.
The cells were then incubated for 24 and 72h. At the end of each time point the culture
medium was replaced with complete RPMI and the cells were further incubated for 12h.
Finally, the cell viability was estimated by standard MTT assay. Briefly, 0.02mL of a
5mg/mL solution of MTT in PBS was added to each well and the plates were incubated
for 4h. The plates were then centrifuged and the supernatant was removed. The resulting
formazan crystals were dissolved in DMSO and the color intensity was measured at
560nm using Spectramax M3 plate reader. The cell viability was determined by comparing
the different treatment groups with the control (untreated) wells.
2.2.2.10. In Vitro Determination of MR Potential
Approximately 10 million A2780-WT and A2780-CisR cells were incubated with LHRHconjugated and unconjugated particles at Fe concentrations of 0.045, 0.09 and 0.18 mM
for a period of 24h. Following incubation, the cells were collected and cell viability was
determined by trypan blue assay. 9 million viable cells were re-dispersed in 0.5mL PBS
and mixed carefully with equal volume of hot 4% w/v agar solution. The samples were
cooled at 4°C for to allow the formation of a solid matrix. As a control 9 million un-treated
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cells were used. Phantom gels were scanned in Siemens Magnetom TIM Trio 3T human
MR scanner. Images of the phantom gels were obtained by using a multigradient echo
pulse sequence at a 1.64ms/3000ms TE/ TR and 40° flip angle for T1 and 112.5ms/
3000ms TE/TR for T2. The cellular phantoms were compared with phantoms of similar
concentrations of formulations without any cells.
2.2.3. STATISTICAL ANALYSIS
Statistical analysis was performed using IBM SPSS 23 statistical software.
Experimental designs with two groups were analyzed by student’s t-tests. Designs with
more than two groups were analyzed by appropriate ANOVA test followed by Bonferroni
post-hoc test for multiple comparisons using IBM SPSS 23.
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2.3. RESULTS
2.3.1. SYNTHESIS AND CHARACTERIZATION OF MAGNETITE NANOPARTICLES
(MNPS)

Figure 2.1. Various heating regimes during the synthesis of MNPs by thermal
decomposition of Fe(acac)3
At the onset of this work we concluded that it was important to control and fine-tune
the sizes of the MNPs as these sizes could affect the properties of the resulting MNCs. In
the modified one-pot solvent-controlled synthesis of magnetite nanocrystals39, 42 benzyl
alcohol acts as a solvent and reducing agent as well as a ligand or a mild surfactant. In
this process the colloidal metal oxide nanocrystal nuclei of MNPs grow by consuming the
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surrounding Fe(acac)3 precursor while Ostwald’s ripening or oriented attachment
mechanisms are not observed.43, 44

Figure 2.2. Effect of the heating patterns on the diameter of magnetite nanoparticles
(MNPs). A1-D1: UV-absorption spectra of the reaction mixtures under different heating
patterns as depicted in Figure 2.1. Aliquots of the reaction mixture were collected at
specific time intervals, precipitated in acetone, centrifuged to separate any formed MNPs
and absorbance spectrum of the supernatant was measured to determine the nucleation
and growth phases during the synthesis of MNPs. The solid lines correspond to
measurement taken at the start of the incubation periods where the reaction mixture was
kept isothermal for two hours. The dashed lines are spectra taken 2 h after incubation of
the system at a given temperature except for D1 where the spectra were taken at the start
of reflux. A2-D2: Amount of unreacted Fe(acac)3 in the reaction mixture at the
corresponding temperatures during the ramp phase of the heating process as measured
by ICPMS. A3-D3: TEM images of the MNPs synthesized by different heating patterns.
Particle size distributions are shown in the respective insets. Diameters of the MNPs were
calculated from the TEM images using Image J software.
Notably, the thermal decomposition of Fe(acac)3 in benzyl alcohol allows good control
over the nucleation and growth stages of the colloidal nanocrystals of magnetite and yields
MNPs with a narrow size distribution as compared to the widely used co-precipitation
technique.39 The rate of decomposition of Fe(acac)3 and therefore the onset, rate and
extent of the nucleation phase in nanocrystallization of magnetite from the organometallic
precursor were controlled by changing the heating rate and temperature of the reaction
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mixture. To determine the rate of decomposition of the precursor during the MNPs
nucleation and growth phases, 5-μL aliquots of the reaction mixture were collected, diluted
with HPLC-grade acetone, centrifuged and the supernatant was analyzed by UV
spectroscopy in the 250-600 nm wavelength range. The broad peaks at 355 and 435 nm
correspond to the precursor while the sharp peak at 330 nm corresponds to the colloidal
nuclei in the reaction mixture.45 The Fe content in the supernatant was also quantified by
ICP-MS. Several heating regimes were evaluated as depicted in Figure 2.1.
1). Slow heating: As the temperature was raised slowly at 0.4°C/min (Figure 2.1A) the
nucleation stage was initiated very early (at ~150°C), as indicated by the attenuation of
the precursor peaks intensities at 355 and 435 nm and elevation of the colloidal nuclei
peak intensity at 330 nm (Figure 2.2A1). Approximately 75% of the precursor was
converted into colloidal nuclei at around 160-180°C (Figure 2.2A2). As the temperature
approached reflux (205°C), the remaining precursor in the reaction mixture was entirely
consumed for the growth of the nuclei as shown by a complete loss of the absorbance
(Figure 1A1). The mean size of the resultant MNPs was 7 ± 4 nm (Figure 2.2A3).
2). Step-wise heating at 150°C: In this regime the reaction mixture was heated to 150°C
at 4°C/min and then the temperature was kept constant at 150°C for 2 hours to prolong
the nucleation stage compared to the regime 1) by slowing down the precursor
decomposition (Figure 2.1B). Under those conditions approximately 70 wt% of the
precursor was consumed during the nucleation stage (Figures 2.2B1 and B2) resulting
in nearly monodisperse MNPs with a mean diameter of 9 ± 2 nm (Figure 2.2B3).
3). Step-wise heating at 180°C: In this regime the reaction mixture was heated at 4°C/min
to 180°C and then the temperature was kept constant for 2 hours at 180°C (Figure 2.1C).
As a result, the nucleation phase was shortened compared to regimes 1 and 2. Under
these conditions, at 180°C and above, a large excess of the precursor was involved in the
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particles growth on the existing nuclei as demonstrated by the attenuation of the peak
intensity at 330 nm (Figure 2.2C1). After 2 hours at 180°C, a significant amount of nuclei
had undergone growth and precipitated as discrete MNPs (Figure 2.2C2). Larger MNPs
with a mean diameter of 11 ± 4 nm and a broader size distribution were obtained using
this regime (Figure 2.2C3).
4). Rapid heating: In the final regime the temperature was increased rapidly at a rate of
5°C/min until the reaction mixture refluxed (205°C) and this was followed by 40 hours of
annealing (Figure 2.1D). Rapid heating of the mixture resulted in an overlap of the
nucleation and growth phases leading to availability of large excesses of the precursor to
promote rapid growth of the formed nuclei (Figures 2.2D1 and D2). This regime resulted
in particles with a mean diameter of 14 ± 7nm (Figure 2.2D3),

Figure 2.3. Magnetization saturation of MNPs with two different core sizes synthesized by
thermal decomposition of Fe (acac)3

90
The rapid increase in temperature and prolonged high temperature annealing is known
to provide a higher degree of control over the crystal size.46 Specifically, high temperature
annealing was shown to enhance the saturation magnetization (MS) of the
superparamagnetic single domain MNPs synthesized by thermal decomposition.47, 48
The magnetic properties of the 7 nm and 14 nm diameter MNPs were studied by
measuring the saturation magnetization (Ms) at 300K (Figure 2.3). The magnetization
curves did not show any hysteresis which is consistent with the superparamagnetic
properties of the MNPs.49 As the particle size increased from 7 nm to 14 nm their MS nearly
doubled from 36.2 emu/g to 65.5 emu/g while their superparamagnetic behavior was
preserved. Larger MNPs, due to their lower surface-volume ratio, have smaller numbers
of atoms at the surface thereby leading to decreased surface effects such as spin-spin
canting and spin-glass-like behavior.50 As a result, the number of atoms contributing to the
magnetic moment of the MNPs increases leading to higher MS values.51 Increase in MS
also leads to an increased T2 relaxation capability of the MNPs.49, 52 Therefore, from the
theranostic perspective, the 14-nm MNPs were expected to have higher T2 relaxivity and
darker negative contrast.
2.3.2. PREPARATION AND CHARACTERIZATION OF POLYMER-STABILIZED MNCS
MNCs stabilized by PLE-b-PEG block copolymers were formed via electrostatic
binding of pendant carboxylate groups of the PLE blocks and the MNP surface (Scheme
2.1). In this study the length of the PEG block of the PLE-b-PEG was kept constant, while
the PLE block length was varied. The hydrodynamic diameters of the resulting clusters
(Figure 2.4) varied in the range of 40 to 70 nm depending on the length of the PLE block
(Table 2.1). All MNCs were negatively charged as was evident from their ζ-potential
values. In this study we also prepared MNCs stabilized by PLE100 homopolymer as well
as PLD100-b-PEG113 block copolymer and PLD100 homopolymer. All these clusters in de-
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ionized water had relatively small particle size (under 100 nm), and negative ζ-potential
(Table 2.2).
Scheme 2.1. Formulation process for preparation of MNP nanoclusters stabilized by
PLE-PEG or ALN-modified PLE-PEG

Figure 2.4. TEM images of (A) E10-MNC, (B) E50-MNC and (C) E100-MNC formulations

Table 2.1: Physicochemical characteristics of MNCs stabilized by anionic PLE-b-PEG block copolymers having different PLE block
lengths
Formulation (a)

Abbreviated
designation

Composition (wt%) (b)
Organic content
Polymer

BA

DLS characteristics (c)

MNP

Deff (nm)

PDI

ζ-potential
(mV)

(d)

PLE10-b-PEG113/MNP

E10-MNC

19

6.7

74.3

51.4 ± 11.3

0.334 ± 0.01

-20

PLE50-b-PEG113/MNP

E50-MNC

65.7

4.6

29.7

45.2 ± 4.3

0.171 ± 0.01

-26

PLE100-b-PEG113/MNP

E100-MNC

56.2

5.5

38.3

68.8 ± 7.8

0.222 ± 0.04

-36

(a)

The size of the MNPs in all formulations was 6 nm as quantified by Image J software from TEM images

(b)

The composition of the MNCs was determined by TGA. 5-8 mg MNCs was heated to 110°C at 5°C/min. The temperature was maintained at
110°C for 10 min. and then elevated to 1000°C at 5°C/min. The polymer content was determined by subtracting the benzyl alcohol ligand content
on the MNP from the overall organic fraction content.

(c)

DLS characteristics were measured in de-ionized water at 0.5 mg/ml MNCs at 25°C.

(d)

BA, benzyl alcohol.

Table 2.2: Physicochemical characterization of MNCs stabilized by homopolymers PLD, PLE, and PLD100-b-PEG113.

(a), (b)

DLS Characteristics b

Formulation a

Abbreviation

PLE100/MNP

Deff (nm)

PDI

ζ-potential (mV)

hE100-MNC

27.3 ± 4.8

0.171 ± 0.03

-34.6

PLD100-b-PEG113/MNP

D100-MNC

94.8 ± 4.2

0.189 ± 0.01

-24.7

PLD100/MNP

hD100-MNC

67.2 ± 3.4

0.168 ± 0.03

-47.2

as described in footnotes under Table 2.1
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Figure 2.5. Colloidal stability of E100MNC as a function of (A) pH and salt composition (20
mM each), (B) concentrations of phosphate buffer, pH 7.4 and (C) NaCl concentration in
10 mM phosphate buffer, pH 7.4 All samples were prepared at a concentration of 0.5
mg/mL. Data are mean ± SD (n = 3)
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Pegylated polymers are preferable in our work because they impart stealth properties
and enhance systemic circulation of nanofomulations.53,

54

PLE-b-PEG was chosen

because of more facile lysosomal biodegradation of PLE compared to PLD and the
respective block copolymer.55, 56 PLD100-b-PEG113 and the corresponding homopolymer
based MNCs were anticipated to undergo degradation at a slower rate and hence were
not developed further.
For the PLE-b-PEG stabilized MNCs, altering the PLE block length affected the
polydispersity and composition of the clusters. Interestingly, the greatest MNPs content in
the clusters, as determined by TGA, was observed in E10-MNC formed using copolymers
with the shortest PLE chain (10 r.u.). As the ionic block length increased, the MNP content
decreased to ~30-40 wt % in E50-MNCs and in E100-MNC compared to ~74 % in E10-MNC.
The presence of the PEG block also appears to have sterically hindered increased
coordination of MNPs with the PLE block in E100MNCs, which may have controlled the size
of the resulting MNCs. Irrespective of the length of the PLE block in the copolymer used
for cluster formation, the MNCs showed considerable sensitivity to the environmental pH,
as well as the concentration and/or composition of the elementary salts in the solution.
For example, E100-MNC appeared to be less stable in magnesium sulfate, pH 6.0 than in
sodium acetate, pH 5.0, sodium bicarbonate, pH 7.2 or disodium phosphate, pH 7.4
solutions (Figure 2.5A). This is possibly explained by the coordination of the divalent
magnesium cation with the PLE block57 resulting in detachment of this block from the
MNPs surface. In the phosphate buffer (pH 7.4) the E100-MNC stability strongly depended
on the concentration of the disodium phosphate (Figure 2.5B) or NaCl (Figure 2.5C). This
was attributed to a relatively weak attachment of the pendant carboxylate groups of the
PLE to the MNP surface that can be substituted by the phosphate ions or disrupted by
increasing the ionic strength.

95
2.3.3. ALN CONJUGATION ON PLE50-b-PEG113 POLYMER
Scheme 2.2. Schematic representation of ALN conjugation on PLE50-b-PEG113 polymer

Introducing anchor groups such as dopamine58-60 or bisphosphonate-containing
compounds that form very strong coordination complexes with the MNPs42, 61 can enhance
binding of the block copolymer to the MNP surface and increase stability of the resulting
MNCs under physiological conditions. Towards this goal we conjugated ALN to the PLE
chain of PLE50-b-PEG113 by EDC/NHS chemistry in DMSO-water system (Scheme 2.2).
The product of the reaction was confirmed by 1H-NMR (Figure 2.6) and 31P-NMR (Figure
2.7). The number of ALN groups linked to the PLE chain, termed here “degree of
conjugation” (Dconj), was quantified by ICP-MS as well as NMR (Table 2.3).
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Figure 2.6. 1H-NMR in D2O of (A) PLE50-b-PEG113, (B) ALN and (C) ALN-modified
PLE50-b-PEG113. Peak assignments are as follows: (A) δ ppm= 1.85 (2H, m, -CH2-; c),
2.2 (2H, m, CH2; b), 4.2 (H, t, -CH-; a); (B) δ ppm= 1.88 (2H, m, -CH2-; e), 2.9 (2H, t, CH2; d); (C) δ ppm= 2.9 - 3.1 (2H, m, -CH2-; d), 4.28 (H, d, -CH-; a).
Table 2.3. Quantitation of ALN conjugation by 1H-NMR
Formulation

ALN units per chain (Dconj)

A6-MNC

5.8

A12-MNC

10.7

A19-MNC-1

19.3

A19-MNC-2

18.5

97

Figure 2.7. 31P-NMR in D2O of (A) unconjugated ALN (δ ppm: 17.73) and (B) ALNmodified PLE50-PEG113 (δ ppm: 18.13)

Table 2.4. Physicochemical characteristics of MNCs stabilized by ALN-conjugated PLE50-b-PEG113 copolymers.

Formulation

Abbreviated
designation

ALN
groups
per
PLE
chain
(a)

Composition (wt %) (d)
COOH
groups
(μmole
per mg
MNC)(b)

MNP
diameter
(nm) (c)

DLS Characteristics (d)

Organic
content

DI water
MNP

Polymer

BA

Deff (nm)

PDI

PBS pH7.4
ζpotential
(mV)

ALN6-PLE50-bPEG113/MNP

A6-MNC

6*

8.5

9

76

2.5

21.5

ALN12-PLE50-bPEG113/MNP

A12-MNC

12

11.5

9

67.3

3.1

29.6

ALN19-PLE50-bPEG113/MNP-1

A19-MNC-1

19

16.5

9

53.7

5.8

40.7

A19-MNC-2

19

26.7

12

68.4

4.8

26.8

ALN19-PLE50-bPEG113/MNP-2

33.4
±6
35.4
± 8.4
69.5
± 5.4
78 ± 7.2

Deff
(nm)

PDI

0.21
±
0.05

-24.6

0.25
±
0.07

-33.1

0.22
±
0.06

-29.7

67.4
± 10

0.24
±
0.03

0.20
±
0.01

-20.4

79.8
±7

0.22
±
0.04

39.6
± 11
34.6
±9

0.31
±
0.05
0.25
±
0.06

(a)

Number of ALN molecules per polymer chain was quantified by ICP-MS except for A6-MNC (*) wherein the number of ALN units per polymer
1
chain were estimated from H-NMR.

(b)

Carboxylic acid (COOH) groups concentration was determined by potentiometric acid-base titration on formulation diluted to 0.1 mg/mL in DI
water.

(c)

The average MNP sizes were estimated from TEM images by measuring a minimum of 400 core particle sizes with Image J software.

(d)

The composition and DLS characteristics of the MNCs were determined as explained in Table 1, except for the last two columns where the DLS
measurements were done in PBS, pH 7.4.
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The cluster size was altered by increasing the concentration of the polymer and MNP
solution by two-folds. The number of ALN groups also strongly influenced the size of the
resulting MNCs (Table 2.5). The A6-MNC and A12-MNC formed using copolymers with
Dconj equal to 6 and 12 respectively were relatively small (~33 – 35 nm). As Dconj increased
to 19 in A19-MNC-1 the particle size increased nearly two fold. Interestingly, TEM images
suggest that A19-MNC-1 particles appear to be more elongated and display greater
proportion of chain-like structures compared to A12-MNC (Figure 2.8). Using the
copolymer with Dconj = 19 and MNPs with different particle diameter (9 and 12 nm) we also
produced two types of clusters, A19-MNC-1 and A19-MNC-2.

Figure 2.8. TEM images of (A) A12-MNC and (B) A19-MNC-1 formulations

Despite the difference in their MNPs sizes the resulting clusters had practically the
same overall particle size. Similar to above described non-stabilized clusters, the MNCs
obtained using the ALN copolymers were negatively charged as was evident from the high
absolute values of their negative ζ-potential (Table 2.5). Perhaps, the greatest difference
between these clusters was in their stability in physiological ionic strength conditions. Thus
all ALN-stabilized clusters had nearly same particle size in PBS, pH 7.4 as in the DI water.
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When compared with each other the A6-MNC and A12-MNC having smaller number of ALN
groups per copolymer were relatively less stable upon storage and aggregated over time
in contrast, A19-MNC-1 was stable in both DI water and PBS at RT and 37°C displaying
little if any change in particles size upon incubation for at least 30 days (Figure 2.9).
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Figure 2.9. Colloidal stability of (A) A6-MNC and (B). A12-MNC formulations in DI water
(DW) and 20mM pH 7.4 PBS at RT and A19-MNC formulation in DW and PBS at (C). RT
and (D). 37oC

Table 2.5. Physicochemical characteristics of cisplatin-loaded MNCs.
DLS Characteristics (b)

MNC used to
prepare cisplatin-

Abbreviated

containing

designation

formulation

(a)

DI Water
Deff (nm)

PDI

PBS pH 7.4
ζ-potential
(mV)

LE
(%) (c)

Deff (nm)

PDI

LC
(%)
(d)

A6E50-PEG113 /MNP

Pt-A6-MNC

38.6 ± 8.2

0.261 ± 0.03

-28.3

36.4 ± 11.4

0.348 ± 0.06

24

3.8

A12E50-PEG113 /MNP

Pt-A12-MNC

41.7 ± 11.3

0.243 ± 0.03

-36.1

43.3 ± 8.2

0.267 ± 0.03

32.7

5.2

A19E50-PEG113 /MNP

Pt-A19-MNC -1

69.3 ± 9.3

0.255 ± 0.02

-35.4

70.2 ± 7

0.203 ± 0.04

37.3

8.4

A19E50-PEG113 /MNP

Pt-A19-MNC -2

86 ± 5.1

0.218 ± 0.02

-43.4

83.8 ± 7.2

0.211 ± 0.01

40

17.6

(a) The loading procedure is described in Materials and Methods.
(b) DLS characteristics were measured in DI water or PBS, pH 7.4 at 0.5 mg/mL MNCs at 25°C.
(c) The loading efficiency (LE) was determined by ICP-MS as the percent of the drug incorporated in MNCs vs. the drug added during loading.
(d) The loading capacity (LC) was determined as the weight percent of cisplatin per the dispersed phase. Briefly, the drug-loaded MNCs were
lyophilized and the amount of cisplatin per mg of the formulation was determined by ICP-MS.
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2.3.4. LOADING OF CISPLATIN IN MNCS
Cisplatin was loaded into the MNCs via the formation of a coordination complex of
drug molecules with the carboxylate groups of PLE chains at pH 9.5. The technique
employed for the drug loading was similar to that previously described by us for the loading
of the cross-linked anionic nanogels.30,
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In addition, the bisphosphonate groups

introduced on the polymer chain are also likely to have a higher binding affinity towards
cisplatin than the carboxylates.63 We targeted 70 mol% of the total carboxylate groups
available in MNCs, assuming that each mole of cisplatin reacts with two moles of the
carboxylate groups. Four different types of ALN-stabilized MNCs described in the previous
section were used in these experiments. The characteristics of the resulting cisplatinloaded MNCs are presented in Table 2.6. In all cases from 24 to 40 % of the drug used
for the loading was actually incorporated in the MNCs. Both, the loading efficiency (LE)
and loading capacity (LC) appeared to increase as the number of ALN moieties elevated
in the following order A6-MNC < A12-MNC < A19-MNC-1. As mentioned earlier, increase in
the bisphosphonate groups (two bisphosphonates introduced per each carboxylate group
attached) is also very likely to contribute to this trend in LE and LC due to higher affinity
for cisplatin. However, in A19-MNC-2, as the size of the MNP grains increased, there was
nearly two-fold increase in the LC compared to A19-MNC-1. Although these two unloaded
clusters had similar particle size, the greater phosphonate and carboxylate groups content
in A19-MNC-2 compared to A19-MNC-1 probably explained the difference in the LC
between them (Table 2.6). Notably, the particle size of all clusters in DI water noticeably
did not change upon loading (Tables 2.5 and 2.6). However, and quite interestingly in all
cases the ζ-potentials of the loaded clusters appeared to become more negative after
loading, which might seem counterintuitive as the ionic groups are partially consumed by
cisplatin coordination. However, we believe that this effect may be explained by the
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thickening of the effective Stern layer that, as previously discussed30 in the nanogel-like
particles, can span throughout the entire particle volume. Coordination of the drug is likely
to displace the counter ions from the interior of the MNCs to the more “hydrodynamically
mobile” surface and periphery layers, resulting in an effective increase in the density of
the uncompensated negative charge and absolute ζ-potential value of the particles.

Figure 2.10. Release of cisplatin from Pt-A6-MNC, Pt-A12-MNC and Pt-A19-MNC-1 at (A)
pH 7.4 and (B) pH 5.5. Data are mean ± SD (n = 3); Statistical analysis performed by
ANOVA using SPSS statistical software, * p <0.05; ** p< 0.01. The graphs in the insets
of both the plots show the release patterns in the first 24h
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2.3.5. RELEASE OF CISPLATIN FROM MNCS
Cisplatin release was studied at 37°C at pH 7.4 (PBS; 0.14M NaCl) and pH 5.5 acetate
buffered saline (ABS; 0.14M NaCl), that mimic conditions in extracellular media and
endosomal compartments, respectively. As shown in Figure 2.10., both pH and Dconj of
the MNCs affected the drug release. In all cases the fastest release kinetics was observed
in Pt-A6-MNC having the smallest number of ALN anchor groups in the copolymer and
lowest LC. As the Dconj increased, the release rate decreased, lowest being in in Pt-A19MNC-1. For all systems the release was faster at pH 5.5 than pH 7.4 although this
difference was the smallest in Pt-A6-MNC and the greatest in Pt-A19-MNC.

Figure 2.11. Colloidal stability of cisplatin loaded Pt-A19-MNC formulation before and after
cisplatin release from the formulation. The particle size (Deff) of the samples used for
release kinetics study (Figure 2.10) was determined by DLS before and at the end of the
release study
The pKa of the protons on the phosphonate groups of ALN may also play an important
role in the drug release. The third pKa of alendronic acid is 6.4.64 Hence, at pH 5.5, the
respective phosphonate groups of ALN can become protonated and if these groups
participate in binding cisplatin this could also cause increase in the drug release rate.
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Interestingly, Pt-A19-MNC-1 at pH 7.4 displayed a complex release kinetics with very
slow release of the drug during the first two days followed its by acceleration thereafter.
The slow phase could be possibly attributed to the initial compact morphology of the
cluster, which becomes looser as the drug loading decreases, thereby facilitating drug
diffusion out of the particle. Notably, the slow release phase was not seen at pH 5.5 with
the drug release being overall much faster and monotonic. It is noteworthy that the
formulations did not aggregate of lose colloidal stability over the entire period of the study
in either buffer systems (Figure 2.11).
2.3.6. RELAXOMETRY MEASUREMENTS OF MNC FORMULATIONS
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Figure 2.12. r1 (longitudinal) and r2 (transverse) relaxivity measurement of different
unloaded (A, B) and cisplatin loaded (C, D) MNCs in PBS. Formulations with maximum
relaxivity values were further dispersed in 4% agar and relaxivities were measured in the
resulting phantom gels (E, F). Relaxivity is the linear slopes of the plots of relaxation time
(R1/ R2) vs. Fe concentration (mM) and expressed as S-1.mM-1 (See Table 2.7)
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The use of contrast agents for MRI depends on their ability to shorten the relaxation
times of the surrounding protons.65, 66 Positive contrast agents reduce T1 relaxation times
to give a brighter signal while negative contrast agents reduce T2 resulting in a darker
signal. The reciprocals of the relaxation times are called the relaxation rates, R1 and R2,
with the effectiveness of contrast agents expressed as relaxivities, r1 and r2, which are
determined from the slope of the relaxation rate curves expressed as a function of total
Fe concentration (mM) (Figure 2.12). In all cases the r1 relaxivity values of MNCs in PBS
pH 7.4 values were relatively low and did not change or decrease upon drug loading
(Table 2.6).

Table 2.6. Longitudinal (r1) and transverse (r2) relaxivity of the different MNC formulations
-1

-1

-1

-1

Formulation

r1 (s .mM ) (a)

r2 (s .mM ) (a)

A6-MNC

0.694 ± 0.07

31.3 ± 2

Pt-A6-MNC

0.66 ± 0.04

56 ± 4.7

A12-MNC

1.91 ± 0.11

48.3 ± 2.2

Pt-A12-MNC

1.02 ± 0.06

86.5 ± 2.8

A19-MNC-1

1.23 ± 0.05

87.8 ± 4.4

Pt-A19-MNC-1

1.02 ± 0.16

154.8 ± 11.5

A19-MNC-1 (b)

1.12 ± 0.1

72.2 ± 4.02

0.9 ± 0.04

120.8 ± 3

A19-MNC -2

1.34 ± 0.08

81.4 ± 3.3

Pt-A19-MNC -2

1.18 ± 0.07

140.3 ± 12

Pt-A19-MNC-1

(b)

(a)

Data are mean ± SD (n = 3)

(b)

Relaxivity measurements of phantom gels in 2% v/v agar. All other measurements were conducted in
PBS pH 7.4.

In contrast the r2 values of MNCs increased progressively as the Dconj value increased
A6-MNC < A12-MNC < A19-MNC-1 (Table 2.7). Notably for each empty and drug loaded
MNCs the r2 value appeared to be higher as the particle size was larger. But quite
unexpectedly for all MNCs the r2 value increased considerably, ~1.6 to 1.8 times after the
drug loading although the particle size (Tables 2.5 and 2.6) did not change that
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significantly. For example, Pt-A19-MNC-1 had r2 values of 154.8 s-1.mM-1 vs 87.8 s-1.mM-1
for the unloaded A19-MNC-1. The T1 and T2 relaxivities of A19-MNC-1 and Pt-A19-MNC-1
were further measured in buffered (PBS pH 7.4) 2% w/w agar gel. Phantom agar gel is
commonly used as reference material to mimic biological tissues due to similarities of its
T1 and T2 values to those of biological tissues.67 In the gel the r1 and r2 values of both the
loaded and unloaded MNCs showed only a minor decline compared to these values in

% Transmittance

PBS dispersion suggesting good potential for negative contrast in biological tissues.
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Figure 2.13. FTIR spectrum of LHRH-conjugated LH-Pt-A19-MNC formulation showing
a. N-H stretch of the primary amine of cisplatin at 3280 cm-1 b. carbonyl stretch of
carboxylic acid on the polymer at 1730 cm-1 c. C-O stretch of PEG at 1110 cm-1 d. N-H
bend of primary amines 1650 cm-1 e. C-N stretch of aliphatic amines at 1260 cm-1 f.
formation of secondary amide bonds following conjugation of LHRH on the PtMNC at
1660, 1580 cm-1 and g. N-H stretch of secondary amide bonds at 3400 cm-
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2.3.7. SYNTHESIS OF LHRH-TARGETED MNCS
Unloaded A19-MNC-1 and Pt-A19-MNC-1 (41 wt% MNP and 8.4 wt% cisplatin) were
used in this work as representative MNCs for LHRH conjugation. Similar to our previous
publication on cisplatin containing nanogels36 (D-Lys6)-LHRH was conjugated through its
lysine primary amino group to the free carboxyl groups of the A19-MNC-1 and Pt-A19-MNC1 using EDC/S-NHS coupling chemistry.
The conjugation was confirmed by an HPLC assay68 by measuring the amount of the
free (D-Lys6)-LHRH in the filtrate after purification of the modified clusters by centrifugal
filtration (3000 MWCO). Only 13.3% and 28.7% of the total reagent added in the reaction
mixtures was present in the filtrates of A19-MNC-1 and Pt-A19-MNC-1 samples,
respectively. The apparent greater yield of conjugation of the peptide to A19-MNC-1
compared to Pt-A19-MNC-1 was explained by availability of a greater number of free
carboxylate groups prior to loading of the drug. The FTIR spectra (Figure 2.13) of the
LHRH-conjugated Pt-A19-MNC-1 (LH-Pt-A19-MNC-1) suggested formation of a secondary
amide bond between the primary amino group of the (D-Lys6)-LHRH and the carboxylic
acid groups of the PLE.
2.3.8. UPTAKE OF LHRH-TARGETED CISPLATIN-LOADED MNCs IN OVARIAN
CANCER CELLS
The cell uptake of the unloaded LHRHr-targeted (LH-A19-MNC-1) and untargeted (A19MNC-1) MNCs was studied by confocal microscopy in LHRHr overexpressing A2780-WT
and A2780-CisR human ovarian cancer cells. A2780 human ovarian cancer cells are
known for LHRHr over-expression. Numerous studies have characterized LHRHr
expression by Western Blot analysis.34-36 As seen in Figure 2.14, untargeted MNCs
showed very low cellular uptake even after 24 hours in both wild type and cisplatin-
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resistant cells. The internalized MNCs were localized in the lysosomal compartments of
the cells visualized by the bright yellow punctate regions in the overlay images.
Conjugation of LHRH significantly enhanced the LH-A19-MNC-1 cellular uptake. In the
A2780-WT cells the LH-A19-MNC-1 were seen localized along the cell membrane (red)
and within the lysosomes (yellow punctate regions) as early as at 1-hour post incubation.
Although the uptake of LH-A19-MNC-1 in A2780-CisR cells was slower, a significant red
fluorescence of the labeled clusters was observed in the cells at as early as 3 hours.
Interestingly, literature reports suggest that certain cisplatin-resistant cancer cells (e.g.
ovarian epidermal carcinoma) exhibit significant reduction in non-receptor mediated fluidphase endocytosis compared to their wild-type counterparts while the receptor-mediated
endocytosis remains unaffected.69 The observed increased uptake of LH-A19-MNC-1 in
A2780-CisR cells specifically, is in line with these reports and strongly suggests that
receptor-mediated targeted therapy is an effective strategy for achieving a faster onset
and selective enhancement of cellular uptake in drug resistant tumors as it circumvents
the defective mechanisms of uptake in drug resistant cancers.
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Figure 2.14. Confocal microscopy of the wild-type A2780-WT and cisplatin resistant
A2780-CisR human ovarian cancer cells at different time points during their incubation
with non-targeted A19-MNC-1 and LHRH-conjugated A19-MNC-1. Live cells were exposed
to the said Alexa-Fluor 647 labeled (RED) MNCs and stained with the lysotracker green
(GREEN) and Hoechst nuclear stain (BLUE) for 30 min. The colocalization of the labeled
MNCs in lysosomes is seen in the overlay (YELLOW punctate regions). (Magnification
63X).
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Figure 2.15. Uptake of LHRH-targeted and untargeted cisplatin-loaded MNCs in A2780WT and A2780-CisR cells as quantified by ICP-MS and presented as (A) Fe levels, (B) Pt
(cisplatin) levels and (C) cisplatin / Fe ratio over time. Data are mean ± SD. Statistical
analysis done by ANOVA using SPSS software. Statistical significance denoted as: *
p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001 (n = 3).
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The uptake was further quantified by ICP-MS. In this case the cells were incubated
with Pt-A19-MNC-1 and LH-Pt-A19-MNC-1 for up to 24 hours and the Fe and Pt content in
the cells was normalized per mg of cellular protein and plotted over time (Figure 2.15).
Similar to the trend observed in the confocal images, LHRH conjugation resulted in an
almost 2-fold increase in intracellular Fe concentration in the A2780-WT cells (Figure
2.15A). In the A2780-CisR cells there was also a significant increase in the uptake of
targeted LH-Pt-A19-MNC-1 compared to untargeted Pt-A19-MNC-1 although, as expected
the overall uptake was slower than that in the WT cells. A similar pattern was observed
for the intracellular Pt content also (Figure 2.15B). It is important to note that LHRH
targeting significantly improved the rate of uptake of the cisplatin-loaded MNCs during the
first few hours, thereby decreasing the effect of the release of free cisplatin in the culture
medium. This was apparent in the analysis of the ratios of the cisplatin/Fe cell levels
(Figure 2.15C). In the case of the non-targeted Pt-A19-MNC formulation the cisplatin/Fe
ratio in both cell lines decreased significantly after 3 hours over time indicating that a
significant amount of drug was released into the media during the incubation time. For the
targeted LH-Pt-A19-MNC-1 formulation this ratio although steadily decreased over time but
remained much higher than that for Pt-A19-MNC-1. This was consistent with more rapid
internalization of the drug-loaded particles prior to a considerable release of the drug into
the media.
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Figure 2.16. Inhibition of intracellular uptake of (A) Fe and (B) Cisplatin (Pt) in A2780-WT
and A2780-CisR cells pre-incubated with D-Lys-6-LHRH peptide for 1h followed by 6h
incubation with targeted and non-targeted PtMNC formulations. Statistical significance: *
p<0.05, ** p<0.01, *** p<0.001 (n=3).

Finally, pre-incubating both cell lines with 100 nM free D-Lys-6-LHRH peptide for 1 h
before adding the MNCs greatly diminished the uptake of LH-Pt-A19-MNC-1 and had little
if any effect on Pt-A19-MNC-1 (Figure 2.16). This suggests that the free peptide
competitively inhibited the uptake of LHRH-targeted LH-Pt-A19-MNC-1 and reinforces the
receptor-mediated mechanism of its internalization in cancer cells.
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Figure 2.17. Formulation toxicity of unloaded non-targeted A19-MNC-1 and targeted LHA19-MNC-1 formulations in (A) A2780-WT and (B) A2780-CisR cells. Cells were seeded
in 96-well plates at a density of 3•103 cells/well and incubated at 37°C in 5% CO2. After
24 h, they were treated with various concentrations of the said formulations and further
incubated for 24h or 72h. At the end of each treatment period cell viability was measured
by MTT assay. Mean ± SD (n = 12).
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2.3.9. ANTI-CANCER OF LHRHr-TARGETED CISPLATIN-LOADED MNCS IN
OVARIAN CANCER CELLS
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Figure 2.18. Cytotoxic efficacy of cisplatin and LHRH-targeted and untargeted cisplatinloaded MNCs in (A, B) A2780-WT and (C, D) A2780-CisR cells exposed for drugs for
(A, C) 24 h and (B, D) 72 h. Data are mean ± SD (n = 6).
Prior to evaluating the anticancer activity of drug formulations the toxicity of unloaded
MNCs was determined in A2780-WT and A278-CisR cells. The cells were incubated with
various concentrations of A19-MNC-1 and LH-A19-MNC-1 for 24 h and 72 hours and cell
viability was measured by a MTT assay. The unloaded formulations did not show toxicity
in a broad range of concentrations (Figure 2.17) and they were further used to assess the
anticancer activity of the drug loaded MNCs.
The anticancer activity of LHRH-targeted and untargeted cisplatin-loaded MNCs was
determined in A2780-WT and A278-CisR cells after 24 and 72-hour treatments. The two
time points were used initially to exclude possible effects of the release of the drug into
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the extracellular media from the untargeted and targeted MNCs. However, the observed
trends in cytotoxicity were essentially the same for both exposure times. As expected, the
untargeted Pt-A19-MNC-1 was several folds less active compared to the free cisplatin in
both A2780-WT and A2780-CisR cells (Figure 2.18 and Table 2.8). LH-Pt-A19-MNC-1
was more active compared to untargeted Pt-A19-MNC-1 in both cell lines. Although LH-PtA19-MNC-1 was still less active than the free drug in the resistant cells, its IC50 was close
to that of cisplatin (10.9 μM vs 7.9 μM; 72 h). This trend in activity of MNC formulations is
consistent with the slow and low cellular uptake of the untargeted MNCs and somewhat
faster uptake of the LHRH targeted particles. Since, as discussed above, during the cell
exposure time the free drug may release from nanoparticles into the extracellular media
and contribute to cytotoxicity, the “actual” difference in the activity of the targeted and
untargeted MNCs could be even greater than revealed herein.
Table 2.7. IC50 values of different treatment groups in A2780-WT and cisplatin resistant
A2780-CisR ovarian cancer cell lines.
Exposure
time(a)

24 h

72 h

Treatment

IC50 values (μM)
A2780-WT

A2780-CisR (μM)

Cisplatin

1.1

9.1

Pt-A19-MNC-1

6.8

28.6

LH-Pt-A19-MNC-1

3.2

18.3

Cisplatin

0.9

7.9

Pt-A19-MNC-1

4.4

16.7

LH-Pt-A19-MNC-1

2.3

10.9
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2.3.10. IN-VITRO EVALUATION OF THE MRI POTENTIAL OF MNCS

Figure 2.19: In vitro evaluation of MRI potential of different formulationsT1 and T2 images
of phantom gels of A2780-WT and A2780-CisR cells incubated with different
concentrations of (A) A19-MNC-1, (B) LH-A19-MNC-1 (C) Pt-A19-MNC-1 and (D) LH-Pt-A19MNC-1. The image contrasts are compared with those obtained from serial dilutions of
A19-MNC-1 and Pt-A19-MNC-1 in the absence of cells (top). The signal-to-noise (S/N)
ratios for the different sets of contrasts were plotted against the corresponding Fe
concentrations to quantitatively compare the contrasts obtained by the four different
formulations A-D. The comparisons of S/ N ratios of T1 and T2-weighted contrasts of
formulations A and C in phantoms with no cells are represented in Figures E and F
respectively. Figures G and I represent the S/N ratios of T1 and T2-weighted contrasts in
phantoms of A2870-WT cells while Figures H and J represent the same of A2780-CisR
cells incubated with different concentrations of formulations A-D.
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The effect of LHRHr targeting on the MRI capability of the formulations was studied in
both cell lines. Following 24 hours of incubation with different unloaded and cisplatin
loaded MNCs A19-MNC-1, LH-A19-MNC-1, Pt-A19-MNC-1 and LH-Pt-A19-MNC-1 at various
Fe concentrations, the cells were washed with 1X PBS, harvested and. 9•106 live cells per
group were molded into agar and scanned in the Seimens 3T human MR scanner to obtain
T1 and T2-weighted contrast images (Figure 2.19). MNPs are predominantly used as
negative (T2) contrast agents. The negative contrast was indeed more prominent and
showed a dose-dependent increase. LHRH conjugation promoted cellular uptake of LHPt-A19-MNC-1 and resulted in greater T2 contrast and this was more profound in the
A2780-WT cells that took up more material than A2780-CisR. In line with the relaxivity
values, the presence of cisplatin resulted in greater contrasts irrespective of the presence
of LHRH. This was more obvious in the case of A2780-CisR cells than in A2780-WT cells
due to overexposure in the latter. Overall, when compared to the contrast obtained with
the phantom gels the targeted MNCs provided significant T2 contrast even after
internalization within the cells.
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2.4. DISCUSSION
Thus,

to

summarize,

we

have

developed

the

new

superparamagnetic

nanoformulations for drug delivery and MRI and demonstrated 1) their use as carriers for
a chemotherapeutic drug, cisplatin, 2) their targeted receptor mediated delivery into drug
resistant and sensitive ovarian cancer cells and 3) and their potential use as MR contrast
agents for future theranostic applications. Structurally, these systems are distant relatives
of previously described nanogels or polymeric micelles with cross-linked polyion cores and
PEG shells that have been synthesized using the anionic block copolymers, including
PLE-b-PEG.30, 36, 70, 71 However, instead of chemical crosslinks the polyion chains of the
block copolymers are physically cross-linked through ionic interactions with the magnetite
MNPs that bind these chains to each other.
To synthesize the MNPs we employed a well-established method of thermal
decomposition of Fe(acac)3, which is a simple one-pot technique allowing to access
relatively uniform MNPs having good magnetization properties. In this method the solvent
serves as a mild surfactant as well as a reducing agent.39 The sizes of the MNPs are
governed by the rate of heating while magnetic properties depend on the annealing
temperature and duration of the reaction.72, 73 High boiling point solvents such as benzyl
ether (298°C) are known to allow for shortening of the duration of synthesis but require
additional surfactants and reducing agents.74 We show herein that in spite of a relatively
lower reflux temperature in benzyl alcohol, the nucleation and growth phases could be
effectively controlled in this solvent by altering the rate of reaction thereby enabling control
over the core size.
Formation of nanoclusters by unmodified block copolymers was governed by the PLE
block length. There exists a complex interplay of the electrostatic interaction between the
carboxylate groups and magnetite surface and the steric hindrance due to the presence
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of the bulkier PEG block during the cluster formation step. The increase in the number of
anchoring groups has been shown to reduce aggregation due to incomplete surface
coating of the MNPs and form more stable clusters of MNPs.

75

The shortest block

copolymer PLE10-PEG113 resulted in interactions of single polymer chain with different
MNPs resulting in higher degree of catenation as well as more MNPs per cluster. The
steric hindrance due to the PEG block eventually curbed the cluster formation process.
However, the so formed E10-MNC nanoclusters had incomplete surface coverage and
hence were also the least stable. Colloidal stabilities of the MNPs of defined size obtained
by this method in aqueous dispersion were obtained by using biodegradable ALN-modified
PLE-b-PEG block copolymer.70 Hydrogels of carboxylated polymers are known to exhibit
significant swelling behavior at physiological pH due to the presence of charged
carboxylate groups.76-78 In the case of crosslinked nanogels formed by anionic block
copolymers such as PLE-b-PEG, swelling results in significant increase in the particle size
that is varied by changing the crosslinking degree. Moreover, crosslinking can significantly
enhance the colloidal stability of nanogels and define the rate of the release of the
encapsulated payload.70, 79
In this work we have demonstrated that MNCs, can be successfully stabilized by
introducing sufficient amount of ALN bis-phosphonate groups onto the PLE block that
tightly anchor the copolymer to the MNP surface. Cisplatin loading in the MNCs was
successfully achieved by coordinating the drug with a fraction of the remaining carboxylic
and phosphonate groups of the PLE chains. The presence of MNPs did not hinder the
loading as was evident from the relatively high LC values. The drug loaded MNCs
exhibited sustained drug release profiles that were altered by changing the number of bisphosphonate “cross-links” between the polymer and the MNPs. The utilization of a few
carboxylate groups for cisplatin loading did not hamper the colloidal stability of the
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formulations. The samples were intact and did not undergo any aggregation throughout
the study period. In addition, we postulate that cisplatin loading can, in fact, further
increase the stability and integrity of the formulation by simultaneously crosslinking the
polymer chains within the cluster.
Recently, Pothayee et al.80 developed theranostic MNCs by adsorbing the polyacrylate
block of an amino functional poly(ethylene glycol-b-acrylate) (H2N-PEG-b-PAA) copolymer
onto magnetite MNP and loaded these MNCs with a cationic antibacterial drug,
gentamycin through electrostatic interactions. Despite some similarities that can be found
with this prior work there were major differences with our nanoformulations. First, in
contrast to H2N-PEG-b-PAA the PLE-b-PEG used here has a biodegradable PLE block,
which is essential for the use of this nanoformulation for systemic drug delivery. Second,
H2N-PEG-b-PAA chains were covalently cross-linked via non-degradable PEG diacrylate
oligomer to form the nanoclusters. In this work we introduced controlled levels of
bisphosphonate groups onto the PLE block via ALN addition. The bisphosphonates form
stronger links to both the magnetite and the Pt from cisplatin than having only carboxylates
present. These interactions allow for facile non-covalent self-assembly of MNCs. Such
clusters based on ALN-modified PLE have stable colloidal sizes in physiological pH and
ionic strength. Selection of an appropriate polymer coating is critical to ensure colloidal
stability, high drug loading capacity, biocompatibility and biodegradability and long
circulation time of the MNP-based nanoformulations. Block copolymers comprising
biodegradable charged polyaminoacid chains can serve as ideal stabilizing agents for
formation of MNCs. In our case, the resulting MNCs contained an excess of carboxyl and
bisphosphonate groups that were used to load an anticancer drug, cisplatin. Since the
loading proceeded through coordination of the drug with the ionic groups, it increased as
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the amount of these groups was increased and achieved a maximum of 17.6%, which is
an excellent LC value for a nanoformulation used in cancer therapy.
A key element in our nanoformulation design is the decoration of MNCs with a
targeting moiety to increase accumulation of the MNCs and their payload in ovarian cancer
cells. Ovarian cancer represents a major health problem accounting for about 22,000 new
cases and over 14,000 deaths annually in the US alone.28 In spite of the dose limiting
nephrotoxicity and other severe side effects,29 cisplatin still remains the first line of
treatment for ovarian cancer. To address the toxicity and delivery issues of cisplatin the
drug has previously been loaded into various polymeric nanocarriers.71 Attempts of
targeted delivery of cisplatin have also been reported. For example, cisplatin has been
incorporated within the folate-decorated crosslinked PEG-b-polymethacrylate (PEG-bPMA) nanogels to treat the folate receptor positive ovarian cancer tumor in mice.30 Here
we targeted LHRHr that is overexpressed in more than 70% of human ovarian cancers as
well as several other cancers.31, 32, 81 These receptors are not present in most visceral
organs, which could help reducing the off-target delivery of the nanoformulations to normal
tissues and decrease side effects. The LHRH peptide, a synthetic analogue of the natural
hormone has successfully been used to improve delivery of chemotherapeutic agents to
LHRHr overexpressing tumors.74 We also previously used this approach with LHRHdecorated PEG-b-PMA nanogels loaded with cisplatin to target LHRHr-positive ovarian
cancer in mice.36 In a separate study MNPs were conjugated directly with LHRH-peptide
in order to improve the uptake of such MNPs in LHRH overexpressing breast cancer
cells.37
As expected, decoration of the MNCs with LHRH resulted in the increased uptake of
both MNPs and the drug presumably due to the LHRHr-mediated endocytosis of the
targeted nanoformulation.82-84 This translated to increased cytotoxic effects of the targeted
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nanoformulated drug in both cisplatin-sensitive and resistant cancer cells. Notably,
cisplatin loaded in untargeted nanoformulations was also active albeit much less than the
free drug. The differences between the free and nanoformulated drug were minimal in the
drug resistant cell line. Interestingly, our targeted nanoformulations were somewhat more
active in A2780 cells in comparison to previously reported LHRH-decorated PEG-b-PMA
nanogels loaded with cisplatin (24 h IC50 ≈ 30 μM).36 We attribute the enhanced efficacy
of our new nanofomulation to the biodegradability of PLE-b-PEG in the lysosomal
compartments, which can enhance the drug release.71 As MNCs accumulate in
endosomal-lysosomal organelles, the drug release is triggered by acidic pH in these
organelles. Hydrolysis of the neutral cisplatin molecule inside the cells results in aquation
of the molecule involving displacement of the chlorine ligand with water. LHRH targeting
further increases influx of the drug-loaded MNCs in the targeted cancer cells where the
paucity of chloride ions facilitates drug activation. The activated cationic mono- and diaqua complexes of cisplatin are thereby released and trapped within the target cells where
they intercalate with the N7 atoms of the purines in the DNA base pairs, which prevents
DNA repair and DNA replication and leads to cell death.71, 85, 86 By incorporating cisplatin
in the targeted MNCs one can protect the drug from premature aquation in the blood that
is responsible for undesired side effects and more selectively affect tumor cells.
Interestingly we also show here that targeting can improve the MRI imaging of cancer
cells, which is consistent with increased uptake of LHRH-decorated MNCs in these cells.
This result reinforces the importance of tissue specific targeting in designing successful
theranostic nanosystems, which can enable diagnosis as well continuous monitoring of
therapy. The MNP-based MR contrast agents have been in commercial clinical use in
several countries for almost a decade.87, 88 To be clinically relevant, negative contrast
agents should have higher transverse (T2) relaxivities. Transverse relaxivity is governed
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by several factors such as MNP core size, chemical nature, oxidation state, applied
magnetic field, site-specific uptake and proximity of the metal ions to the water.89-92 A
formulation that enables deeper penetration of the water molecules towards the magnetic
core allows for faster relaxation of the protons and a higher T2-relaxivity.82 Clusters of
magnetic nanoparticles experience a greater force and magnetic moment than single, well
separated MNPs in a magnetic field gradient resulting in an increase in saturation
magnetization.23 Clustering of several MNP cores into compact agglomerates has been
shown to be beneficial especially in the case of T2 relaxivity.93, 94 It was previously reported
that aggregates comprising few closely held MNPs measured with long pulse-echo times,
can result in greatly improved T2-relaxivity.95, 96 Berret et al.97 have shown that ionic block
copolymers having an opposite charge to that of the MNPs can be successfully used to
formulate stable MNCs wherein the aggregation number of the MNPs can be controlled
by altering the copolymer block length. The MNCs discussed herein exhibited a similar
trend, where T2 relaxivity was governed by the cluster size and MNP loading in the
clusters. In contrast the T1 relaxivity was only marginally affected either by cluster
formation or increased uptake since the primary factor governing T1-weighted positive
contrast is the MNP core size. Only ultra-small superparamagnetic iron oxide
nanoparticles (less than 5-6 nm in size, are known to exhibit positive contrast
enhancement as well.98 Hence, the 9 nm MNP cores were expected to produce only
marginal changes in T1 images.
Unexpectedly, we discovered that cisplatin loading in the MNCs considerably
increased the T2 relaxivities for all of our nanoformulations. It is well known that platinum
(Pt) has paramagnetic properties and incorporation of Pt in MNPs results in significant
enhancement in relaxivities of FePt alloys.99 Although our MNPs are comprised of
magnetite only, we speculate that cisplatin molecules introduced in close proximity to

125
magnetite MNPs can play a similar role. Each mole of cisplatin can interact with two moles
of carboxylate and bisphosphonate groups on the polymer chains. This can cause
additional intra or inter cluster crosslinking, thereby leading to further immobilization and
stabilization of the MNCs and an increase in T2 relaxivity. Several metal-cluster
compounds, made of different metals such as Pt and Ni closely held together via
coordination complexes by organic ligands containing carbonyl anchor groups, have been
shown to exhibit significant increase in magnetic susceptibility of the resulting clusters. 100
The magnetic moments of these ‘metal-carbonyl’ clusters increased with increase in
metallic composition of the clusters with larger clusters. Pt in particular contributed to a
small but significant increase in the net susceptibility of these clusters.

The cisplatin-

loaded MNCs formulated in this paper closely mimic such metal-carbonyl clusters and the
loaded Pt (~8wt%) can contribute significantly to the net susceptibility and hence relaxivity
of the superparamagnetic MNCs. Lastly, incorporation of cisplatin can also enhance water
penetration in close proximity of the MNPs by diminishing the hydrophobicity around the
core, which can also further enhance the T2 contrast capability of the cisplatin-loaded MNC
formulation. This effect, nonetheless, deserves further study and could play positive role
in theranostic applications using cisplatin loaded MNCs.
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2.4. CONCLUSION
We have produced stable MNCs by reacting magnetite MNPs with the biodegradable
PLE50-PEG113 block copolymer having ALN anchor groups attached to some of the
carboxylic group of the PLE via polymer-analogous modification. The resulting MNCs were
loaded with cisplatin using remaining carboxylic and bisphosphonate groups of the PLE.
The MNCs were decorated with the LHRH as the targeting groups to enhance delivery of
the nanoformulations to ovarian cancer cells overexpressing LHRHr. The LHRH
modification enhanced uptake of the MNCs and their drug and MNP payload in the wildtype as well as cisplatin-resistant ovarian cancer cells. Enhanced uptake further translated
into superior MRI contrast and significant enhancement in cytotoxicity of the
nanoformulated drug. Thus, theranostic nanoformulations were developed here that can
be applied for simultaneous MR imaging and targeted drug delivery in cancer cells. The
encouraging in vitro results certainly warrant further investigation of the in vivo efficacy of
the proposed theranostic nanosystem.
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2.5. FUTURE DIRECTIONS
Our in vitro studies have demonstrated that MNCs formulated with ALN-modified PLE50b-PEG113 polymer are relatively non-toxic as carriers of potent anti-cancer agents such as
cisplatin. The results of in vitro cytotoxicity studies of the LHRHr-targeted formulations in
ovarian cancer cells are very encouraging and we have initiated steps in the direction of
in vivo evaluation of the formulation. Apart from that, further studies will be aimed at
increasing the loading capacity of MNPs and therapeutic payloads in the formulation. We
aim to do this by employing a polymer with a longer PLE block such as PLE100. Further
refinements in the bisphosphonate conjugation procedure have enabled us to achieve
higher Dconj on PLE100-b-PEG113 polymer. For theranostic formulations such as these it is
extremely important to strike a correct balance between the contrast agents and the
therapeutic agents. Finally, we aim to extend the application of these theranostic MNCs
by exploring potential targeting to other malignancies such as glioblastoma and prostate
cancer. Our choice of these types of cancers is guided by the fact that till MRI is one of
the most efficient contrast systems for imaging of the brain with maximum details. We aim
to study, if our biocompatible and biodegradable MNC formulations can address this need,
which we perceive as an unmet one.
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CHAPTER 3
CATIONIC MAGNETIC NANOCLUSTERS STABILIZED BY POLY
(L-LYSINE)-B- POLY (ETHYLENE GLYCOL) FOR CANCER
THERANOSTICS

3.1 INTRODUCTION
Poly-L-lysine (PLK) is a cationic polypeptide that has been used as a modifier for
drug-loaded nanoparticles and has been shown to enhance the cellular uptake of drugs1
by increasing the permeability of various compounds.2-4 This property of PLK-based
polymers has been effectively exploited in designing non-viral vectors for gene and protein
delivery. Cationic polymer-based non-viral vectors have been considered as favorable
candidates for clinical gene therapy due to their advantages over viral vectors in numerous
vital properties including low immunogenicity, easy fabrication, low cost, ease of
modification and functionalization such as incorporation of targeting ligands. They were
commonly used to package plasmid DNA (pDNA) into nanoscale polyplexes, which can
protect pDNA from enzymatic degradation and transport genes into target cells through
an endocytic pathway. In addition to PLK, numerous other polymeric gene delivery vectors
have been investigated, including poly (ethyleneimine) (PEI)5-7, chitosan8-10, poly(amino
ester)11,

12

, dendrimeric poly(amidoamine) (PAMAM)13-15, and their block or graft

copolymers with poly(ethylene glycol) (PEG). Among all, PEI and PLK are two of the
mostly studied polymers as gene carriers. Both polymers possess high charge density
essential for effective pDNA complexation and condensation.
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The success of magnetic nanoparticles (MNPs) as theranostic agents relies on their
ability to generate superior soft contrasts in the tissue of interest while simultaneously
delivering a therapeutic dose to the organ. Both require significant accumulation in the
organ. The type of stabilizing agent used to render hydrophilicity and stability to the
otherwise hydrophobic and unstable MNPs dictates tissue accumulation of MNPs. In the
previous chapter we discussed strategies of enhancing tissue specific uptake of anionic
magnetic nanoclusters (MNCs) stabilized by PLE-PEG polymer modified with
bisphosphonates. The high charge density of PLK-PEG block ionomers has also been
employed to form stable aggregates of magnetic nanoparticles (MNPs), which have been
successfully tested for a variety of biological applications. For instance, PLK-labeled
MNPs have been extensively used in labeling specific cells such as stem cells16, dendritic
cells17 and non-phagocytic T cells18. Wang et al.19 observed a specific peroxidase-like
activity within PLK-modified MNPs that could greatly reduce intracellular peroxide activity
in labeled cancer stem cells derived from glioblastoma. The ability to introduce different
functionalities on the side-chain amino groups makes PLK-stabilized MNPs a smart choice
for simultaneous drug delivery and MRI.
In this study, we evaluated the efficacy of different PLK-PEG polymers in forming
stable magnetic nanoclusters (MNC). Moreover, we modified the available side chain
amino groups to conjugate anti-cancer agent doxorubicin onto the stable clusters via a pH
sensitive hydrazone linker (DOX-MNC). This end group modification reduced the positive
charge density on the clusters, which reduced the uptake-driven toxicity of the PLK-based
magnetic nanoparticles. This DOX-MNC formulation exhibited excellent MRI potential with
significantly high T2 relaxivities. The stimuli-responsive drug delivery helped achieve a
sustained release exclusively in an acidic environment only, thereby preventing premature
leakage of the anti-cancer payload. End group modification did not hinder the intracellular
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uptake of the formulations. The formulations were preferentially localized in the acidic
lysosomal compartments (~pH 4.5 – 5.5)20 of A2780 and MDA-MB-231 cancer cells where
the pH-driven cleavage of the hydrazone bond resulted in drug release and significant
cytotoxicity.

3.2 EXPERIMENTAL SECTION
3.2.1 MATERIALS
Chemicals: Poly (L-lysinex-b-ethylene glycol113) polymer (PLK-PEG; x = 10, 50 and 100)
was purchased from Alamanda Polymers (Huntsville, AL). N-Succinimidyl 3-[2pyridyldithio]-propionate (SPDP), iron (III) acetylacetonate (Fe(acac)3), benzyl alcohol
(anhydrous),

nitric

acid

(TraceSELECT),

hydrochloric

acid

(TraceSELECT),

Fluorescamine and 3-(4,5-dimethyl thiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT)
were purchased from Sigma-Aldrich (St. Louis, MO). Acetone (histology grade), n,ndimethylformamide (DMF), 3, 3´-N-[ε-Maleimidocaproic acid] hydrazide (EMCH),
trifluoroacetic acid salt, dithiothreitol (DTT), 5,5'-dithiobis-(2-nitrobenzoic acid) (DTNB),
DMSO and all other anhydrous HPLC grade organic solvents were purchased from
Thermo Fisher Scientific (Waltham, MA). Doxorubicin hydrochloride salt was purchased
from LC Laboratories (Woburn, MA). Alexa Fluor®-647, Lysotracker Green and Hoechst
33342 were purchased from Life Technologies (Carlsbad, CA).
Cell lines: Triple negative MDA-MB-231 breast cancer cells and wild-type A2780 ovarian
cancer cells were purchased from American Type Culture Collection (ATCC, Manassas,
VA). MDA-MB-231 cells were maintained in DMEM (high glucose) supplemented with 10%
fetal bovine serum (FBS) and 1% penicillin/streptomycin from Thermo Fisher Scientific
(Waltham, MA). A2780 cells were maintained in RPMI 1640 media supplemented with
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10% FBS and 1% penicillin/streptomycin. All cell cultures were maintained in 37°C and
5% CO2 atmosphere.
3.2.2 METHODS
3.2.2.1 Synthesis of Magnetic nanoparticle cores (MNPs).
Magnetic nanoparticles were synthesized by thermal decomposition of iron (III)
acetylacetonate (Fe (acac)3) in benzyl alcohol by two methods:
a. Ramp-soak method. This method was similar to Profile B described in section 2.2.2.1
of the Chapter 2, except for a minor change in the initial heating rate from 110°C to 150°C.
Briefly, 6.2μmoles of Fe(acac)3 precursor was mixed with 45mL anhydrous benzyl alcohol.
The reaction mixture was initially heated at 110°C for 1h to ensure complete removal of
moisture. The reaction temperature was gradually increased to 150°C at 2°C/min and
maintained constant for 2h. After 2h the mixture was further heated under reflux to 205°C
at a rate of 4°C/min and maintained at that temperature for 40h.
b. Hot injection method. This method differed from the previous methods described here
and in 2.2.2.1 of the Chapter 2. While in the other methods Fe(acac)3 was dissolved in
benzyl alcohol and the entire mixture was heated to reflux at different heating rates, in in
this method, only 80% (35mL) of the total solvent without any Fe(acac)3 was heated to
reflux. Separately, 6.2μmoles Fe(acac)3 was dissolved in remaining 20% (10mL) benzyl
alcohol at RT and rapidly injected into the hot solvent at reflux with the help of a glass
syringe. The reaction mixture was allowed to regain the reflux temperature and further
heated for 40h under reflux.
The final product was obtained by precipitation and washing in acetone followed by
vacuum evaporation. The physico-chemical characteristics were determined by TEM,
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TGA and SQUID to determine their particle size distribution, surface benzyl alcohol
content and magnetization saturations, respectively.
3.2.2.2 Preparation of cationic magnetic nanoclusters (MNCs).
Cationic MNCs were prepared by the same method as described in Chapter 2 section
2.2.2.3a and depicted graphically in Scheme 2.1. Briefly, 40mg of PLL-b-PEG polymers
with different PLL block-lengths were dissolved in de-ionized (DI) water at a concentration
of 4 mg/mL. The pH of this solution was adjusted to 10.5 with 1N NaOH. MNP cores were
dispersed separately in 10mL of alkaline water (pH 11.9-12.1) at a concentration of 2
mg/mL to obtain a colloidal dispersion. The polymeric solution was added to the magnetic
colloidal dispersion under constant stirring. The mixture was further stirred overnight on a
magnetic stirrer at approximately 400 - 500 rpm. The excess polymer was then filtered by
extensive dialysis in DI water for 72h with six water changes. The dialyzed intermediate
was filtered serially through 0.45 μm and 0.22 μm Anotop filters to obtain the final product.
The cationic nanoclusters thus obtained were lyophilized and stored under vacuum until
further use.
3.2.2.3 Physico-chemical characterization of MNCs.
a. Size and ζ-potential.
The hydrodynamic diameter (z-average) and ζ-potential of the formulations were
determined by dynamic light scattering using a Malvern Zetasizer (Malvern Instruments,
Malvern, UK). The formulations were diluted to 1mg/mL of total formulation before
measurements were performed in clear disposable zeta cells.
b. MNC composition.
The composition of the unloaded nanoclusters was determined by thermogravimetric
analysis (TGA) using 5-10mg of the lyophilized unloaded MNC formulation. The
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temperature was raised at 5°C/min to 110°C and kept isothermal for 10 minutes in order
to remove the moisture followed by steady heating at 5°C/min to 1000°C. The obtained
thermogram was analyzed using the Universal Analysis software (TA Instruments, DE) to
deduce the total loss of the organic components (LOI) and amount of MNPs per mg of
MNCs. The content of benzyl alcohol coating was determined by loss of organic
components upon thermal decomposition of MNPs by TGA. The LOI of MNCs was
corrected by subtracting the content of benzyl alcohol in the MNPs to obtain the content
of polymer in the MNCs.
c. Relaxivity measurements
Longitudinal (T1) and transverse (T2) relaxivity measurements of the different
formulations were conducted using a Bruker Biospec MRI and Spectroscopy (MS) system
(7T/21 cm; Bruker, Karlshure, Germany). The stabilized colloidal dispersions were diluted
to 0, 0.018, 0.045, 0.09, 0.18, 0.27 and 0.36 mM Fe with distilled water and 20mM PBS.
T1 and T2 relaxation times were measured and converted to their corresponding relaxation
rates (R1 and R2; 1/T; s-1). The sequence used for T2 mapping was a CPMG phase cycled
single slice multiecho sequence. One 1 mm thick coronal image was acquired with an
acquisition matrix of 256 x 128, 40 mm field of view, 32 echoes at 10 ms first echo time
and 10 ms echo spacing, repetition time of 3000 ms, one average, for a total acquisition
time of 6.4 min. The r1 (longitudinal relaxivity) and r2 (transverse relaxivity) values (s-1.mM1

) were obtained as the slope of the plots of R1 or R2 versus the corresponding Fe

concentrations.
d. Colloidal stability of MNCs.
The different formulations were dispersed in 20mM PBS (pH 7.4) at a concentration of
1mg.mL-1 and their colloidal stability was measured at RT for one month during which
period the particle size was measured by DLS at regular intervals.
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3.2.2.4 Preparation of pH sensitive doxorubicin-conjugated MNCs
Doxorubicin was conjugated by a pH-labile hydrazone linkage at the ε-amino end
group of the PLL block on the MNCs via a hetero-bi-functional linker SPDP. The
conjugation procedure is described in brief as follows.
a. Synthesis of activated DOX-hydrazone linker.
The 13-keto position on the doxorubicin (DOX) molecule was targeted by activating
DOX with EMCH (3,3´-N-[ε-Maleimidocaproic acid] hydrazide).21 Then, 0.1 mmol of
DOX.HCl was dissolved in 15mL anhydrous methanol in a dry 25mL round bottom flask.
EMCH (0.2 mmol) was dissolved in 2mL methanol and added to the DOX.HCl solution.
Two drops of trifluoroacetic acid were added to the reaction to catalyze the conjugation of
the hydrazide to the 13-keto position of the DOX. The reactants were stirred at room
temperature in the dark for 8h. The reaction solution was concentrated by rotary
evaporation to 4mL and the DOX-HZN conjugate was obtained by precipitation in ice-cold
anhydrous acetonitrile. This purification step was repeated thrice. The product was
collected by centrifugation and dried under vacuum. The DOX-HZN was characterized by
1H-NMR and stored at -20°C till further use.
b. Formation of SH-MNC intermediate
First, the available primary amine groups in the formulation were quantified by
Fluorescamine assay.22 Briefly, 2mg of MNC-4 formulation was dispersed in DI water at a
concentration of 0.05mg/mL. Fluorescamine reagent was dissolved separately in acetone
at a concentration of 3mg/mL. About 0.15mL of the formulation was placed in a flat-bottom
black-walled 96-well plate. 50μL of the Fluorescamine reagent was added to each sample
and mixed vigorously for a minute. The fluorescence was measured immediately at ex/em
wavelengths of 400/460nm on a plate reader. A 6.7 mg/mL (equivalent to 10 μmoles/mL
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of –NH2 group) solution of PLK10-PEG113 polymer was diluted at concentrations equivalent
to 0.01, 0.05, 0.1, 0.25, 0.5, 1 and 2 μmoles of –NH2 group, mixed with Fluorescamine
and fluorescence intensities were measured to obtain the standard curve.
Of the total available -NH2 groups, 25, 50 and 75 mol% were targeted for conjugation
with the heterobifunctional linker SPDP. Briefly, the formulation was dispersed in DDW at
10 mg/mL and divided into three parts of 5mL each. 15mg (48μmoles) SPDP was
dissolved in DMF to obtain a 20mM solution and volumes corresponding to 5, 11 and 16
µmoles of SPDP were added to the three vials containing the MNC-4 formulation. The
reaction was stirred in dark for 4h followed by centrifugal filtration (3000 MWCO) and three
washings to remove the unreacted SPDP and resuspended in PBS. DTT was dissolved
in PBS at 10 mg/mL. 0.2mL of this solution was added to each sample and stirred for 8h.
Excess DTT was quickly removed by centrifugal filtration. The sample was washed twice
and re-suspended in water to obtain the stable SH-MNC intermediates. The success of
the conjugation reaction and conversion of the disulfide to free thiol was assessed by
DTNB assay for free thiol.23
c. Formation of DOX-MNCs
DOX-MNCs were synthesized by conjugation of the activated DOX-HZN to the SHMNC intermediate. Briefly, DOX-HZN was dissolved in methanol and added to the SHMNC at a 2:1 molar ratio. The reaction was stirred overnight in dark. The final DOX-MNC
formulations namely 4a, 4a and 4c were obtained by centrifugal filtration and extensive
washing in PBS to remove the unbound drug. The conjugation efficiency (%CE) was
estimated by fluorimetry in pH 4 acetate buffer at ex/em 480/580 nm.
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3.2.2.5 Doxorubicin release study
Doxorubicin release from the final formulation was studied in sodium acetate buffer
solution pH 5.5 (ABS), sodium phosphate buffered saline pH 7.4 (PBS) and in a
combination of PBS (1 day) followed by ABS (4 days). Briefly, the MNC-4B formulation
was diluted to concentration equivalent to 10μg/mL DOX in respective buffers. 1mL of
each dilution was placed in Float-a-Lyzer dilution membrane tubes and placed in an amber
colored vial (30mL) containing 24mL of the corresponding buffer at 37°C as the release
medium. The samples (n = 3 per pH group) were stirred at 100rpm. 0.2mL aliquots were
collected from the release medium at regular time points and replaced by same volume of
fresh buffers. The drug release was quantified by fluorimetry at Ex/ Em of 480/ 580 nm
respectively. For the combination group, after 24h in pH 7.4, the release medium in the
vial was replaced by same volume pH 5.5 ABS and the study was continued for 4 more
days.
3.2.2.6 Determination of Formulation toxicity
The effect of amine-group modification on toxicity of the empty formulations was
studied in A2780 human ovarian cancer and MDA-MB-231 triple negative human breast
cancer cells by MTT assay. Briefly, 3x103 cells per well were seeded in 96 well plates and
allowed to adhere for 24h. The cells were then treated with different concentrations of
each of the three SH-MNC-4 formulations and incubated for 24h and 72h. At the end of
each time point, the supernatant medium was replaced with fresh complete medium and
the cells were incubated further for 12h to allow the cells to revive. Finally, the cell viability
was measured by standard MTT assay. Briefly, 20μl of a 5mg/mL solution of MTT dye in
PBS was added to each well and incubated for 3.5h. The supernatant was then removed
and the formed formazan crystals were dissolved in DMSO. Formazan concentration was
quantified through measurement of absorbance at 560nm. Cell viability was normalized to
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the untreated control to obtain viability percentage values. The cell viability of the modified
formulation was compared with that of the unmodified MNC-4 formulation.
3.2.2.7 Cellular uptake of MNCs
A2780-WT ovarian cancer cells and MDA-MB-231 triple negative breast cancer cells
(6 million cells/ flask) were treated with a 5mL colloidal dispersion of the different DOXMNC formulations (equivalent to Fe concentration of 5μg/mL) and incubated for 24h. At
various time points during the incubation period the cells were washed once with ice-cold
PBS and acid saline (pH 3) and harvested. The viability was determined by trypan blue
assay and then the cells were centrifuged to form a pellet. The supernatant was removed
completely and 0.5mL of a 100ppb solution of Iridium in 2% HNO3 was added to the pellets
as an internal standard. The cells were then lysed mechanically by probe-sonication. 50μL
concentrated nitric acid (TraCERT; Fluka) was added to the cell lysates and the samples
were digested overnight at 70°C. The digested samples were then appropriately diluted to
5mL with 2% HNO3. The cell debris was separated by ultra-centrifugation at 7500 rpm for
10 min. The supernatant was further filtered through 0.2μm syringe filters and analyzed
by Nexion 300-D ICP-MS equipped with collision cell and autosampler (Perkin Elmer,
location USA). The intensity of the
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Fe isotope was considered for quantification of the

uptake. The final Fe content was normalized to the total protein content of the cells (as
determined by standard Bicinchoninic acid (BCA) assay) and MNC uptake was expressed
as μg of Fe per mg of total cellular protein.
Simultaneously, live-cell confocal microscopy was performed to study the cellular
localization pattern of the different fluorescent-labeled DOX-MNC formulation. A2780-WT
and A2780-CisR cells were incubated with Alexa Fluor®-647 labeled DOX-MNCs for 1, 3
and 24h followed by visualization under a LSM 710 (Zeiss, CA) confocal microscope
equipped with a live-cell imaging stage.
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3.2.2.8 In vitro Cytotoxicity of DOX-MNCs
The in vitro cytotoxic potential of the DOX-MNC formulations was estimated in A2780WT human ovarian carcinoma and MDA-MB-231 triple negative human mammary
adenocarcinoma cell lines. Briefly, the cells were cultured in complete DMEM in conditions
mentioned previously. Cells were seeded at a density of 5x103 per well in 96-well plates
24h before treatment. The cells were treated with free DOX, blank MNCs or the three
DOX-MNC formulations at different concentrations. The cells were incubated for 24h and
72h. At the end of each time point the cells were washed, the culture medium was replaced
with fresh complete DMEM and the cells were further incubated for 12h. Finally, the cell
viability was estimated by standard MTT assay and described previously in Chapter 2.
3.2.2.9 In vitro determination of MR potential
Approximately 10 million A2780-WT and MDA-MB-231 cells were incubated with DOXMNC-4c formulation at Fe concentrations of 0.009, 0.018 and 0.09 mM for a period of 24h.
After incubation for specified time points, the cells were harvested and cell viability was
determined by trypan blue assay. Approximately, 9x106 viable cells were re-dispersed in
0.5mL PBS and mixed carefully with equal volume of hot 4% w/v agar solution taking care
to prevent entrapment of air bubbles in the solidified gel. The samples were cooled to RT
for to allow the formation of a solid matrix. As a control 9x106 un-treated cells were used.
Phantom gels were scanned in Siemens Magnetom TIM Trio 3T human MR scanner.
Images of the phantom gels were obtained by using a multi-gradient echo pulse sequence
at a 1.64ms/3000ms TE/ TR and 40° flip angle for T1 and 112.5ms/ 3000ms TE/ TR for T2.
The cellular phantoms were compared with phantoms of similar concentrations of
formulations without any cells.
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3.3 RESULTS
3.3.1 SYNTHESIS AND CHARACTERIZATION OF CORE MNPS

Figure 3.1. Synthesis of core MNP particles from thermal decomposition of
Fe(acac)3. TEM images of MNPs synthesized by A. ramp-soak and B. direct
injection method of thermal decomposition and respective size distributions C
and D. Magnetization potential (M) of the two MNPs was determined by SQUID
magnetometer (E).
Core MNPs with two different mean particle sizes were synthesized by thermal
decomposition of Fe (acac)3 in benzyl alcohol using two different techniques. In the first
ramp-soak method wherein the reaction mixture was kept isothermal at 150°C for 2hrs,
MNP cores of mean size 9.3 nm (Figure 3.1A) were obtained with a broad size distribution
(Figure 3.1B). In comparison, the hot injection method yielded MNPs with a larger core
size of 14.4nm (Figure 3.1C) with a very narrow size distribution (Figure 3.1D) and a
significant fraction of the MNP population above 13nm. The magnetization potential of
MNP cores was further studied by SQUID magnetometer. MNPs synthesized by hot
injection exhibited significantly higher magnetization saturation (Ms) of 74.3 emu/g
compared to 24.7emu/g for 9.3nm particles (Figure 3.1E).
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3.3.2 PREPARATION AND CHARACTERIZATION OF CATIONIC MNCS
Poly (l-lysine)x-PEG113 polymers of different poly (L-lysine) block lengths (x = 10, 50
or 100) were used to stabilize the MNPs into clusters by a process described previously
in Chapter 2. The physico-chemical characteristics of the different formulations are shown
in Table 3.1. The cluster formation was effected by electrostatic interactions between the
MNP surface and the positively charged ε-primary amine end group of the cationic PLK
block. As seen in Figure 3.2, the cluster size was affected by the poly (L-lysine) block
length as well as the size of the core MNPs. 9.3nm MNPs stabilized by PLK10-PEG113,
PLK50-PEG113 and PLK100-PEG113 had hydrodynamic diameters (Deff) of 36.4, 44.2 and
82.1 nm respectively. MNC-1 formulation showed the maximum MNP content of 29.2 wt%.
On the other hand, MNC-4 formulation, comprising of 14.4nm MNP had Deff of 121.3 nm
with 28.3 wt% MNP content. The size (r.u.) of the PLK block of the cationic copolymer and
the resulting polymer content in the MNCs, together dictated the colloidal stability of the
clusters (Figure 3.3). While all the formulations maintained colloidal stability over a onemonth period in PBS (20mM, pH 7.4), MNC-1, stabilized by PLK10-b-PEG113 showed a
significant increase in Deff from 36.4nm to 68.3nm over this period.

Table 3.1: Physico-chemical characterization of magnetic nanoclusters stabilized by different PLK-PEG block copolymers

Composition
Core
MNP
Formulation

Abbreviation

Size
(nm)

(b)

DLS Characteristics

(wt%)
Organic

DI water

Components
MNP

(a)

Polymer

(d)

BA

Deff
(nm)

PBS pH 7.4

PDI

ζpotential
(mV)

Deff

PDI

(nm)

PLK10-PEG113MNP-9

MNC-1

9.2

66.9

3.9

29.2

36.4 ±
6.3

0.211 ± 0.01

+20.5

32.3 ±
3.3

0.202 ± 0.01

PLK50-PEG113MNP-9

MNC-2

9.2

74.7

3.1

22.2

44.2 ±
4.1

0.183 ± 0.01

+28.3

43.1 ±
5.2

0.211 ± 0.01

PLK100PEG113-MNP-9

MNC-3

9.2

73.3

3.8

22.9

82.1 ± 6

0.209 ± 0.03

+35.4

76.2 ±
5.1

0.219 ± 0.02

PLK50-PEG113MNP-14

MNC-4

14.4

68.3

3.8

28.2

121.3 ±
3.4

0.143 ±
0.001

+44.7

114.7
± 2.4

0.137 ± 0.02

a) The average core size was estimated from TEM images by measuring a minimum of 400 core particle sizes with Image J software.
b) Composition of the MNCs was determined by TGA
c) Benzyl alcohol: Briefly, the content of benzyl alcohol coating on the MNPs was determined by loss of organic components upon thermal
decomposition of MNPs. The total loss of the organic components upon thermal decomposition of the MNCs was corrected by subtraction of
the content of BA to determine the polymer content of the MNCs
d) DLS characteristics were measured at 25°C at a concentration of 1 mg/mL in DI water and 10mM PBS at pH 7.4 in clear disposable zeta cell
with Malvern Nano-ZS Zetasizer. Measurements in PBS were performed in 10 mM PBS at pH 7.4.
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Figure 3.2. TEM images of A. MNC-1, B. MNC-2, C. MNC-3, D. MNC-4 clusters
synthesized from PLK-b-PEG113 polymers with different PLK r.u.
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Figure 3.3. Colloidal stability of different MNCs stabilized by PLK-b-PEG with
different r.u. of PLK.

A

B
MNC-4
MNC-4 GEL 150
100

0.6
R2

R1

0.8

MNC-1
MNC-2
MNC-3

0.4
0.2
0.0

50

0.1

0.2 0.3
Fe (mM)

0.4

0
0.0

0.1

0.2 0.3
Fe (mM)

0.4

Figure 3.1. Relaxivity measurements of different MNC formulations in PBS. R1
(A) and R2 (B) Relaxation rates of were plotted against Fe concentration to obtain
r1 and r2 relaxivities (s-1.mM-1; Table 2) as the slopes of the linear curves so
obtained. MNC-4 gel sample dilutions were made in 4% agar gel in PBS
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Table 3.2. Longitudinal (r1) and transverse (r2) relaxivity values of different MNCs

Formulation

r1
.-1

r2
-1

.-1

(s .mM )

(s .mM-1)

MNC-1

0.9 ± 0.04

93.2 ± 2.2

MNC-2

0.62 ± 0.02

177.3 ± 6.5

MNC-3

1.28 ± 0.02

294.1 ± 2.1

MNC-4

1.02 ± 0.01

358.5 ± 7.4

MNC-4 in gel

1.01 ± 0.08

313 ± 12.9

Relaxivity measurements of the different MNCs were performed in DI water and
PBS on a 7T MRI scanner (Figure 3.4). The ability of MNPs to decrease the relaxation
time of the surrounding water protons is quantified as relaxivity i.e. the slope of the
plots of longitudinal (R1) or transverse (R2) relaxation rates vs. Fe concentrations. As
tabulated in Table 3.2, the transverse relaxivity (r2) of the different formulations
increased with the cluster size and as a function of the total MNP content of the
formulations with the exception of MNC-1 formulation, which in spite of having a high
MNP content of 29.2 wt%, had the lowest r2 of 93.2 ± 2.2 s-1.mM-1. This can be
attributed to the smaller cluster size of 33nm as well as the lack of compactness of the
clusters (Figure 3.2). MNC-2 and MNC-3 clusters had identical MNP content of 23
wt%, but the MNC-3 showed significantly higher relaxivity (358.5 ± 7.4s-1.mM-1) than
MNC-2 (294.1 ± 2.1 s-1.mM-1), which had nearly half the Deff as that of MNC-3. MNC4 formulation, with the core MNP size of 14.4nm, largest cluster size and evidently a
higher MNP content of 28 wt% had the maximum r2 relaxivity of 358.5 ± 2.2 s-1.mM-1.
MNC-4 exhibited only a marginal decrease in relaxivity even when embedded in
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phantom agar gels. As noted in Chapter 2, agar gel is widely used to mimic soft tissues
in in vitro assessment of MRI contrast agents. Given the physical characteristics of the
MNPs used for MNC preparation, none of the formulations exhibited high longitudinal
relaxivity (r1).
3.3.4 DOXORUBICIN CONJUGATION ON MNCS VIA PH SENSITIVE LINKER
Scheme 3.1. Doxorubicin conjugation to MNC-4 formulation via hetero-bifunctional linker SPDP

MNC-4 formulation was selected for all further studies due to its excellent colloidal
stability and high relaxivity in physiological buffer (PBS). Doxorubicin HCl (DOX) was
conjugated onto the formulation via the heterobifunctional pH sensitive linker SPDP in a
stepwise manner. Firstly, DOX was activated at its 13-keto position with EMCH, a
heterobifunctional hydrazide linker in presence of trifluoroacetic acid as a catalyst as
shown in Scheme 3.1A. The activated DOX-HZN molecules were characterized by 1H-
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NMR (Figure 3.5). In a separate reaction, the side-chain primary amine groups of the poly
(l-lysine) block were conjugated to another heterobifunctional linker SPDP. Following
successful conjugation to the MNCs the disulfide linkage on the other end was reduced
by DTT and DOX-HZN was conjugated to the MNCs via a thioester bond to the SPDP
molecule (Scheme 3.1B). Three different target conjugation efficiencies were attempted
as tabulated in Table 3.2.

Figure 3.5. 1H-NMR of (A) free DOX and (B) DOX-HZN. Selected peak assignments
common to both (A) and (B) are as follows: δ ppm = 1.7 (2H, m, -NH2, 4), 3.39 (3H, s, CH3, 2), 4.69 (2H, d, -CH2, 5), 5.37 (1H, s, -OH, 3), 7.65 (1H, s, -CH, 1). Additional peak
assignments of the modified DOX-HXN are as follows: 1.32 (2H, s, -CH2, 7), 4.0 (2H, s, CH2, 8), 7.86 (H-H, CH-CH, 9), 10.57 (1H, s, -NH, 6).
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Depending on the number of primary amino groups targeted for DOX-HZN, all three
formulations showed a %CE of approximately ~5 wt%. Formulation DOX-MNC-4c
exhibiting the maximum %LC of 2.48 wt%. DOX conjugation had no effect on the cluster
size as well as PDI of the formulations. However, this modification significantly reduced
the zeta potential of the final formulations. MNC-4 formulation had a zeta potential of +44
mV before DOX conjugation, which reduced to less than +25 mV (Table 3.3) following
DOX-HZN conjugation, which we anticipated would help reduce the charge-induced
formulation toxicity of the MNCs.

Table 3.3: Physico-chemical characteristics of DOX-MNC conjugates
DLS Characteristics in DDW(b)

Formulation

Target Conjugation (Eq.
mol % of available primary
amino groups (a)

Deff

PDI

DOX-MNC-4a

15

129.7 ± 4.2

0.163 ± 0.005

DOX-MNC-4b

30

121.7 ± 5.3

DOX-MNC-4c

50

125.7 ± 2.7

%CE

ζ-potential
(mV)

%LC

(C)

(d)

21.5

5.3

0.93

0.161 ± 0.004

17.7

4.2

1.51

0.153 ± 0.002

13.8

4.6

2.48

a) The total primary amino groups (μmoles) available for DOX conjugation per mL of the MNC formulation was determined by
Fluorescamine assay.
b) Physical characteristics of the final DOX-MNC formulations was determined by DLS
c) Conjugation efficiency: Defined as the %fraction of the targeted μmoles of primary amino groups that was conjugated by DOX.
DOX content per mL of the formulation was quantified by fluorimetry at Excitation/ Emission wavelengths of 480nm/ 580nm
d) Loading Capacity was determined as the weight percent of DOX.HCl per the dispersed phase. Briefly, the drug-loaded MNCs were
lyophilized and the amount of DOX.HCl per mg of the formulation was determined by fluorimetry. Briefly 0.2mL of the final DOXloaded formulations was lyophilized. The lyophilized formulation was weighed and dispersed in pH 4.5 acetate buffer for 48h
followed by sonication for 1h and ultra- centrifugation at 10,000 rpm for 15 minutes. The fluorescence of the supernatant was
measured by fluorimetry as mentioned in (c)
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3.3.5. PH RESPONSIVE RELEASE OF DOX FROM MNCS
The efficacy of the acid-labile hydrazone linkage in achieving a physiological stimuliresponsive drug release was studied on DOX-MNC-4b formulation, which had the
intermediate %LC of the three formulations. We evaluated DOX release separately for a
period of five days in pH 7.4 PBS, pH 5.5 ABS. In addition, we also studied the effect of
sequential exposure to both pH conditions. For this study the formulation was placed in
PBS for 24h after which the release medium was changed to pH 5.5 ABS and the release
was further monitored for the remaining four days. The last approach was adopted
specifically to evaluate the potential effect of pre-exposure to physiological buffer may

% Cumulative Release

have on the release rate of the drug in acidic pH.

pH 7.4 PBS
pH 5.5 ABS
pH 7.4/ pH 5.5
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Figure 3.6. Release of DOX from MNC-4b formulation at different pH conditions. DOX
release was measured in either 50mM pH 5.5 sodium acetate buffer (ABS), 10mM pH
7.4 PBS or sequentially in pH 5.5 ABS buffer for 24h followed by pH 7.4 PBS for a total
of 5 days Drug release was quantified at regular time points by fluorimetry at Ex/Em
wavelengths of 480/580 nm. (n = 3 per group). Data are mean ± SD. ****: p < 0.0001
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As expected, the acid-labile hydrazone bond efficiently prevented the release of DOX
from the clusters (Figure 3.6). Only 4.3% drug was release in PBS in the first day and
overall only 23.3% DOX was released in PBS over a five-day period. On the other hand,
formulation in pH 5.5 ABS responded favorably to the acidic environment and 22% of the
conjugated DOX in the first 24h. Over a five-day period 92% release was achieved in ABS.
Formulation exposed sequentially in PBS for 1day followed by ABS for four days did not
show any aberration in the release profile following changeover to ABS medium from PBS
after 24h.
Thus, DOX conjugation on the MNCs via acyl hydrazone linkage allows for controlled
release in response to pH stimuli inside the cell. However, it is noteworthy that hydrazone
hydrolysis occurs rather slowly even at pH 5.5, a condition similar to that found in
subcellular compartments. In summary, the rate of drug release appears to be determined
primarily by the intrinsic rates of hydrazone hydrolysis and is governed by pH changes
only.
3.3.6 FORMULATION TOXICITY STUDIES
Cationic polymers such a poly (L-lysine) and nanocarriers thereof present with one
major challenge; that of charge induced toxicity of the polymer itself. It is now known that
molecular weights as well as the cationic charge density of the polycations are the key
parameters for the interaction with the cell membranes and consequently cell damage. 24
Studies on poly(ethyleneimine) (PEI) polymer revealed that the polymer does not cause
apoptosis but rather a necrotic cell reaction.

Nonetheless, cationic polymers are

exclusively used in gene delivery wherein condensation of the negatively charged DNA
neutralizes the net charge of the polyplexes.
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Figure 3.7. Toxicity of SH-MNC formulations prior to DOX-HZN conjugation in
MDA-MB-231 (A,B) and A2780-WT cells at 24h (A,C) and 72h (B, D)
In order to determine the toxicity of our formulation before DOX conjugation we
conducted toxicity studies on the unloaded MNC-4 formulations (SH-MNC-4a-c) in the two
cancer cells lines, namely MDA-MB-231 triple negative breast cancer cells and A2780 wild
type ovarian cancer cells. Cells were exposed to different concentrations of SH-MNC
formulations for 24h and 72h. At the end of each time point, the treatment was removed,
the cells were washed with heparinized PBS (0.2 mg/mL Heparin sulfate) and allowed to
grow for additional 12h in fresh media. The cell viability was measured by MTT assay as
described in Section 2.2.2.9 of Chapter 2. SPDP conjugation and subsequent reduction
of the disulfide bond significantly reduces the toxicity of the cationic MNC-4 formulations
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(Figure 3.7). Depending on the extent of SPDP conjugation on the side-chain primary
amine, the formulation toxicity decreased as SH-MNC-4a > SH-MNC-4b > SH-MNC-4c.
The formulations exhibited marginally higher toxicity in A2780 cells at 24h compared to
MDA-MB-231 cells. However, at the end of 72h both the cell lines showed similar toxicity
profiles. Overall, all the modified formulations were well-tolerated up to concentration
equivalent to 10 μg/mL of Fe with cell viabilities being above 80% in all cases. Formulation
SH-MNC-4a showed relatively higher toxicity at 25 μg/mL of Fe. Nonetheless, compared
to the unmodified MNC-4 formulation, all the SH-MNC-4 formulations showed marked
reduction in charge-induced toxicity.
3.3.7 CELLULAR UPTAKE STUDIES
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Figure 3.8. Cellular uptake of SH-MNC formulations in A. 2780 (wild type) and B.
MDA-MB-231 cells over a period of 24h quantified by ICPMS Data represented as
Mean ± SD. Statistical significance denoted as **: p< 0.01, ***: p< 0.001
Intracellular uptake of the cationic formulations was studied by ICPMS and confocal
microscopy in A2780-WT ovarian cancer and MDA-MB-231 triple negative breast cancer
cells. We first evaluated the effect of SPDP conjugation on the cellular uptake of the three
SH-MNC formulations by ICPMS. It was observed that the degree of modification inversely
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affected the cellular uptake. Thus, SH-MNC-4a formulation, which had the least SPDP
modification and a higher positive zeta potential showed maximum uptake in both the cell

167

Figure 3.9: Qualitative estimation of cellular uptake of DOX-MNC-4c formulation over a
period of 24h in A2780-WT ovarian cancer and MDA-MB-231 cancer cells by confocal
microscopy. Cells were incubated with DOX-MNC-4c formulation (Orange) conjugated
with Alexa-Fluor 647 (Red) for different time intervals followed by incubation with
Lysotracker (Green) and Hoechst nuclear stain (Blue). Colocalization of the MNCs in
lysosomes is seen in overlay (yellow punctate regions).
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lines. The other two formulations did not show a significant difference in cellular uptake.
Between the two cell lines, uptake rate was faster in the ovarian cancer cell line. At the
end of 24h ovarian cancer cells showed an uptake equivalent to 8.4 μg/mg of total protein
while the breast cancer cells showed an uptake of 6.6 μg/mg of total protein (Figure 3.8).
Of the three DOX-loaded formulations, DOX-MNC-4c was further selected for confocal
microscopy studies to qualitatively evaluate the uptake of the formulation and also to study
the cellular localization pattern of the formulation. For this study the cells were seeded in
8-Chamber confocal slides and allowed to grow for 24h. The cells were then incubated
with Alexa-Fluor 647-labelled DOX-MNC-4c formulation for 1h, 3h and 24h. At end of each
time period the cells were washed thoroughly and further incubated with lysosomal marker
lysotracker green and Hoechst nuclear stain for 1h and 30min respectively. As seen in
figure 3.9 cationic formulations (red/ red + orange) were associated with the cell
membrane immediately (1h) post incubation. As time progressed, the membraneassociated MNCs were internalized and localized within the lysosomes as seen from the
yellow overlay images. DOX, either bound with the formulation or as a free drug (orange
punctate either by itself or embedded in red MNC fluorescence) was also seen localized
within the lysosomes. Confocal microscopy confirmed the results of ICPMS wherein
A2780-WT cells showed rapid cellular uptake than MDA-MB-231 cells.

169
3.3.8 IN VITRO ANTI-CANCER EFFICACY STUDIES OF DOX-MNC FORMULATION
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Figure 3.10: Cytotoxic efficacy of different DOX-MNC-4 formulations in MDA-MB-231 (A,
B) A2780-WT (C, D) cells at 24 and 72h. Data represented as Mean ± SD (n = 6)
Table 3.4: IC50 values (μM) of the different DOX-MNC-4 formulations in A2780-WT
ovarian cancer and MDA-MB-231 breast cancer cells
A2780-WT

Group

MDA-MB-231

24h

72h

24h

72h

DOX.HCl

0.024 ± 0.013

0.014 ± 0.003

0.496 ± 0.028

0.08 ± 0.009

DOX-MNC-4a

0.145 ± 0.01

0.059 ± 0.006

--

0.371 ± 0.021

DOX-MNC-4b

0.103 ± 0.006

0.038 ± 0.01

--

0.382 ± 0.019

DOX-MNC-4c

0.162 ± 0.002

0.042 ± 0.008

1.55 ± 0.024

0.223 ± 0.016
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The in vitro therapeutic efficacy of the three cationic DOX-MNC-4 formulations with
different %LC of DOX was determined in A2780-WT and MDA-MB-231 cells by MTT
assay. As anticipated, all formulations showed higher IC50 values than free DOX. The
cytotoxicity was dependent on the rate of uptake of the formulations. Also, DOX release
was guided by a pH-dependent mechanism wherein the drug could be released and
available for activity only in the lysosomal pH. Likewise, all formulations showed lower
cytotoxicity at the end of 24h, particularly in MDA-MB-231 cells wherein only DOX-MNC4a formulation exhibited at least 50% toxicity (Figure 3.10 and Table 3.4). At 72h,
however, the formulations exhibit toxicity proportional to %LC of DOX in each. Thus, DOXMNC-4b and 4c formulations had similar IC50 of 0.038 and 0.042 μM respectively in
A2780-WT cells. Triple negative MDA-MB-231 cells, due to a slower uptake rate showed
a nearly 4-fold higher IC50 than A2780 cells across all treatment groups, with DOX-MNC4c formulation showing the highest cytotoxicity of all the nanoformulations tested. The IC50
of DOX-MNC-4c in MDA-MB231 at 72h was 0.223 μM.
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3.3.9 IN VITRO DETERMINATION OF MRI POTENTIAL OF CATIONIC MNCS

Figure 3.11: In vitro evaluation of MRI potential of DOX-MNC-4c formulation. T1 and T2
images of phantom gels of A2780-WT and MDA-MB-231 cells incubated with different
concentrations of DOX-MNC-4c formulation. The contrasts of the cellular phantom gels
were compared with those obtained from serial dilutions of the formulation in absence of
cells

In the next step, we evaluated the MRI potential of DOX-MNC-4c formulation was
evaluated in both the cell lines mentioned in the previous section. Following 24h incubation
with the said formulation at concentrations equivalent to 0.009, 0.018 and 0.09 mM Fe,
the cell viability was determined by trypan blue assay and 9 million live cells per group
were mixed uniformly with molten agar and cooled to mimic soft tumor mass. These gels
were then scanned in Siemens 3T human scanner to obtain T1 and T2-weighted contrasts
(Figure 3.11). The phantom contrasts without cells echoed the trend seen in relaxivity
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measurements. The formulation did not show any change in positive (T1) contrast. The
negative (T2) contrast, on the other hand showed a dose dependent increase. The cellular
phantom gels also showed significant dose-dependent increase in contrast. A2780 cells
showed a greater contrast compared to MDA-MB-231 cells due to comparatively higher
uptake in A2780 cells. It is noteworthy that the contrast obtained for the cationic MNC is
significantly higher in comparison to that obtained with the anionic MNCs discussed in the
previous chapter.
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3.4. DISCUSSION
In spite of significant advances made in the field of nanomedicine for cancer therapy,
numerous problems continue to plague the successful entry of these promising drug
delivery systems into clinical use. A major cause of this impediment is insufficient
characterization and lack of understanding of the interactions of various nanoformulations
in vivo. Although the enhanced permeability and retention (EPR) effect is viewed as a key
motivation for the use of nano-scale drugs to treat solid tumors, physiological barriers
posed by the tumor microenvironment hamper uniform delivery of nanoparticles in
amounts sufficient to eradicate cancer. Nanoparticle size, shape and surface charge (zeta
potential) have been seen as key factors interacting with physiological tissues and thus
affecting the uptake of the particles. Predominantly, zeta potential or surface charge
density of the nanoparticles significantly affects their intracellular uptake. Even relatively
small positive zeta potential has been shown to cause more than two folds increase in
intracellular uptake as well as transvascular flux of the nanoparticles.25

PLK-based

nanocarriers, by virtue of their high cationic nature, have shown significant increase in
cellular uptake of such nanocarriers in vitro as well as in vivo. Cationic nanoparticles made
from these polymers have shown significant anti-angiogenic properties in animal models26
due to the enhanced uptake and accumulation of these intravenously administered
cationic systems in the tumor tissue. Poly (L-lysine) serves as a good polymer for
development of nanocarriers capable of interacting favorably with the cell membranes to
achieve enhanced drug delivery.
Development of MNPs for cancer theranostics requires development of nanoparticle
cores with superior magnetic properties, which are governed by their core size. A precise
control over the nucleation and growth phases during the synthesis of core MNPs is a
prerequisite

to

synthesizing

monodisperse

magnetic

nanoparticles.

Thermal
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decomposition method provides this control over particle size, thereby enabling synthesis
of larger MNPs, which are known to show higher T2 relaxivity. The prolonged in situ
tempering of the formed MNPs at high temperatures further enhances the magnetization
saturation of the resulting MNPs. Size distribution of the cores so formed is also a critical
parameter. In the ramp and soak technique, which was similar to the techniques described
in the precious chapter, this separation was achieved by heating the reactants at 150°C
(nucleation temperature deduced in chapter 2) for 2hrs during which time maximum
amount of Fe(acac)3 was reduced by the solvent to form nuclei. The subsequent ramp in
temperature to reflux initiated the growth phase, which utilized the remaining precursor for
increasing the core particle size. This method resulted in a broad size distribution. Hot
injection method offered significant advantages over this conventional method. The fast
injection of the precursor in a solvent, which was already at reflux, induced a high degree
of super-saturation, resulting in a transient burst of nucleation as the temperature dropped
to about 165°. As the temperature rose rapidly once again to reflux it prevented any further
nucleation and promoted uniform growth of the formed nuclei. This entire step was very
short and lasted for about 10 minutes only and led to large-sized nanoparticles above
13nm and with a very narrow size distribution.
The prolonged high temperature annealing of the formed MNPs imparts superior
magnetic properties to the MNPs formed by both methods. However, several factors affect
the magnetic properties, most predominant being the core diameter and size distribution.
In the nanometer regime, the MNPs comprise of single domains and hence exhibit
properties different than those of the bulk material. In such clusters of single-domain
MNPs, the magnetic moment of each particle interacts with its neighbors and the field to
align in the direction of the magnetic field. The magnetization at which all the moments
are aligned is referred to as the saturation magnetization (Ms).27 Particles obtained by hot
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injection method exhibited nearly 3-fold higher Ms compared to those obtained from the
ramp soak method. Even in comparison to the once commercially available Feridex®28,
the MNPs obtained by hot injection method had higher Ms. This is predominantly due to
the particle size and narrow size distribution of the core particles. The complete absence
of hysteresis indicated absence of any remnant magnetization upon removal of the
magnetic field, thereby confirming their superparamagnetic nature.
MNCs were prepared by formation of coordination complexes between the MNP
surface and the pendant primary amino groups of the PLK-b-PEG copolymers. Due to the
absence of strong hydrophobic surfactants such as oleic acid and oleylamine coating the
MNP surface, this synthesis could be carried out by a completely hydrophilic process
similar to the process described in Chapter 2. The resulting cluster size was dictated by
the r.u. of l-lysine in the PLK block. The block length also affected the colloidal stability of
the MNCs. In a sharp contrast with the MNCs stabilized by anionic block copolymers in
the previous chapter, the cationic MNCs showed significant stability thus suggesting that
the coordination complex between the primary amino group and MNP surface is
significantly stronger than that between the carboxylate group and MNPs. Hence, none of
the clusters showed complete loss of stability. MNC-1 clusters however, showed an
increase in Deff over the period of one month. This increase can be attributed to the lack
of compactness in the MNCs (Figure 2) formed by the shortest copolymer (PLK r.u. 10).
.Compared to the other MNCs, MNC-1 also had significantly less polymer content, which
also indicates incomplete surface coverage and hence a high propensity to lose colloidal
stability. In comparison, MNC-4 clusters, which were synthesized from PLK50-b-PEG113
and MNPs with core size 14.4nm, showed only marginally higher polymer content than
MNC-1 and yet this formulation showed significantly higher colloidal stability. This
highlights the important role played by the PLK block length in stabilization of the clusters.
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Copolymers with a larger PLK block imparted significantly greater interactions with the
MNP surface, thus covering a greater MNP surface area, thus preventing agglomeration
and loss of colloidal properties.
As mentioned in Chapter 2, relaxivity is an important property of MNPs. It is a measure
of the MRI potential of the contrast agent. Numerous factors such as method of MNP
synthesis, MNP core size, the type of stabilizing agent and the MNP content in the cluster,
all cumulatively affect relaxivity of MNP-based MR contrast agents. This reflects in the T2
relaxivity (r2) of the MNCs as mentioned in Table 3.2. In spite of having the highest MNP
content amongst the four different types of clusters synthesized, MNC-1 showed the
lowest r2 values. The lack of compactness of the MNC-1 clusters is a prime cause of this
result. MNPs are known to exhibit higher r2 when held together closely in clusters. The use
of hydrophilic polymers further enhances r2 by increasing not only the diffusion but also
the retention time of water molecules in close proximity with the MNP surfaces.29-31 As a
result, in clusters with same core MNP sizes, the composition of the cluster, cluster size
and the resulting compactness governed the diffusion and retention of water molecules in
the interior of the clusters and hence also the relaxivity. MNC-4 clusters exhibited the
maximum r2 relaxivity due to a large core size, largest cluster size and effectively
maximum water retention in the core.
DOX loading onto the MNCs was achieved by conjugation of the modified DOX-HZN
molecule to the pendant –NH2 groups on the MNC clusters. DOX molecule can be
activated at two sites, the 3’-amino and the 13-keto position. However, DOX ligated at 3’amino group has reduced anti-cancer activity due to energetically unfavorable
intercalation of DOX in the minor groove of DNA.32 Conjugates obtained by modification
at 13-keto position do not cause any change in the activity of the molecule. Hence we
selectively targeted the hydrazine-containing EMCH molecule to this site to obtain a pH
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sensitive DOX-HZN molecule Further, the DOX-HZN was conjugated to the SPDPmodified MNCs via thioether ester over the traditional disulfide linkage due to the
previously reported reduced stability of the disulfide bond under physiological conditions.33
The disulfide bond is susceptible to reductive mechanisms such as those of molecules
such as glutathione and other thiol containing molecules in the liver and plasma, which
can lead to premature release of the molecule and undesired toxicity. We intended to
achieve drug release selectively in the acidic environments of the lysosomal-late
endosomal compartments. Stimuli-responsive systems are specifically designed in order
to achieve rapid release only under specific conditions such as pH. The acid labile linkers
such as cis-aconityl26, 32 or hydrazone linkers34, 35 exhibit sufficient extracellular stability
and prevent the encapsulated payload from leaching during circulation. Such strategies
are also advantageous from the point of reducing the drug dose, as the likelihood of
maximum dose reaching the target tissue is very high in comparison to the passive slow
diffusion of the drug from the nanocarriers, which is governed primarily by hydrolysis. Drug
conjugation also imparts considerable control over the amount of drug loaded in the
nanocarriers. This control is absolutely essential in case of nanocarriers carrying multiple
modalities such as diagnostic and therapeutic payloads. An optimum drug: MNP ratio
needs to be achieved in the development of co-encapsulating theranostic nanosystems in
order to achieve a good contrast in the target tissue while ensuring that the DOX levels
are also sufficient to achieve a therapeutic effect.

Shielding of the ε-amino groups by thiol end groups marginally reduced the
positive zeta potential of the formulations. However, it did not affect the chargeinduced intracellular uptake of the MNCs in human ovarian and triple negative
breast cancer cells. The MNCs were internalized as early as 1h-post incubation.
The shielding of the ε-amino groups also reduced the toxicity of the unloaded
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clusters significantly. The higher uptake of the formulations translated into
significant intracellular toxicity of the formulations.
DOX is an anthracycline antibiotic used in the treatment of a wide variety of
malignancies such as breast, ovarian, sarcomas, lymphomas, and acute luekemias.
Intracellular free DOX accumulation varies from one cell line to another. However, most
36

cells achieve intracellular steady-state levels within 2–8 hr.

In addition to intracellular

accumulation, doxorubicin’s mechanism of action is also variable for different cell types.
For instance, Fulda et al.37, 38 concluded that DOX induces the apoptotic death signal in
different ways depending upon the cell line. Also, in comparison to the free drug
(DOX.HCl), DOX encapsulated within or bound to nanovehicles is expected to show a
slower onset of action, which is governed by the release profile of the drug from the
nanocarriers. Although in this case, the cationic MNCs show significantly faster uptake
within the first three hours, the pH-triggered release of DOX is a relatively slow mechanism
as seen in the in vitro drug release studies (Section 3.3.5 and Figure 3.6). All these
factors contribute to the slower onset of cytotoxicity and hence a higher IC50 compared to
the free drug. The different formulations exhibit different cytotoxic potential depending on
the %LC of DOX. This trend was seen in both cell lines, though was more prominent in
MDA-MB-231 cells wherein DOX IC50 values decreased with increase in DOX loading. We
attribute this difference to the DOX: MNP ratio in the three formulations.

A lower DOX

%LC or more MNP content can sterically hinder the exposure of the hydrazone linkage to
acidic pH and thus can retard DOX release. Nonetheless, the systems successfully
function as a pH controlled drug release nanoformulation, which by virtue of a sustained
release can prolong the therapeutic effect.
While MNPs larger than 7nm are predominantly negative contrast agents, the cluster
size and compactness of the cluster plays an important role in the enhancement of T2-
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weighted MR capability. DOX loading did not affect the MR potential of the MNCs. The
core MNPs used in MNC-4 clusters were above 13nm in diameter. The resulting high Ms
and significantly high r2 relaxivity values translated into superior negative contrasts of the
clusters embedded in agar phantom gels. The significantly higher cellular uptake of the
MNCs further enhanced the contrast of the MNCs.
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3.5 CONCLUSION
In summary, we successfully synthesized MNP cores devoid of any hydrophobic
surfactants and in the 14-20nm-size range by a one-step direct injection method.
Compared to the conventional ramp-soak method, the cores were highly monodisperse.
The larger 14nm MNPs showed stronger magnetic susceptibility and had a higher Ms
compared to the 9.3nm cores, which had a broader size distribution. PLK-PEG polymers
form a stable complex with MNP surfaces depending on the lysine block-length. The
cluster size also governed the relaxivity of the formulations. In comparison to the relaxivity
of Feridex (269.4 s-1.mM-1), MNC-4 formulation stabilized by PLK50-b-PEG113 showed
significantly higher relaxivity values. The cellular uptake of these formulations was
facilitated by their interaction with the negatively charged cell surface and subsequent
endosmolytic uptake. Compared to anionic formulations discussed in the previous
chapter, cationic MNCs showed a significantly higher cellular uptake. This can induce
significant toxicity in the cells. Modification of the free cationic side-chain primary amino
groups by heterobifunctional linker SPDP and subsequent reduction by DTT to introduce
thioester functionality significantly reduced the toxicity of the cationic formulation. DOX
modified by hydrazone linker was conjugated onto these thiol end groups to form a stable
thioester conjugate which would cleave only at the hydrazone linkage at an acidic pH with
no effect of redox conditions. Introduction of the pH sensitive linker resulted in a sustained
release of DOX exclusively in the acidic pH. End group modification also reduced the zeta
potential of the formulations, which in turn also altered the uptake of the formulations
depending on the degree of modification.
The formulations showed differential uptake in A2780 ovarian cancer and MDA-MB231 triple negative breast cancer cells. This difference in uptake also influenced the
cytotoxic efficacy of the DOX-MNC-4 formulations. Interestingly, formulation DOX-MNC-
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4a, which had the least %LC also showed significantly higher IC50 values in both the cell
lines. This difference can be attributed to the higher MNP content in the 4a formulation,
which can shield the cleavage of the hydrazone bond and further prolong the release of
DOX from the clusters. Finally, the higher cellular uptake also resulted in significantly
higher MRI potential of the cationic formulations. The formulations resulted in higher
negative contrasts at lower Fe concentrations compared to the anionic formulations. Thus
we can conclude that cationic polymers are capable of forming very stable stimuliresponsive theranostic MNCs without any modification of the polymer to introduce
favorable functional groups.
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3.6 FUTURE DIRECTIONS
This work holds tremendous potential in development of protein theranostics. PLKPEG, by virtue of this positive charge can efficiently condense proteins and nucleic acids
onto itself. We have initiated initial studies to load anti-oxidant enzymes such a superoxide
dismutase (SOD) and catalase, which show tremendous potential in neurodegenerative
disorders.
Previous work in our group has already demonstrated the ability of MNCs to alter
enzyme kinetics in response to an alternating (AC) magnetic field.39 We intend to study
the effect of such AC fields on the structural integrity of these clusters. Our initial work has
shown promising results. However, additional confirmatory studies are required before the
phenomena can be revealed.
Finally, in vivo pharmacokinetics of the DOX-conjugated MNC will be evaluated in
xenografts models and therapeutic efficacy studies will be conducted in near future.
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CHAPTER 4
NON-IONIC MAGNETIC NANOCLUSTERS FOR DUAL-PURPOSE
MRI IMAGING

4.1 INTRODUCTION
Superparamagnetic iron oxide nanoparticles (MNPs) are well known for being able to
shorten the transverse relaxation time of water protons and have been used as a negative
contrast agents in MRI.1 Recently, aggregated or assembled MNPs are drawing greater
attention in MRI applications because they can provide even higher contrast than
individually dispersed MNPs.2-6 For biomedical applications such as diagnostics and drug
delivery, several characteristics of MNPs such as core particle size, cluster size, surface
charge, colloidal stability and biocompatibility of stabilizing compounds are of critical
importance since these control the various pharmacokinetic parameters of the MNPs in
vivo.
Different methods have been used to automate and precisely control the process of
formation of uniform magnetic nanoclusters (MNCs) such as spray drying7, mixing with a
conventional high speed homogenizer8, Confined Impinging Jet (CIJ) mixer9, 10 and MultiInlet Vortex Mixer (MIVM)11. In comparison to thermodynamically controlled processes
such as dialysis and emulsification-evaporation12, which are slow and result in drug/matrix
separation and low drug loading, kinetically controlled techniques such as flash
nanoprecipitation with the MIVM and jet impingement have been shown to result in high
drug loading and formation of the stable complexes.13-16 The CIJ mixer and MIVM show
numerous advantages over uncontrolled self-assembly method such as narrow particle
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size distributions, ability to control the particle size and particle composition and enhance
drug loading capacity.14 These kinetically controlled methods of self-assembly were
chosen for their ability to induce mixing and resultant precipitation in significantly lesser
time than the characteristic precipitation times of organic/inorganic materials.17 These
kinetically controlled processes have two requisites. First is the creation of a region of
highly turbulent energy dissipation. High-energy dissipation occurs for impinging jets
because the kinetic energy of each jet stream is converted into a turbulent-like motion
through collision and redirection of the flow in a very small volume. Second requisite is to
ensure that the process streams for mixing pass through the high intensity region. The
first step ensures the proper scale for mixing and the second ensures that the desired
molar flow ratios are preserved during the rapid mixing process.11
Rapid precipitation of organic and inorganic components of nanoparticles at high
supersaturation requires controlled homogenous mixing to control the particle size
distribution, which is possible to achieve in a Multi-Inlet Vortex Mixer (MIVM). The fourstream MIVM allows control of both, the supersaturation and the final solvent quality by
precisely varying stream velocities with the help of precisely defined Reynolds numbers
(Re). The Reynolds number is defined as the ratio of momentum forces to viscous forces
and consequently quantifies the relative importance of these two types of forces for given
flow conditions.18 Reynolds numbers frequently arise in fluid dynamics and are used to
characterize different flow regimes within a similar fluid, such as
•

Laminar flow: Occurs at low Reynolds numbers, where fluid viscosity is dominant,
and is characterized by smooth, constant fluid motion;

•

Turbulent flow: Occurs at high Reynolds numbers where inertial forces are
dominant tend to produce chaotic eddies and other flow instabilities
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The MIVM design enables mixing of streams of unequal volumetric flows, which is not
possible with alternate confined impinging jet (CIJ) mixing geometries, thus making it a
more versatile method with a potential for complete automation, high degree of
reproducibility and control of critical parameters such as particle size and distribution.
We first employed the MIVM to control the cluster formation process of MNPs with the
help of Pluronic amphiphilic tri-block copolymers. As mentioned earlier, the magnetic
properties and MRI potential of MNPs such as T2 relaxivity is enhanced when they are
packed into compact and stable clusters.19 We studied the effect of numerous factors such
as MNP and polymer content at different mixing speeds which were controlled by adjusting
the Re. Subsequently, we also attempted to co-encapsulate a hydrophobic anti-cancer
agent paclitaxel (PTX) with these MNCs formed by kinetically controlled flash
nanoprecipitation in a MIVM. The results showed that MIVM served as an ideal method
for rapid and formation of large volumes of MNCs with precise control over the cluster
size. Pluronic F127 by itself or in combination with Pluronic P123 efficiently encapsulated
the oleic acid coated MNPs (OMPs) alone to form very well defined MNCs. However, the
tri-block Pluronic polymers showed a potential limitation. Negligible to no paclitaxel loading
was achieved when using F127 alone. Inclusion of P123 as a stabilizing polymer
increased the encapsulation efficiency, but the % loading of PTX albeit, was still very low.
Nonetheless, the excellent control over cluster formation is very encouraging and warrants
further work as mentioned in the future directions of this chapter.
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4.2 MATERIALS AND METHODS
4.2.1 Materials
Iron (III) acetylacetonate (Fe(acac)3), Benzyl ether, nitric acid (TraceSELECT), ICP
grade standards for Fe (Fluka) were purchased from were purchased from Sigma-Aldrich
(St. Louis, MO), Ethanol (200 proof), tetrahydrofuran (anhydrous), n-hexane, acetone
(histology grade), chloroform (anhydrous), acetonitrile (HPLC grade), methanol (HPLC
grade) and other HPLC grade solvents were purchased from Thermo Fisher Scientific
(Waltham, MA). Pluronic F127 (M. wt 12,600, PEO100PPO65PEO100) and Pluronic P123
(M.wt. 5750, PEO20PPO70PEO20) were kindly provided by BASF (Florham Park, New
Jersey). Paclitaxel (PTX) was purchased from LC Labs (Woburn, MA).

4.2.2. Design of a Multi Inlet Vortex Mixer (MIVM)

Figure 4.1. Design of a multi-inlet vortex mixer used for fabrication of MNCs
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The MIVM is made from a fiberglass composite material, which is resistant to organic
solvents typically used in the chemical industry.

Four external inlets lead vertically

downwards to the four inlet streams (1.1mm diameter) that open tangentially in the
boundary of the central mixing chamber (5.9mm). The final product exits the mixing
chamber at the center as shown in Figure 4.1.
The theory behind the functioning of the MIVM is that the different flow rates and hence
the different energies from each stream contribute separately to drive fast micromixing
into the chamber. In MIVM different volumetric flow rates in each stream, defined by the
Re, can be run and still obtain good mixing. One of the advantages of using the MIVM is
that the final fluid phase is mostly aqueous. Therefore, the stability of the nanoparticles
increases in solution by depressing the rate of Ostwald ripening, when the solubility of the
precipitating species is high enough to permit this process. The importance of the vortex
mixer is that a turbulent region can be created to form and precipitate homogeneous
nanoparticles. The momentum of the four inlet streams through the mixing chamber
creates the turbulent region. Once in the confines of the mixing chamber, the four fluid
streams mix by convection energy (macro scale). Turbulent eddies formed in the mixing
chamber (meso scale) result in formation of daughter vortices by turbulent diffusion.
Eventually, molecular diffusion occurs in the turbulent eddies and eliminates region of
segregations, resulting in efficient encapsulation of the organic components within the
polymeric nanostructures.20
The inlet velocities are selected by choosing an appropriate Re, inlet velocities, and
physical properties of the inlet streams. The inlet velocities depend on the desired
Reynolds numbers and volume fractions in the mixing chamber. The four inlet flow rates
can be controlled using mechanical pumps. Re depends upon the inlet stream velocities
(ui) and kinematic viscosities (νi) of the inlet streams and is defined as11 :
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Re = Dmixer [u1/v1 +u2/v2 + u3/v3 + u4/v4]

Eqn 4.1

where Dmixer is the diameter of the mixer
4.2.3 METHODS
4.2.3.1 Synthesis of oleic acid coated MNPs
Oleic acid-coated MNPs (OMPs) were synthesized by thermal decomposition of
Fe(acac)3 by at method previously described by Sun et al.21Briefly, 2mmoles of Fe(acac)3,
6mmoles of oleic acid, 6mmoles of oleylamine, 10mmoles of 1,2 hexadecandiol were
dissolved in 20mL benzyl ether in a 3-necked round bottom flask. The mixture was heated
at 110°C for 30 minutes in order to remove any traces of water in the reaction mixture.
The temperature was then raised to 200°C at 3°C/min. The reaction was kept isothermal
at 200°C for 2h following which the temperature was further increased to reflux (~295°C)
and maintained isothermal for 2.5h. At the end of the reaction, the mixture was cooled and
precipitated with twice the amount of reagent alcohol. The precipitate was separated by
centrifugation at 4000 rpm for 45 minutes and washed with reagent alcohol.

The final

product was dried by rotary evaporation and stored under vacuum for further use.
4.2.3.2 Preparation of MNCs by flash nanoprecipitation
a. Determination of critical aggregation concentration (cac) of F127
We determined the concentration at which Pluronic F127 (CMC 2.8μM)22 started
aggregating in a mixture of 9.1%v/v aqueous mixture of tetrahydrofuran (THF) by DLS.
Briefly, F127 was dissolved at different concentration in 9.1% v/v THF and allowed to rest
for 15 minutes prior to measurements. The kilo counts per second function of DLS
measurements was recorded for each dilution and plotted as a function of the
concentration of F127. The point of inflection was determined as the cac of F127 for the
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given solvent system. For all further mixing procedures, the polymer concentration was
maintained above the cac value.
b. Determination of supersaturation (S) of paclitaxel
Prior to determination of S, the solubility of paclitaxel (PTX) in 9.1% v/v THF was
determined. Briefly, 10mg of PTX was dispersed in 5mL of 9.1% THF and stirred
continuously at RT for 72h. The dispersion was centrifuged at 10000 rpm followed by
filtration of the supernatant through 0.2μm nylon syringe filter. The amount of PTX
dissolved in the supernatant was determined by HPLC and denoted as Cinf.
Supersaturation (S) of PTX in the chamber was determined as a ratio of the total drug
exiting the mixer (mg) and Cinf. S is a critical parameter to ensure efficient precipitation of
the drug in the given solvent system along with the other organic components. It is
recommended to maintain S at values above 40. Similar study was performed for MNPs
and for all further experiments, the SMNP was maintained above 3x1010.
c. Cluster-formation
All organic components, namely Pluronic, MNPs, and PTX (wherever included), were
dissolved in THF. The MIVM was connected to two high-speed syringe pumps in order to
obtain two different flow rates for the organic and aqueous phases. One inlet of the MIVM
was connected to the glass syringe filled with organic solution and placed on one of the
two pumps. The other three inlets were connected to 140mL syringes filled with DI water.
The pump flow rates could by controlled separately by computer software to which the
pumps were connected. We performed different trials by changing the Re, the theoretical
loading capacity (%TLCMNP) of the MNPs and PTX (%TLCPTX) loading as tabulated in table
4.1. In all experiments THF: water ratio was maintained at 0.091 (9.1%v/v). The crude
product exiting the mixer was immediately placed in centrifugal filters (30,000 MWCO) and
centrifuged at 1500 rpm. The concentrated product was further washed thrice with water
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and passed serially through 0.45 and 0.2μm nylon syringe filter. The dead micelles, i.e.
Pluronic micelles without any MNPs encapsulated in them were removed by magnetic
separation to obtain the final product.
Table 4.1: MIVM and formulation parameters for the different trials
Theoretical Loading
Formulation

Polymer

Re
%LCMNP

%LCPTX

A1

44

11

6300

A2

9

4

8400

A3

9

4

12000

15

8

12000

A5

8

10

12000

A6

4

15

12000

A7

8

7

12000

A4

F127

B1

20% P123+

10

5

12000

B2

80% F127

5

5

12000

4.2.3.3 Characterization of MNCs
a. DLS: The particle size and zeta potential of the MNCs so formed was determined by
DLS, as described in chapters 2 and 3. The total solid content of the aqueous formulation
was determined by TGA and the formulations were diluted to 1mg/mL in DI water for DLS
analysis.
b. Composition: The composition of blank formulations (without PTX) was determined by
TGA by a method described in the previous chapters. The total polymer content was
obtained by subtracting the oleic acid content on the MNPs from the total loss on ignition
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(LOI). In case of PTX loaded MNCs, PTX %LC was determined by HPLC connected to a
reverse phase C18 column (Phenomenex, Torrance, CA) column and a diode array
detector. Briefly, the 0.1mg of the lyophilized formulation was dispersed in acetonitrile and
sonicated for 45 minutes following which the sample was centrifuged at 10000 rpm. The
supernatant was diluted with mobile phase (Acetonitrile: water 55:45) and injected to
obtain a peak at 8 minutes with a method run time of 10 minutes.
c. Colloidal stability of MNCs
Colloidal stability of the MNC formulation was determined on 1mg/mL solutions of
MNCs in DI water and phosphate buffered saline (PBS; 10mM; 0.14mM NaCl) at room
temperature (RT) and 37°C. The particle size and PDI of the formulations was measured
over the period of one month.
4.2.3.4 Evaluation of MRI contrast capacity in phantom gels
MRI contrast capacity of formulations B1 and B2 was determined by embedding the
formulations in 2% agar gels in 10mM PBS and taking scans in a 3T human MRI scanner
using the protocol mentioned in Chapter 2.
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4.3 RESULTS AND DISCUSSION
4.3.1 SYNTHESIS OF OLEIC ACID COATED MNPS

Figure 4.2. TEM image of magnetic nanoparticles coated with hydrophobic fatty acid
surfactants oleic acid and oleylamine
Particle size of MNPs obtained by thermal decomposition of Fe (acac)3 in presence of
oleic acid and oleylamine surfactants were analyzed by TEM. MNPs so formed had a core
size of 6.3 ± 2nm. We further determined the amount of hydrophobic coating on the core
particles by TGA. The MNPs had a surfactant coating of 22.6% w/w.
A surfactant-mediated synthetic approach was adopted for this project since we aimed
to form the clusters by flash nanoprecipitation by using amphiphilic Pluronic block
copolymers. In this synthesis, 1,2 hexadecandiol was added as a reducing agent for the
thermal decomposition of Fe(acac)3. The oleic acid and oleylamine acts as a surfactant
during the synthesis for the formation of the iron oleate nuclei at 200°C, which act as the
seeds growth of the crystals. These hydrophobic coatings also act as ligands for anchoring
of the central PPO block of the Pluronic moieties. Benzyl ether was chosen for its high

199
boiling point (~295°C). This allowed for the rapid annealing of the MNPs once the growth
is complete. It has been extensively reported that amphiphilic block copolymers such as
Pluronic stabilize MNPs by a ligand exchange mechanism wherein the polymer exchanges
with the hydrophobic surfactant on the crystal surface.23, 24 Surfactant-mediated synthesis
enables precise control over the size of the cluster in a two-step process wherein the initial
cores in the 3-6 nm range are further used as seeds to grow particles as large as 50nm.21

kcps (DLS)

600

400
cac : 1.63 mg/mL at 9.1% THF

200

0
0.001 0.01

0.1

1

10

F127 concentration (mg/mL)
Figure 4.3. CAC determination of Pluronic F127 in 9.1%v/v aqueous THF solution
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4.3.2 PREPARATION AND CHARACTERIZATION OF MNCS BY MIVM
Scheme 4.1. MNC purification process post MIVM. A Scheme showing magnetic
separation of final product from a crude mixture. B Different components of the crude
product obtained after MIVM removal of organic solvent.

Prior to MNCs preparation the critical aggregation concentration (cac) of Pluronic F127
was determined by DLS. Pluronic had a cac value of 1.63 mg/mL in the selected solvent
systems comprising of 9.1% v/v THF in water. Hence, for all trials, care was taken to
maintain the polymer concentration in the mixing chamber above the cac value.
Different trials, as mentioned in table 4.1, were conducted for formation of MNCs by
MIVM. As shown in figure 4.3, the crude formulation consists of a mixture of desired
MNCs, un-encapsulated MNPs, dead micelles i.e. micelles with only drug and no MNPs
encapsulated (shown by empty black circles) and un-encapsulated crystalline drug (PTX).
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Figure 4.4. TEM images of the different purified MNCs formulations obtained from
different trials in Table 4.1 A. Formulation A1 obtained at Re 6300 B. Formulation A2
obtained at Re 8400, and formulations A3 (C.) and A6 (D) obtained at Re 12000.
The TEM images of the final products obtained after magnetic separation are shown
in Figure 4.3. It can be seen that at lower Re values, the mixing was inefficient. As a result,
there was a significant population of MNPs, which were either individually or at least very
loosely held together by the polymer (figures 4.5A and B). In contrast, Re values above
10,000, resulted in distinct, well-defined MNCs (figures 4.5C and D). As observed from
the DLS data (Figure 4.6), all formulations showed particle sizes in the 50-150nm ranges
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and good PDI. Formulations A1 and A2 in particular, showed lower Deff due to the
presence of a large population of individual and loose MNPs stabilized by Pluronic F127.
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Figure 4.5. Particles size (A) and Zeta potential(B) of different formulations prepared by
MIVM
The cluster size was governed by the targeted %LCMNP in the formulations prepared
at Re 12000. Also, introduction of a more hydrophobic P123 polymer resulted in an
increase in cluster size while the PDI was reduced significantly. Zeta potentials of the
formulations were in the -15mV to +10mV range hinting at a mild surface charge. We
further determined the composition of selected formulations prepared at Re 12000 by TGA.
For this study, PTX loading was determined separately by HPLC and that along with the
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surfactant content were deducted from the total loss of ignition (LOI) to obtain the polymer
content in the clusters. As seen in Figure 4.7, the targeted loading capacities of MNPs
(%TLCMNP) dictated the composition of the formulations. Polymer type did not affect MNP
encapsulation. However, incorporation of P123 polymer resulted in an increased in drug
loading (%LC). However, the MNC formulations did not have high PTX loading.
Inclusion of P123 has been shown to significantly increase the %LC of PTX and other
hydrophobic drugs in Pluronic-based micellar systems.25-28 Hence we had anticipated a
similar effect with MNC formulations as well. However, the effect was only marginal. We
speculate that the hydrophobic block of Pluronic is insufficient to encapsulate both MNCs
as well as PTX and hence MNC encapsulation predominates over PTX.
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Further, we conducted extensive colloidal stability studies of formulation A4 in PBS
(pH 7.4;10 mM) and DI water at room temperature (RT) and physiological temperature.
The formulation was stable over the entire period of the study with minimal increase in
both size as well as PDI (Figure 4.8).
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Figure 4.7. Colloidal stability of formulation A6 in A. Water and B. PBS (pH 7.4)
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4.3.3 MRI CAPACITY OF MNCS PREPARED BY MIVM

Figure 4.8. MRI potential of MNCS prepared by MIVM

Finally, we studied the MRI potential of two MNC formulations prepared from a blend
of P123 and F127 (1:4 wt%) with 10% (Formulation B1) and 5% (Formulation B2)
%TLCOMP respectively. MNCs were prepared at Re 12000. We prepared serial dilutions of
the MNCs in 2% w/v molten agar gel. After the gels solidified at RT, MRI scans were taken
in a 3T Siemens human MRI scanner. The protocol for T1 and T2-weighted images was
similar to that followed in the previous chapters. As seen in figure 4.9, the contrast
intensities were governed by %LCMNP. Formulation B1, with 10% TLC showed stronger
negative contrast at lower concentrations than formulation B2 which had a 5% TLC.
Interestingly, the formulations also exhibited superior T1 (positive) contrasts as well at
higher concentration. It should be noted at MNPs less than 7nm core sizes (USPIOs) have
been successfully used as T1 contrast agents. The MNPs used in this case were 6.3nm
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and hence showed an enhanced positive contrast as well. Further, the compact cluster
formation also added to the phenomenon.
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3.5 DISCUSSION
The advent of nanotechnology in the field of medicine and healthcare has initiated a
radical change in the treatment of various diseases, especially those which, till now were
perceived as fatal and untreatable. Several research studies have provided significant
proofs of the concept by demonstrating unprecedented therapeutics efficacy of these
nanoparticles loaded with the same therapeutic agents currently used in clinical practice,
albeit with limited efficacy and severe side effects. However, large-scale production of
uniform-sized nanoparticles of organic and inorganic hydrophobic compounds by an
economical, scalable process is a considerable challenge. Flash nanoprecipitation is an
advanced technique that relies on fast mixing of two or more streams to create
supersaturation. In this technique dissolved solute/ solutes and stabilizing amphiphilic
polymer are rapidly mixed with an anti-solvent to create supersaturation over a time period
shorter than the typical nucleation and growth time scales for the hydrophobic
components. The rapid nucleation and uniform growth of the nanoparticles is curbed by
the uniform adsorption of the amphiphilic block copolymers on the particle surface. The
process results in very narrow particle size distributions.
An understanding of rapid precipitation of the dissolved components requires an
understanding of the role of macro-, meso- and micromixing on the development of
supersaturation. Different types mixing devices have been developed and characterized,
such as stirred-tank precipitators29 and impinging-jet precipitators17. Johnson and
Prud’homme have studied the dependence of mixing time on a critical process parameter
called the Reynolds number (Re) and geometry in a Confined Impinging Jet mixer (CIJ).20
The MIVM overcomes a prime shortfall of the CIJ such as the requirement of equal flow
rate of the solvent and anti-solvent streams entering the device. The ability to modulate
the momentum of each stream contributes independently to drive micromixing in the cell.
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The choice of Re dictates the performance of the MIVM and is independent of the
configuration of the inlet streams. Above a certain threshold Re value, usually about 2000,
very uniform mixing can be obtained for simple reaction mixtures. This threshold changes
with the type of application. For nanoparticle formation Re value above 5000 usually
provides highly uniform mixing and results in nanoparticles with significantly low PDI
values. In case of MNCs formed by MIVM, this threshold Re value in the range of 50006000.
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The physicochemical properties of the solute encapsulated in the clusters plays

a significant role in the efficiency of cluster formation. The solubility of the various
components of the organic anti-solvent stream such as the drug, the MNPs and the
polymers are significantly different and thus it is essential to select an appropriate Re such
that all the components precipitate simultaneously upon super saturation in the mixing
chamber. In addition, the concentration of the organic solutes in comparison with that of
the stabilizing amphiphilic polymer was also a critical parameter. Thus, MNCs prepared in
trial A1, showed a significant population of loosely held MNPs, which were individually
stabilized by Pluronic following mixing at a Re 6,300. The PDI of this formulation was low
most likely due to the presence of a significant proportion of individual highly
monodisperse 7nm MNPs. This population of individually stabilized MNPs or ‘loose MNCs’
decreased significantly upon reducing the MNP concentration in the THF stream to 20
wt% of that in Trial A1 and increasing Re to 8400. Further increase in Re to 12,000 and
beyond resulted in complete absence of ‘loose MNCs’ with significant improvement in PDI.
As the momentum of the mixing streams increased, it increased the mixing speed thereby
prompting simultaneous precipitation of the MNPs and polymer and causing the polymer
to stabilize the cluster promptly and efficiently. Any further increase in Re up to a maximum
of 16,250 did not cause any improvement in the MNC characteristics or PDI (data not
shown).
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The negligible %LCPTX in all trials conducted with F127 only can be due to two factors.
First is the type of polymer being used and second is the precipitation rate of the drug in
the mixing chamber. Encapsulation of hydrophobic payloads within micellar systems or
related core-shell structures comprising of a hydrophobic core and hydrophilic shell is
governed by the properties of the amphiphilic polymers used for formation of the
nanostructures. Pluronic F127 is a triblock copolymer with a relatively small central
hydrophobic poly (propylene oxide (PPO) block having a molecular weight of 3775 Da (65
PO r.u.). MNPs with fatty acid ligands on the surface are known to be stabilized by a
process known as ligand exchange.31-33 As known from the previous two chapters and as
discussed in the literature,33 there exists a hierarchy of binding of different functional
groups with catechol showing the maximum ligand exchange with oleic acid from MNP
surfaces followed by phosphates, amines and lastly carboxylates. Given the structure of
the central PPO block of Pluronic and absence of any of these functional groups, we
believe that the efficient micromixing in the mixer further accentuates the strong
hydrophobic interactions between the PPO block and the oleic acid brushes on the MNP
surface and it is these interactions that result in the formation of stable and well-defined
spherical MNCs. However, in doing so, the PPO blocks get completely utilized by the
MNPs leaving absolutely no hydrophobic polymeric region available for entrapment of
PTX. Attempts were made to reduce MNP feed and increase PTX feed (trial A6). However,
these attempts resulted in a high proportion of dead micelles and unentrapped free PTX
with only a marginal increase in %LCPTX. Given the high HLB of Pluronic F127 (HLB 22),
it is also very likely that upon reaching supersaturation in the mixing chamber, PTX
precipitates rapidly leading to separation stabilization by the polymer and thus minimal coentrapment in the MNCs. In order to decrease the HLB of the polymeric system, 20 wt%
Pluronic P123 (M.wt. 5750, HLB 8, PPO block M.wt. 3775) was mixed with 80 wt% of F127
(Trials B1 and B2). Such a mixture has been shown to significantly enhance loading
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capacity of hydrophobic drug in resulting mixed micellar systems due to a decrease in the
overall.26-28 This approach resulted in a significant increase in PTX loading. However, from
the point of therapeutic efficacy and balance between the two functional components, this
%LC was not sufficient and highlighted the limitations of Pluronic polymers for synthesis
of co-encapsulated nanosystems such as the MNCs prepared here. An amphiphilic diblock copolymer with a larger hydrophobic block of at least 6 KDa may be required to coencapsulate both the hydrophobic components in appreciable amounts in order to achieve
the desired theranostic goals.
It should be noted here that %LCMNP could be controlled easily by changing MNP
concentration in the THF stream. This was evident when the MRI potential of the MNCs
obtained from Trials B1 and B2 was studied in phantom gels. MNCs synthesized in Trial
B1 with 10 wt% concentration of MNPs in THF stream resulted in 39 wt% MNP content in
comparison with Trial B2 wherein the MNP content in the THF stream was 5 wt% and
resulted in 22 wt% MNP content (Figure 4.7). Interestingly, these MNCs showed
significantly higher r1 signals as well. MNPs, specifically, USPIOs in the core size range
of 4-7nm are known to undergo both R1 and R2 relaxation resulting a dual-modal contrast
capability.34-36 This finding further expands the scope of biomedical applications of these
MNCs beyond tumor contrast and drug delivery agents. Such MRI contrast agents can
also function effectively as blood pool agents in cardiovascular and cerebrovascular
disorders.
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3.6 CONCLUSIONS
. Flash precipitation or MIVM involves rapid nucleation at rates less that 50ms, growth
and kinetically induced polymeric stabilization of the nanoparticles. We attempted to
design theranostic magnetic nanoclusters by co-encapsulating anticancer agents PTX
along with oleic acid coated MNPs (OMPs) stabilized by Pluronic block copolymers during
the rapid micro-mixing of the organic solvent stream containing dissolved polymer, MNPs
and PTX into miscible anti-solvent streams at time scales in the order of 1-2ms. MNCs
fabricated by MIVM displayed uniform spherical structure and had a narrow size
distribution and relatively low polydispersity. By changing the Reynolds number (Re), the
cluster size and size distribution could be controlled easily. Given the higher HLB of
Pluronic F127, inclusion of a relatively hydrophobic Pluronic P123 enabled successful
encapsulation of Paclitaxel along with the MNPs. Although, considerably less than
conventional micellar systems, the obtained PTX loading was in line with our anticipation
given the relatively smaller hydrophobic blocks of Pluronic F127 as well P123. These
resulting compact MNC formulations produced a higher negative T2-weighted contrast
under a 3T MRI scanner indicating at significantly higher relaxivity (r2) values. Thus, we
report the successful fabrication of a biocompatible theranostic system with potential
applications in cancer therapy wherein the site-specific chemotherapeutic efficacy and
visualization of tumor regression can be achieved simultaneous over an extended period
of time.
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3.5 FUTURE DIRECTIONS
The ability of MNCs prepared by MIVM to function as both T1 and T2 contrast agents,
as shown in the phantom gel results is a highly desirable feature and hence we propose
that the same core size be used. While Pluronic block copolymers resulted in stable MNCs
by MIVM, the polymer structure was the main factor limiting the co-encapsulation of PTX
and MNPs. Hence future studies will be directed towards studying the effect of polymers
with longer hydrophobic blocks. Given the advantages of polypeptide-based polymers, we
propose to design MNCs stabilized by poly (phenyl alanine)-PEG polymer. Given the
highly hydrophobic nature of poly (phenyl alanine), synthesis of the diblock copolymers
may require a longer PEG block, such as that with M. wt 10,000 in order to balance a poly
(phenyl alanine) block of more than 50 r.u. Subject to successful loading of both MNPs
and significant amounts of PTX or any other anti-cancer agents, we also propose
extensive in vitro and in vivo studies to establish the theranostic potential of these MNCs
prepared by MIVM.
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CHAPTER 5
SUMMARY
The superparamagnetic properties of magnetic nanoparticles (MNPs) have continued
to attract the attention of scientists from various field for more than three decades. These
concerted efforts have resulted in numerous applications of magnetic iron oxide
nanoparticles as noted in the previous chapters. Of particular interest are the biomedical
applications of MNPs. The ability to precisely control the sizes of MNPs from a few
nanometers to a few tens of nanometers further expands the scope of these biomedical
applications. These MNPs can be manipulated by an external magnetic field gradient. The
magnitude of such a manipulation depends largely on the size of the magnetic cores. This
‘remote control’, combined with the fundamental penetrability of magnetic fields into human
tissue can be exploited in numerous applications such as those involving the transport
and/or immobilization of magnetic nanoparticles, or of magnetically tagged biological
entities. MNPs or polymer-stabilized formulations thereof can be developed to deliver a
wide variety of therapeutic payloads such as an anticancer drug, or a regiment of
radionuclide atoms to a targeted region of the body, such as a tumor. The magnetic
nanoparticles can be made to transfer of energy in the form of heat from the exciting field
to the nanoparticle. This has led to their use as hyperthermia agents, producing toxic
amounts of thermal energy in targeted bodies such as tumors; or as adjunct therapy in
combination with chemotherapy and radiotherapy.
These and many other possibilities are available in nanomedicine as a result of the
special physical properties of MNPs. Of all these application, the ability of MNPs to serve
as MRI contrast agents has attracted tremendous attention from the theranostic view point.
However, the successful design of MNPs into theranostic agents requires a formulation
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that shows minimal toxicity, sufficient drug loading capacity and most importantly a precise
balance between the two components i.e. MNPs (diagnostic) and chemotherapeutic
agents. Achieving this balance is critical to the success of MNPs as co-encapsulated
theranostic agents, and certainly poses significant challenges in the development of MNPs
for cancer theranostics.
This dissertation was aimed at designing a biodegradable theranostic nanosystem
capable of simultaneous drug delivery of anti-cancer agents and MRI contrast agents i.e.
MNPs which serve as excellent T2- contrast agents. Based on the published literature on
development of MNPs as theranostic agents, it can be concurred that there are critical
factors for the successful development of a MNP-based theranostic system. They are:a. The physicochemical characteristics of the core MNPs
b. The selection of the stabilizing polymer
Accordingly, our efforts were focused on synthesizing MNP cores with enhanced
magnetic properties followed by a comprehensive evaluation of different block copolymers
as potential stabilizing and cluster forming components of the resulting MNCs. Given the
continued emphasis of your group on development of biocompatible drug delivery
technologies, we employed biocompatible and biodegradable polymers in these projects.
In Chapter 1 we first modified a simple on-pot procedure for synthesis of MNPs by thermal
decomposition of the organometallic precursor Fe(acac)3. The magnetic properties of
MNPs, which are essential for their MRI contrast function, are governed by the chemical
nature and oxidation state of the MNP crystal along with the size of the MNPs. We
successfully demonstrated that we can control the crystal size by precisely controlling the
rate of heating of the reaction mixture. The rate at which the reaction mixture was heated
controlled the two critical staged of crystallization i.e. nucleation and growth. Thus the
largest particles (14nm) were achieved by increasing the reaction rate to 4°C/min.
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The stabilization of these MNPs were carried out by coating with completely
hydrophilic anionic poly (glutamic acid)-b-poly (ethylene glycol) polymers with different
poly (glutamic acid) block (PLE) lengths. However, the clusters so formed were unstable
in physiological media resulting in aggregation and loss of colloidal properties. This was
attributed to the PLE block length and the weak coordination complex formed between the
carboxylate endgroups of the polymer and the MNP surface, which was easily displaced
by the physiological electrolytes that have a higher affinity for MNP surface. This
necessitated the structural modification of the polymer to incorporate bisphosphonate
containing end groups, which are known to form very strong coordination complexes with
MNP surfaces. Inclusion of bisphosphonate containing end groups on the PLE block
significantly enhanced the colloidal stability of the MNCs in physiological conditions. The
degree of conjugation (Dconj) of the bisphosphonate-containing ALN molecule on the PLE
block dictated the stability of the clusters with maximum stability obtained at a Dconj of 19
and a cluster size of approximately 70nm.
Cisplatin was successfully conjugated on the MNCs via electrostatic interactions with
the available carboxylate groups at pH 9.5. The release rate was also controlled by Dconj.
MNCs with highest Dconj also exhibited the slowest release profile. Overall, the MNCs
exhibited a sustained pH dependent release profile which was significantly faster at the
acidic pH. The Dconj and the resulting cluster size, along with the size of the core MNP
particles controlled the magnetic properties of the MNCs. In addition, inclusion of cisplatin
also positively affected the T2 relaxivity of the resulting MNC formulations. The
incorporation of the Pt metal resulted in close proximity with the MNPs resulted in a metal
cluster effect which is speculated as a reason for the increase in relaxivity of the MNCs
following cisplatin incorporation.
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These anionic MNCs had very low nonspecific cellular uptake in ovarian cancer cells.
This is a highly desired feature in nanoformulations as it enables site specific targeting of
the nanoformulations thereby significantly reducing the undesired side effects due to
uptake in the healthy tissue as well. We targeted this formulation exclusively to ovarian
cancer tissue overexpressing LHRH receptor. The MNCs were decorated with synthetic
LHRH peptide. LHRH conjugation enhanced the cellular uptake significantly. The effect
was more pronounced in cisplatin resistance ovarian cancer (A2780-CisR) cells than the
wild type cells (A2780-WT). This active targeting strategy successfully translated into
enhanced anticancer efficacy wherein the targeted formulations reduced the IC50 by
almost half in comparison to the non-targeted MNCs. LHRHr targeting and the resulting
increase in target-specific uptake of the MNPs significantly enhanced the in vitro MRI
contrast of the formulation when measured in ovarian cancer cells embedded in agar
phantom gels.
Following the successful evaluation of the anionic biocompatible polymer PLEX-bPEG113 as a surface stabilizer for theranostic MNCs, we studied the potential of a cationic
block copolymer in development of stable of MNCs for cancer theranostics (Chapter 3).
For this purpose, we employed classical poly (l-lysine)-b-poly (ethylene glycol) block
copolymers of different l-lysine repeating units (X = 10, 50 or 100). The MNPs synthesis
was modified to further enhance the magnetic properties without compromising on the
larger core size and greater saturation magnetization. (Ms). MNCs stabilized by PLKX-bPEG113 polymers. The cationic block copolymers stabilized the MNPs more efficiently than
the anionic PLE-based polymers discussed in Chapter 1. However, similar to the anionic
block copolymers, the stability of the resulting clusters was dictated by the PLK block
length. Nonetheless, the resulting cationic MNCs did not exhibit any instability in
physiological buffers.
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The MNCs so developed exhibited significantly higher T2-relaxivities which increased
depending on the MNP size as well as the Deff of the clusters.MNC-3 and MNC-4 had r2
values significantly higher when compared to the once commercially available T2-contrast
agent Feridex®. The therapeutic functionality was introduced onto the most stable MNC-4
clusters in the form of anti-cancer agent doxorubicin (DOX). DOX was conjugated onto
the MNCs at the pendant side chain primary amino group via a pH sensitive hydrazine
bond using hetero-bi-functional linker SPDP. The utilization of this end terminal
significantly reduced the charge induced toxicity of the formulations. A maximum of 2.5
wt% DOX conjugation was achieved on the MNCs. The pH sensitive hydrazine bond
successfully prevented premature release of the chemotherapeutic agent in the
physiological medium. As desired, the drug was released rapidly in a sustained manner in
acidic pH. The cationic MNCs had significantly higher cellular uptake; almost 20-folds
higher when compared that of the targeted anionic MNCs discussed in the previous
chapter. Of the two cell lines tested, triple negative breast cancer MDA-MB-231 cells
exhibited a relatively slower rate of uptake than the A2780-WT ovarian cancer cells.
Confocal microscopy of the ovarian cancer and triple negative breast cancer cells revealed
that post-internalization, the clusters were lodged in the lysosomal vesicles, thus
supporting the strategy adopted for triggering the drug release from the clusters. Finally,
the DOX-loaded pH sensitive MNCs exhibited cytotoxicity efficacy consistent with that
expected from a stimuli-responsive sustained release nanoformulation. The IC50 values of
the formulations was dependent on the drug loading. DOX-MNC-4c formulation was
further tested for its MRI contrast potential in vitro by incubating it with the above
mentioned cell lines for a 24h period. Cationic MNCs, by virtue of a higher cellular uptake
exhibited significantly stronger T2-weighted contrast in agar phantom gels. Thus, the
cationic polymers are more efficient in stabilizing bare uncoated (without oleic acid) MNPs
into larger and more compact clusters when compared to anionic polymers. MNPs
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synthesized by thermal decomposition have seldom been stabilized via hydrophilic routes
and hydrophilic. We showed that in comparison with the co-precipitation technique for
synthesis of MNPs, the MNCs formed here were significantly superior from the point of
stability, cluster integrity and magnetic properties. Based on the observations in Chapters
2 and 3, it can also be concluded that the strength of the coordination complexes between
the MNP surface and the polymers is dictated by the available functional groups and that
the strength of these complexes increases as follows –COOH < -NH2 < (PO(OH)2)2.
In Chapter 4, we studied the effect of multi-inlet vortex mixing (MIVM) or flash
precipitation on cluster formation and co-encapsulation of MNPs and hydrophobic anticancer agent paclitaxel (PTX). MIVM technique is based on the principal of kinetically
controlled supersaturation and the resulting kinetically controlled precipitation of MNPs
into highly monodisperse MNCs stabilized by amphiphilic block copolymers. In sharp
contrast to the MNPs and polymers used in the previous chapters, here we employed the
widely used thermal decomposition technique to coat the MNPs with hydrophobic
surfactants oleic acid and oleylamine in situ while the polymers were triblock amphiphilic
Pluronic block copolymers.
The clustering formation is governed by four critical factors namely
a. The flow rate of the opposing streams during the mixing process (Reynolds
number Re)
b. The final ratio of organic and inorganic solvents in the mixing chamber, which leads
to supersaturation and precipitation
c. The concentration of the organic components in the miscible organic fraction and
the critical aggregation concentration (cac) of all the organic components in the
final mixed solvent system in the chamber
d. The HLB of the polymer and the length of the hydrophilic block
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The cluster formation process showed maximum efficiency at Re between 9000
and 12,500. Beyond 12,500 the cluster formation showed no significant improvement.
Re controls the supersaturation of the system and hence the onset and rate of
precipitation of the organic components. The Re was optimized to 12000. Any further
increase in Re did not cause any changes in the efficiency. Polymer characteristics
play a significant role in MNC formation. Since the cluster formation is caused by
interaction of the hydrophobic block of the polymer and the hydrophobic surfactants
coating the MNPs, the hydrophobic block length and thus the overall HLB of the
polymer played a critical role in MNC formation as well as co-encapsulation of PTX
along with the MNPs. With Pluronic F127 and P123, the hydrophobic blocks do provide
ample hydrophobic environment for co-encapsulating significant amounts of PTX,
most likely due to the presence of MNPs, which utilize most of the hydrophobic blocks
for stabilization into clusters. Nonetheless, in comparison to single polymer F127, a
4:1 blend of F127 and P123 resulted in an increase in co-encapsulation of PTX. Thus,
MIVM provides a highly efficient technique for formation of MNCs with low
polydispersity. Due to technical difficulties, the drug loading could not be maximized.
Nonetheless, the results have provided a good understanding into the variables that
are critical to the enhancement of drug loading.
Thus, to summarize, we successfully studied the physicochemical factors affecting
formation of MNP-based theranostic. In doing so, we successfully developed highly
stable theranostic MNCs from three different types of block copolymers namely,
anionic, cationic and non-ionic block copolymers. This success and the insights gained
into the development of MNPs as MRI contrast agents warrant further research into
the in vivo characterization of these different theranostic nanosystems.

